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Abstract 
Regeneration is a word that has inspired the imagination of artists and 
scientists alike ever since the word’s inception in mid-14th century from Latin 
meaning “being born again.” Today, medical research labs are fascinated with the 
aim of directing native repair mechanisms to heal damaged tissues.  
Amongst the most rapidly renewing tissues in the mammalian body, the 
lining of the intestine (epithelium) is a particularly pertinent system in which to 
study regeneration driven by the extraordinary potential of intestinal stem cells 
(ISC). Prevailing evidence demonstrates the existence of two ISC populations in 
the intestinal crypts: active stem cells (termed crypt base columnar (CBC) cells), 
responsible for epithelial cell maintenance during homeostasis, and facultative 
stem cells (FSC), important to the replenishment of the CBC compartment when 
damaged (e.g. irradiation, disturbance of the stem cell microenvironment).  
In this thesis, I examined the molecular mechanisms regulating the cellular 
changes mediating the regenerative response stimulated by intestinal damage. 
The scientific literature describes intestinal regeneration as a complex multiphasic 
response modulated by a network of signaling factors and cellular compartments 
(including epithelial Paneth cells and pericryptal subepithelial cells) that aim to 
restore homeostasis. However, significant knowledge gaps remained with regard 
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to how the intestine responds to injury, and mobilizes FSC cell populations to 
remedy the damage.  
My studies characterize the intestinal response to irradiation-mediated CBC 
loss, and propose a mechanism by which damage stimulates the non-epithelial 
cells in close juxtaposition with the intestinal crypts (termed pericryptal 
subepithelial cells) to signal to crypt epithelial cells via IGF1 (Chapter II). IGF1 
stimulates epithelial cell mTORC1 signaling, which results in mobilization and 
activation of FSCs to repopulate the vacant CBC compartment.  
In my investigations of the intestinal response to irradiation damage, I also 
demonstrate that commonly employed CreERT2 mouse models exhibit inherent 
toxicity, with CreERT2  expressing-CBCs exhibiting impaired function (Chapter III). 
Activation of CreERT2  by tamoxifen treatment leads to DNA damage, which results 
in delayed intestinal regeneration after irradiation injury. My discoveries inform the 
GI field in ways to minimize the confounding factor of CreERT2 genotoxicity.  
In addition to characterizing the mechanisms directing regeneration from 
known intestinal injury methods (Chapter II), my studies also characterized a novel 
method of intestinal damage resulting from acute inhibition of a molecular pathway 
critical to ISC activity: Notch (Chapter IV). While Notch regulation of the ISC niche 
has been defined in the context of chronic or persistent Notch modulation, no 
study has yet sought to understand the consequence of short-term Notch 
inhibition. My data report rapid Paneth cell loss following acute Notch inhibition, 
which transiently impairs CBC function, and initiates regeneration of the Paneth 
cell compartment fueled in part by Dll1-expressing FSCs, but not by HopX-
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expressing FSCs. This report is the first indication that certain FSC sub-
populations can be selectively activated depending on the nature and/or degree of 
the intestinal insult, which is critical to understanding the biological nuances of the 
regenerative response in different damage situations (e.g. developmental 
abnormalities, disease, irradiation).  
My thesis work serves to define key niche cells and pathways regulating 
ISC function during crypt regeneration after stem cell injury.  
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Chapter I : Introduction1 
1.1 Overview of Intestinal Structure and Development 
1.1.1 Anatomy and function 
The intestine is amongst the largest organs in the mammalian body, a long 
convoluted tube that is part of the gastrointestinal tract, which extends from mouth 
to anus. The intestine is categorized into the small and large intestine, the former 
being connected to the stomach via the duodenum, the most proximal section of 
the small intestine. From proximal to distal, the small intestine is composed of the 
duodenum, which is connected to the stomach, the jejunum and the ileum. The 
large intestine is connected to the ileum via the cecum, which connects with the 
rest of the organ including the colon, rectum and anal canal. My thesis work 
focuses primarily on the small intestine, particularly the duodenum, with a few 
studies pertaining to the ileum. The intestine holds the incredible responsibility of 
absorbing nutrients to sustain life, and its structural and cellular composition are 
uniquely tailored to that aim.  
                                            
1 Note this chapter is adapted from the following textbook chapter: 
Dempsey, P. J., Bohin, N. and Samuelson, L. C. (2018). Notch Pathway Regulation of 
Intestinal Cell Fate. In: H. M. Said, F. K. Ghishan, J. D. Kaunitz, J. L. Merchant and J. D. 
Wood, ed., Physiology of the Gastrointestinal Tract, 6th ed. Academic Press, pp.141-183.286 
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The intestine is composed of cells originating from each of the three germ 
layers: the epithelium from endoderm, the mesenchyme (muscle, myofibroblasts) 
from mesoderm, and the enteric nervous system from ectoderm. The homeobox 
transcription factor caudal type homeobox 2 (CDX2) is a master regulator of 
intestinal identity, and Cdx2 expression is essential for specification of the 
intestinal epithelium from the primordial gut endoderm, and for establishing normal 
epithelial-mesenchymal interactions.1 After morphogenesis of the intestine, stem 
and transit-amplifying progenitor cells continuously divide and differentiate to 
maintain the epithelium throughout the lifespan of the organism. At least six 
distinct epithelial cell types are formed. This includes absorptive enterocytes and 
three secretory (granulocytic) cell types: mucus-producing goblet cells, 
antimicrobial peptide-producing Paneth cells, and hormone-releasing endocrine 
cells. Less frequent intestinal cell types include tuft cells, also called brush cells, 
which are chemo-sensory cells, which orchestrate intestinal responses to parasite 
infection,2–4 and microfold, or M, cells, which transport luminal antigens across the 
epithelium to mucosa-associated immune cells. The general structures of 
developing and adult intestine, including epithelial and mesenchymal components, 
are shown in Figure 1.1.  
A complex network of signaling pathways and transcription factors work in 
concert to maintain homeostasis by regulating proliferation and cellular 
differentiation. Many studies have demonstrated the central importance of Notch 
signaling for homeostatic control of the intestinal epithelium, regulating both 
progenitor cell proliferation and cell fate determination. In addition, other 
  
 
3 
fundamental signaling pathways are critical for intestinal development and 
homeostasis, including WNT, Hedgehog (HH), and Bone Morphogenetic Protein 
(BMP).5 The specific roles of each of these pathways in regulating intestinal stem 
and progenitor cells to maintain homeostasis has been the topic of extensive 
research with many breakthroughs emerging primarily from analysis of genetically 
engineered mouse models.  
1.1.2 Intestinal Stem Cells 
1.1.2.1 Introduction 
The intestinal epithelium is renewed at an extraordinary rate, outpacing 
almost all other tissues in the mammalian body. A tightly regulated intestinal stem 
cell (ISC) compartment is therefore required to replenish the various intestinal 
epithelial cell types to maintain proper tissue function. Substantive evidence 
suggests that there are two stem cell populations:  active stem cells, also termed 
crypt base columnar (CBC) cells, and facultative stem cells (FSCs), also termed 
quiescent or reserve stem cells (Figure 1.2).6–14 While the former is responsible 
for maintenance of intestinal epithelial homeostasis, FSCs respond to damage by 
contributing to the repopulation of the damaged epithelia (Figure 1.3).  
A stem cell is a cell that is capable of giving rise to mature cell types. These 
cells can be functionally identified by various means, although three main 
techniques have been employed in the intestine: lineage tracing, label retention 
and intestinal organoid formation. Lineage tracing is a technique that allows 
permanent labeling of a given cell and all of its progeny via activation of a reporter 
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gene. If a stem cell is labeled by this method, and intestinal sections are analyzed 
after some time, a “ribbon” of labeled cells extending from the base of the crypts 
upwards will be observed. Label retention assays are aimed at identifying slowly 
cycling cells by labeling their DNA. An injection, or ‘pulse,’ of a DNA label (e.g. 
bromodeoxyuridine (BrdU)) will mark all cells. The pulse is followed by a ‘chase’ or 
‘washout’ period, during which most cells turnover, or divide. In the latter case, 
mitotically active cells dilute the DNA label with each division, diminishing the 
labeling intensity. Cells with an adequate labeling intensity are termed ‘label-
retaining cells’, and constitute a mitotically dormant or slow cycling cell population 
believed to represent a subset of the stem cell compartment. Intestinal organoids 
are three-dimensional intestinal epithelial structures grown in vitro whose growth is 
fueled by stem cells. Establishing organoids from ISCs and assessing intestinal 
organoid formation, or growth, provides information about ISC activity.  
Stem cell activity is regulated by signaling cues from the stem cell 
microenvironment, also known as the niche. Dysregulated niche signaling can 
result in unchecked proliferation and tumor formation.15,16 It is therefore 
fundamental to our understanding of intestinal homeostasis, regeneration after 
injury and tumorigenic pathways to uncover the molecular program of ISC 
regulation.   
1.1.3.2 Crypt base columnar stem cell  
 The discovery of the putative ISC was originally driven by the hypothesis 
that stem cells would be slowly cycling in order to contribute to intestinal 
  
 
5 
maintenance throughout life. As such, Potten and colleagues proposed a DNA 
label-retaining cell type located at the +4 position (4th cell up from the crypt base) 
to be the putative ISC.17 On the contrary, the ISC we now know to maintain 
intestinal homeostasis is rapidly cycling, and known as the CBC, thin cells located 
at the base of the crypts intercalated between Paneth cells (Figure 1.2 and 
1.3).18,19  
The discovery of CBC-specific markers, described in the subsequent 
section and defined as genes or proteins expressed in a particular cell population 
that help identify it, facilitated characterization of this cell type. It was demonstrated 
that these cells were capable of long-term self-renewal, and multipotency.20 
Further, single isolated CBCs were shown to be able to give rise to intestinal 
organoids that contained all intestinal lineages, and could be passaged virtually 
indefinitely.21 Together these data helped cement CBCs as bona fide ISCs. As 
such, it was most surprising to the field when complete diphtheria toxin-induced 
ablation of CBCs had little effect on intestinal homeostasis.22 Fittingly, as with 
other proliferative cells, CBCs were shown to be highly sensitive to intestinal 
damage, with dramatic loss of this cell population following administration of DNA 
damaging agents (e.g. chemotherapeutics, γ-irradiation).20 Together these reports 
suggest that another cell type is capable of compensating for the elimination of 
CBCs and restoring homeostasis following injury, paving the way for the 
characterization of FSCs described in a subsequent section.    
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1.1.3.3 Markers of crypt base columnar stem cells 
CBC stem cells were first described by Cheng and LeBlond, and the 
Clevers laboratory subsequently identified the first molecular marker of CBCs, 
Lgr5 (Figure 1.2).18 The Lgr5 gene is regulated by WNT pathway signaling, which 
is a critical pathway promoting intestinal proliferation and CBC function.18,23,24 
Using a mouse strain with an inducible Cre allele knocked-in to the Lgr5 locus and 
the ROSA26-lacZ reporter allele for lineage tracing analysis, and 5-
bromodeoxyuridine (BrdU)-labeling studies, it was determined that Lgr5-positive 
cells are actively cycling with an average of one round of cell division per day.23 
Importantly, lineage tracing to mark the progeny of Lgr5-positive cells, labeled all 
epithelial cell types, with a time period of ~5 days for a migrating “ribbon” (defined 
in the previous section) to reach the villus tip, a timing consistent with the known 
rate of epithelial cell differentiation and migration.25 The labeling was shown to be 
long-lived, with labeled ribbons maintained 14 months after induction.25 Thus 
demonstrating that Lgr5-positive cells were long-lived self-renewing stem cells. 
Lgr5 family members (Lgr4, 5 and 6) encode G-protein coupled transmembrane 
proteins that act as receptors for R-Spondin (RSPO) and potentiate WNT 
signaling, a developmental pathway whose intestinal activity is described in a 
subsequent section.26–29 Lgr5 is expressed in the proliferative, intervillus zone of 
the intestine at developmental stages,30 while it is expressed most highly in CBCs 
in adulthood with a decreasing gradient of expression moving up the crypt. 
Analysis of genes enriched in Lgr5-positive cells identified additional 
markers of the CBC stem cell including achaete scute-like 2 (Ascl2; also called 
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Mash2),31 olfactomedin4 (Olfm4),32 Sox9,33,34 and others (Figure 1.2).13 
Importantly, Olfm4 is a Notch target gene, suggesting that the CBC stem cell is a 
direct cellular target of Notch signaling.35 Ascl2, a WNT target gene encoding a 
transcription factor, was shown to direct the expression of a number of other WNT 
target genes, including Lgr5. Mechanistically, Schuijers et al. recently showed 
ASCL2 forms a bimodal switch that interprets WNT levels and cooperates 
transcriptionally with β-catenin/TCF4 to stabilize the stem cell identity of Lgr5-
positive CBCs.36  
1.1.3.4 Facultative stem cell   
In support of Potten and colleagues’ original hypothesis,17 the field has 
demonstrated the existence of ISCs distinct from CBCs, known as FSCs, a sub-
population of which were described as slowly cycling and label retaining. Current 
evidence indicates FSCs are a heterogeneous population of intestinal crypt cells 
with the potential to be mobilized, or activated to stem cell status, during repair or 
regeneration (Figure 1.3). As stem cells, FSCs have the capacity for self-renewal 
and multipotency, however this capacity is induced by loss of or damage to the 
actively cycling CBC compartment. Following injury-induced activation, FSCs 
contribute to repopulation of CBCs, as well as all intestinal epithelial cell 
lineages.37 Similarly to CBCs, the characterization of this cell population was 
facilitated by marker discovery, described in the subsequent section. 
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1.1.3.5 Historical perspective on facultative stem cells 
Decades of research have generated different models regarding the identity 
of FSCs in the intestinal crypts. Originally termed “+4” cells for their location 
around the +4 position (Figure 1.3) as originally suggested by Potten,17 early FSC 
marker discovery and label-retaining studies indicated a population that was 
mitotically dormant or quiescent and long-lived.37 However, the evidence now 
shows that multiple different crypt cell types can function as FSCs, in that they can 
re-acquire stem cell characteristics and contribute to repair, due to crypt cell 
plasticity described in the subsequent section. FSC function has been defined 
using Cre mouse models that mark different types of cells, including mitotically 
dormant cells, transit-amplifying committed progenitors, and differentiated cells.  
Bmi1 and HopX were amongst the first FSC markers identified, describing a 
cell type functionally distinct from Lgr5-expressing CBCs originally termed “+4 
cells”,6,38 but that we now know labels only a small subset of FSCs originally 
termed “+4 cells.” A member of the Polycomb group gene family that functions in 
chromatin silencing,39 BMI1 has been shown to participate in the self-renewal of 
neuronal, hematopoietic, and leukemic cells.40–42 In the intestine, BMI1 has been 
observed to mark cells at the +4 position (as identified by lineage tracing from 
Bmi1-CreERT2 mice), a location previously noted to contain long-term label-
retaining cells, which were presumed to be stem cells by Potten and others.18,43–45 
Indeed, BMI1 was confirmed to mark a long-lived cell.43 Lineage tracing for the 
progeny of Bmi1-positive cells using a Bmi1-CreERT2 mouse crossed to a 
ROSA26-lacZ reporter strain, revealed minimal lineage tracing in the absence of 
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damage a week after induction of tracing,46 while many confluent lineage stripes 
were observed a week following irradiation-mediated CBC loss.47 Further, single 
isolated Bmi1-positive cells were shown to have organoid forming capacity, giving 
rise to all intestinal epithelial cell types, including CBCs.47 This report also 
suggests that single cell culture of Bmi1-positive cells triggers activation of these 
cells to reconstruct the intestinal epithelium in the form of an organoid. The marker 
HopX shares many similarities with Bmi1, and actually, HopX-positive cells were 
shown to co-stain with Bmi1-expressing cells.38 HOPX is an atypical 
homeodomain-containing protein studied in the heart and neural stem cells.48–50 
Similarly to BMI1, it marks a slow-cycling quiescent label-retaining cells at the +4 
position capable of lineage tracing and giving rise to CBCs following irradiation-
induced CBC loss.38,51 Isolated HopX-positive cells were also shown to have 
organoid forming activity.38 These studies led to the theory that FCSs and CBCs 
have a hierarchical relationship, with FCSs set aside to replenish the active CBC 
stem cell pool with injury. 
This view has been challenged more recently by many studies that 
identified additional markers of FSCs by observation of enhanced lineage tracing 
from cell-specific Cre mouse models following intestinal damage. Among others, 
they include mTert, Krt19, Lrig1, Sox9, Alpi1, Dckl1, Neurog3, and Lyz (Figure 1.2 
and 1.4),12,38,52–56 markers that describe committed progenitors as well as 
differentiated cells within the crypts, thus challenging the hierarchical stem cell 
view first developed from the studies of Bmi1- and HopX-positive FSCs. This is 
discussed in more detail in the next section. 
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1.1.3.6 Crypt cell plasticity 
As alluded to above in describing the various cell types encompassed by 
the term FSC, the intestinal crypt demonstrates incredible plasticity (Figure 1.3 
and 1.4). In addition to the originally described quiescent FSCs, FSC activity, the 
ability to mobilize to repopulate the damaged intestinal epithelium, has been 
reported in committed epithelial progenitor cell types.12,53 Alpi-positive enterocyte 
progenitors have been shown to have the capacity to dedifferentiate and to 
become multipotent and self-renewing following targeted ablation of Lgr5-positive 
CBCs.53 The Notch ligand-expressing, Dll1-positive secretory progenitors have 
also demonstrated the capacity to repopulate all mature intestinal epithelial cell 
types following damage, and to form organoids,12 although they have yet to be 
fully characterized. 
These studies reveal that FSCs are a highly heterogeneous population 
(Figure 1.3 and 1.4), encompassing quiescent cells in the lower mid-crypt region 
(Bmi1, HopX, mTert) as well as fated progenitors in the middle to upper crypt 
region (Alpi, Dll1), revealing the incredible plasticity of the intestinal 
crypt.6,12,38,43,52,53,57 Further indication of the latter point is the reported ability of 
mature intestinal epithelial cells residing in the crypt, Paneth and enteroendocrine 
cells, to de-differentiate and adopt ISC-like characteristics to respond to 
damage.58–60 The Paneth cell is described in more detail in the next section. 
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1.1.3.7 Niche cells 
 Defining the specific components of the ISC regulatory environment or 
niche, has been the aim of myriad research laboratories over the years, including 
describing the signaling pathways involved (including HH, BMP and WNT 
signaling, described in subsequent sections), as well the specific cellular 
components (epithelial and mesenchymal). Niche cells support ISC function by 
stimulating regulatory pathway activity in ISCs via secretion of niche factors or cell-
to-cell contact signaling.  
For close to a decade, the putative niche cell has been proposed to be the 
Paneth cell.61 First identified in 1872 by Dr. Schwalbe and subsequently 
extensively described by Dr. Paneth,62,63 Paneth cells are pyramid-shaped cells 
with basally-situated nuclei and strikingly large apically-situated granules filled with 
antimicrobial peptides and other immune regulating molecules (including pro-
inflammatory cytokines).64 In the mouse, emergence of these cells occurs 7 to 30 
days after birth, together with the formation of crypts.65–67 Paneth cells are mature 
intestinal epithelial cells, yet they escape the upward cellular migration 
concomitant to epithelial cell differentiation, by flowing downward to intercalate 
between CBCs. In addition to being the only mature intestinal cells known to reside 
at the base of the crypts, and their close juxtaposition with CBCs, Paneth cells are 
also unique for being long-lived. While other mature epithelial cells on the villi 
turnover approximately every 5 days, the lifespan of Paneth cells has been 
reported to be about 30 days.64  
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The close juxtaposition of Paneth cells to CBCs first hinted at their potential 
niche-supporting function. The Gordon laboratory, however, rejected this 
hypothesis when first investigating this question in a Paneth cell ablation mouse 
model, where a mouse genetic approach expressed attenuated diphtheria toxin A 
fragment from the Paneth cell-specific cryptdin-2 gene (CR2) locus.68 They came 
to the conclusion that Paneth cells did not secrete essential niche factors because 
they did not detect deleterious effects to crypt cell proliferation in their mouse 
model of Paneth cell ablation.68 However, significant technological advancements 
since that time have allowed reassessment of this conclusion, albeit with 
controversial outcomes. Two mouse genetic studies published in 2012 agreed with 
the Gordon study. Both studies induced deletion of the transcription factor ATOH1, 
essential to secretory cell differentiation, which led to complete loss of Paneth 
cells, as well as other secretory cell types.69,70 On the other hand, other studies 
using the Gordon mouse model of Paneth cell ablation, as well as a new model 
involving deleting the transcription factor SOX9, saw a loss of CBCs concomitant 
with Paneth cell ablation.61,71–74 Further, a significant study found that isolated 
CBCs infrequently form intestinal organoids; however, organoid formation was 
significantly enhanced when isolated Paneth cells were plated with CBCs.61 These 
studies in favor of a Paneth cell niche role are supported by the finding that Paneth 
cells express several niche factors, such as epidermal growth factor (Egf), Wnt3, 
and Notch ligands.61 The Sabatini lab also suggested that Paneth cells can serve 
as nutritional sensors to modulate CBC function via the activity of mTOR complex 
1 (mTORC1).75 This compilation of work suggests that Paneth cells serve a niche-
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supporting function, but their loss (or their absence in early life) is tolerated by 
unknown mechanisms. A potential explanation that has yet to be investigated is 
that in the absence of Paneth cells, CBCs are reprogrammed to function more like 
immature stem cells, to a state where they rely on niche factors signals coming 
from non-Paneth sources. This is likely to be a key aspect of cellular plasticity in 
the intestinal crypt. 
In recent years, the existence of a non-epithelial niche cell has been an 
intriguing avenue of investigation. The controversy of crypts tolerating Paneth cell 
loss reported by some studies, combined with Paneth cells being absent from the 
colon and immature postnatal intestine, does hint at other niche-supporting 
sources. Stromal subepithelial populations have been suggested to be one such 
source. These cells in the lamina propria are closely apposed to the crypt base 
and CBCs, and have been believed to support the ISC niche for some time 
(Figure 1.1).76,77 Stromal subepithelial cells are thought to be direct, paracrine 
mediators of various niche signals that regulate stem cells, including WNT 
signaling.76 A 2011 study found that stromal subepithelial cells could support the 
growth of organoids from culture of isolated human intestinal crypts without 
addition of FGF10, WNT3A or even RSPO.78 These data suggested that stromal 
subepithelial cells could supply CBCs with the necessary niche factors for 
intestinal epithelial maintenance.78  
Within the last few years, several studies have come out seeking to identify 
the extra-epithelial source of WNT ligand supporting CBCs.79–81 In 2016, after 
showing that a subset of mesenchymal cells closely apposed to intestinal crypts 
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expressed the winged-helix transcription factor Foxl1, the Kaestner group 
employed mouse models expressing diphtheria toxin receptor under the control of 
a Foxl1 promoter to ablate the Foxl1-positive pericryptal mesenchymal cells.79 This 
cell ablation resulted in a dramatic cessation of epithelial cell proliferation, and a 
loss of epithelial cell WNT signaling.79 The same year, the Basler group globally 
deleted Wntless (Wls), which is required for WNT secretion.80 Mice with ablated 
Wls deletion displayed intestinal crypt loss and a dramatic reduction in expression 
of CBC markers.80 Systemic delivery of WNT3A was able to partially rescue the 
loss of crypts and CBCs, and WNT2B administration in culture rescued the inability 
of Wls organoids to form.80 This group identified WNT2B-secreting cells to be 
predominantly Gli1 or Acta2 positive.80 Two years later, the Kaestner group 
characterized Foxl1-positive mesenchymal cells as subepithelial telocytes, thin, 
sub-epithelial mesenchymal cells with extended cell processes known as 
telopodes.81–83 They found that these cells also express Gli1, suggesting overlap 
between the Kaestner group’s Foxl1-positive telocytes and the Basler’s group 
WNT2b-secreting Gli1 or Acta2 positive subepithelial myofibroblasts.80,81 To test 
the role of WNT ligand expression in Foxl1-positive telocytes, Porcupine (Porcn), 
which is required for WNT secretion, was deleted in Foxl1-CreERT2 mice. Loss of 
WNT secretion from these mesenchymal cells led to a radical reduction in stem 
and progenitor cell proliferation and epithelial WNT pathway signaling.81 These 
studies suggest that Foxl1-positive subepithelial telocytes induce WNT signaling in 
CBCs via secretion of key WNT ligands such as WNT2B. 
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Future research is likely to uncover more niche-supporting cells in the 
intestine, as work from the Shivdasani group suggests.84 They found that 
conditional ablation of WNT ligand secretion, using a Porcn-null mouse strain in 
the intestinal epithelium (using Villin-CreERT2 mice) and from smooth muscle cells, 
including stromal subepithelial cells, (using Myh11-CreERT2 mice) did not disrupt 
intestinal homeostasis.84 The authors suggested another source of WNT ligand is 
at play in the intestinal milieu. This source could include the Kaestner laboratories’ 
Foxl1-positive mesenchymal cells, since the Kaestner group’s characterization 
suggests Foxl1-positive cells are negative for α smooth muscle actin (αSMA; 
encoded by Acta2) and thus would not have been targeted by the Shivdasani 
laboratory’s mouse model. Given these gaps in our understanding, significant 
advances remain to be made to understand the incredible signal transduction 
network that exists in the intestinal stem cell niche, including epithelial cells, 
stromal cells, smooth muscle cells, vasculature, neurons and components of the 
extracellular matrix. Of particular interest to the field is the question of how 
communication between epithelial and mesenchymal cells induces crypt repair 
responses. In the next sections, developmental signaling pathways whose inter- 
and intra-compartmental communication is critical to intestinal regulation, will be 
described.  
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1.1.4 Developmental signaling pathways 
1.1.4.1 Hedgehog Signaling Restricts the Proliferative Zone  
In the intestine, HH signaling is exclusively paracrine. The pathway ligands 
Sonic HH (SHH) and Indian HH (IHH) are secreted from epithelial cells and 
activate downstream signaling through their receptors Patched1 and 2 and 
effectors GLI1, 2, and 3 in the mesenchyme.85–87 GLI2 appears to be the main 
effector of HH signaling in the developing intestine.88 At embryonic day 8.5 of 
mouse development (E8.5), Ihh and Shh are expressed in the gut endoderm in 
overlapping patterns,89,90 and by late fetal development, this expression pattern is 
restricted toward the proliferating epithelium of the intervillus zone.91 Mesenchymal 
cell clusters that form just beneath the epithelium at these zones are HH ligand 
responsive and drive villus formation starting at E14.5.92 Mice deficient in SHH or 
IHH die perinatally and exhibit many gastrointestinal defects, including changes in 
enteric nervous system development, loss of smooth muscle, and altered epithelial 
proliferation.93 Similar phenotypes were observed in studies that examined the 
consequences of blocking signaling by treating neonatal mice with a HH 
neutralizing antibody or a pharmacological inhibitor, or by using a genetic mouse 
model that expressed a secreted form of the pan-HH inhibitor HH interacting 
protein (HHIP) from the intestinal epithelium via the Villin promoter (Villin-Hhip 
mice).86,92,94 Phenotypes of loss of HH signaling include increased epithelial 
proliferation and formation of ectopic crypt-like structures, and reduced smooth 
muscle.86,92,94 HH signaling is also important for maintaining intestinal homeostasis 
in the adult. Mice with Cre-activated Hhip expression, or a conditional deletion of 
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Ihh in the intestinal epithelium showed expansion of the proliferative zone and 
progressive loss of smooth muscle.95–97 Thus, HH signaling is critical to intestinal 
development and homeostasis, controlling proliferative capacity and smooth 
muscle differentiation.  
In addition to its role in restricting epithelial cell proliferation and maintaining 
stromal cell differentiation, HH signaling has also been implicated in the inhibition 
of ISC self-renewal and differentiation, likely through suppressing WNT 
signaling.95–100 Thus, the combined effect of HH signaling is important for villus 
formation, smooth muscle proliferation and differentiation, and restriction of the 
epithelial proliferative compartment in perinatal and adult intestine. Furthermore, 
since HH signaling mutants display epithelial phenotypes, a feedback mechanism 
that can signal from the mesenchyme back to the epithelium in response to HH 
signaling must exist. Pertinently, the Foxl1-positive putative mesenchymal niche 
cell described in the previous section has been shown to be HH-responsive to 
affect WNT and BMP signaling, pathways described in the two subsequent 
sections.81 If HH signaling regulates Foxl1-positive telocyte control of the intestinal 
niche, and how, remains to be uncovered, and will be critical to understand niche 
regulation. 
1.1.4.2 BMP Signaling Restricts Crypt Number  
Active BMP signaling is transduced through the cytoplasm to the nucleus by 
the SMAD transcription factors following BMP ligand-mediated receptor activation. 
BMP signaling in the intestine is bidirectional with genes encoding multiple BMP 
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ligands, receptors, and SMAD transcription factors, and BMP inhibitors being 
expressed in both the epithelium and mesenchyme.101,102 Mesenchymal cells at 
intervillus and intercryptal regions have been shown to secrete BMP2 and BMP4 
ligands.89,103,104 In the epithelium, it appears that the most active BMP signaling, as 
determined by the presence of nuclear phospho-SMAD1, 5, and 8 transcription 
factors, occurs in the villus rather than the crypts.95,103 This is likely due to 
inhibition of BMP signaling in the crypt region resulting from enriched expression of 
BMP inhibitors, including Noggin and Gremlin1 expressed in subcryptal 
mesenchymal cells.101,105,106 The pattern of BMP ligand and inhibitor expression 
leads to the formation of an increasing BMP activity gradient along the crypt-villus 
axis.105,106 Pericryptal Foxl1-expressing cells in the mesenchyme, proposed to 
signal to the intestinal crypts, have been shown to express multiple BMP signaling 
components (e.g. Bmp4-7, Gremlin1, Bmpr1a), indicating this pathway is likely to 
be critical in the niche supporting role of these cells and deserving of additional 
investigation.81 
A study employed a transgenic mouse in which the villin promoter was used 
to drive intestinal epithelial expression of the BMP inhibitor Xenopus noggin (X-
noggin). These mice presented with ectopic crypt structures in 3-month-old mice 
and adenomatous foci development in older mice.107 This suggested that BMP 
signaling normally functions to limit crypt number. These types of epithelial 
changes are reminiscent of a rare, autosomal-dominant gastrointestinal syndrome 
called familial juvenile polyposis (FJP), which is characterized by development of 
hamartomatous polyps throughout the gut. Accordingly, mutations in SMAD4 and 
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BMPR1A have been identified in FJP patients,108–110 consistent with BMP signaling 
alterations in the pathogenesis of this syndrome. Indeed, a second mouse model 
in which the Bmpr1a receptor was conditionally deleted using the interferon-
inducible Mx1-Cre (induces expression in all interferon-responsive cells resulting in 
varied recombination in different tissues) also exhibited polyp formation.105 In 
contrast, loss of Bmpr1a in the epithelium only showed increased proliferation and 
a defect in secretory cell differentiation, but not formation of ectopic crypts or 
polyps,111,112 suggesting that epithelial BMP signaling is not sufficient for driving 
FJP. Potential candidates that have also been implicated in FJP include WNT 
signaling, described in the next section, and PTEN, a tumor suppressor 
antagonistic to mTORC1 signaling, a pathway described in a later section whose 
role in the intestine has yet to be fully characterized.113   
In agreement with BMP signaling not being the sole driver of FJP 
hyperproliferation, depleting BMP signaling exclusively in pericryptal fibroblasts 
resulted in increased mesenchymal proliferation, development of a reactive 
stroma, and increased polyposis formation at 1 year.112 These reports suggest that 
mesenchymal BMP signaling is primarily responsible for suppressing epithelial 
hyperproliferation. It is thought that epithelial BMP signaling limits epithelial stem 
cell proliferation via restriction of ISC self-renewal.105,111,114–117 There is some 
evidence that BMP represses ISC self-renewal via WNT pathway suppression;105 
however, this is uncertain as some studies showed no change in WNT signaling 
after repression of epithelial BMP signaling,111 or observed that BMP regulation 
was WNT-independent.116  
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It is likely that BMP signaling is a key factor mediating HH effects on 
epithelial proliferation and villus morphogenesis. BMP4 and BMP7 are positively 
regulated by HH signaling,96 and the ectopic crypt phenotypes in the HH loss-of-
function Villin-Hhip, and the BMP loss-of-function X-noggin mice are 
similar.86,107,118,119 During development, HH-responsive mesenchymal clusters 
(closely apposed collection of mesenchymal cells that drive villus emergence) 
express BMP ligands in addition to other yet uncharacterized signaling proteins.120 
Manipulating BMP signaling via BMP antagonist or exogenous BMP ligand 
administration, and conditional Bmpr1a receptor deletion in HH-responsive 
mesenchymal cells resulted in altered formation of mesenchymal clusters, and 
hence, diminished villus size and emergence.121 Together these studies 
demonstrate an important role for BMP in regulating intestinal development and 
ISC homeostasis, likely via regulation of the niche. 
1.1.4.3 WNT Signaling Promotes Proliferation  
In opposition to the anti-proliferative effects of the HH and BMP signaling 
pathways, canonical WNT signaling is a key pathway promoting proliferation in the 
intestinal crypts. Overactive WNT signaling, such as that seen in the APCmin 
mouse model, leads to enlarged crypts with enhanced proliferation and 
progression to adenocarcinoma.122,123 Conversely, blocking WNT signaling by 
forced expression of the secreted WNT inhibitor Dickopff (Dkk1), or inactivation of 
the critical WNT pathway components T-cell-specific transcription factor 4 (TCF4), 
the signaling effector β-catenin, the TCF4 target gene Myc, or deletion of Rspo/Lgr 
complex components, leads to decreased proliferation and crypt loss.124–129 There 
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is also evidence that non-canonical WNT signaling through WNT5A is important 
for aspects of gastrointestinal development and regeneration and inflammation;130–
135 however, canonical WNT signaling through β-catenin and TCF4 appears to be 
the most important for maintaining survival and promoting proliferation of 
ISCs.124,125 Accordingly, downstream targets of TCF4-mediated WNT signaling 
include pro-proliferation genes such as c-Myc,24,136 and Ccnd1,137,138 as well as 
stem cell markers Lgr5 and Ascl2.18,23,24,31 
Numerous WNT ligands, receptors, and co-receptors are expressed in the 
intestine, with ligands produced in different epithelial cell populations as well as in 
pericryptal mesenchymal cells.139 The key cellular source and identification of 
specific WNTs functioning as ISC niche factors have been an area of active 
investigation. Global ablation of WNT ligand secretion by pharmacologic inhibition 
of PORCN led to reduced ISC numbers and blocked proliferation and 
regeneration.84,140 Surprisingly, ablation of WNT ligand secretion in the epithelium 
via genetic deletion of Porcn did not disrupt intestinal homeostasis and 
regeneration, 84,140 demonstrating, as suggested in a previous section, that 
epithelial cells, such as Paneth cells, are not the key niche cell source of WNTs. 
Moreover, Porcn deletion in Myh11-positive subepithelial myofibroblasts did not 
affect intestinal homeostasis and regeneration.84 However, pericryptal Myh11-
negative Foxl1-positive telocytes have been shown to be a critical source of WNT 
signaling by their secretion of WNT ligands, including WNT2b, WNT5a, and 
RSPO3 among others.81 Conditional genetic ablation of Porcn in these cells 
ablated WNT signaling in intestinal crypts, depleted stem and progenitor cell 
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proliferation and impaired intestinal epithelial regeneration.81 This data suggests 
Foxl1-positive telocytes may be the most important providers of WNT ligand for 
CBC WNT signaling. 
In addition to regulating stem and progenitor cells, WNT plays a role in cell 
fate determination in the intestine, with WNT target genes Sox9 and EphB2/ 
EphB3 mediating the differentiation of Paneth cells as well as their retention in the 
crypt base.73,74,127,128,141–143  
1.2 Notch Signaling in the Intestine  
1.2.1 Introduction to Notch signaling in the intestine 
The Notch pathway is an evolutionarily conserved signaling pathway 
present in all metazoans that influences a wide range of developmental and 
physiological processes, including the maintenance of self-renewing adult cells 
and tissues. Since Notch is a critical regulator of proliferation and differentiation in 
both development and tissue homeostasis (Figure 1.5), it is not surprising that 
dysregulation of Notch activity or mutations within the Notch signaling pathway 
have been linked with inherited human disorders, as well as cancer.144–148 First 
named after a Drosophila partial loss-of-function mutation that resulted in “irregular 
notches” in the wing margin,149,150 the Notch pathway has been the focus of 
numerous studies in worms, flies, and mammals.151–153 Canonical Notch signaling 
mediates direct cell-to-cell communication to establish differential cell processes in 
neighboring cells (Figure 1.6). Activation of the Notch pathway involves direct 
physical contact between cells expressing membrane-bound ligands (signal 
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sending) and cells expressing Notch receptors (signal receiving). Ligand-binding 
activates sequential proteolytic processing of the Notch receptor to release the 
Notch receptor intracellular domain (NICD), which subsequently travels to the 
nucleus to activate the transcription of specific target genes (e.g. Hes1). Thus, 
Notch signaling induces differential gene expression programs in neighboring 
cells. Signaling events are normally transient, with rapid degradation of NICD 
limiting the duration of the response. Responses are determined by the cellular 
context of the signaling, with NICD-targeting specific effector genes to transduce 
tissue-specific biological responses.  
The Notch pathway therefore represents a unique mechanism for short-
range cellular communication between juxtaposed cells. Developmental studies, 
particularly in invertebrates, have shown that this short-range signaling can 
function in distinct ways to regulate varied and often divergent responses through 
effects on cell specification, proliferation, apoptosis, differentiation, and tissue 
patterning.153–155 For example, Notch signaling is involved in the process of lateral 
inhibition in which subtle differences in Notch signaling between two equivalent 
progenitor cells are transcriptionally amplified such that a bias in productive Notch 
signaling occurs between each cell. This unequal priming of Notch signaling leads 
to the establishment of neighboring cells as either signal-sending or signal-
receiving to pattern the developing tissue. Notch signaling can also occur between 
two distinct cell populations to establish boundary or inductive cell fate interactions 
associated with tissue patterning. Moreover, Notch signaling can control binary cell 
fate decisions between two daughter cells that are dependent on asymmetrical 
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inheritance of Notch regulatory components. Lastly, Notch signaling has been 
implicated in stem cell maintenance and self-renewal through cellular interactions 
between stem cells and juxtaposed niche cells. In many cases of complex tissue 
and organ formation, these different modes of Notch signaling are used iteratively 
or in a combinatorial manner to generate complicated differentiation programs and 
outcomes (Figure 1.5).151–153 Importantly, Notch signaling does not act alone in 
these events, and invariably the Notch pathway interacts or cross-talks with other 
key signaling pathways, including the HH, BMP and WNT signaling pathways 
detailed in the previous sections (and also JAK/STAT, RTK, TGFβ) to establish 
functional and complex signaling networks required for development and tissue 
homeostasis.156–158 Several excellent reviews on canonical Notch signaling have 
been published and should be consulted for additional detail beyond the scope of 
my thesis work.151–153,156,158–161 Not surprisingly, Notch signaling has been shown 
to play a critical role in gastrointestinal tissues. This section summarizes the 
current understanding of canonical Notch signaling mechanisms, and highlights 
the important role that Notch plays in the intestinal epithelium to regulate stem cell 
self-renewal, progenitor cell proliferation, and cell fate determination. 
1.2.2 Features of Notch signaling in the intestine 
All of the Notch ligands (Dll1, Dll3, Dll4, Jag1, and Jag2) and receptors 
(Notch1, 2, 3, 4) are expressed in the mouse gut during early development (E13.5) 
through adulthood with the exception of Dll3, whose expression recedes after early 
development.162,163 Based on mRNA expression patterns, the Notch ligands Dll1, 
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Dll4, and/or Jag1 and receptors Notch1 and Notch2 were thought to be the most 
likely mediators of epithelial Notch signaling in the adult intestine.163 It has not 
been fully determined which intestinal cell populations express specific ligands and 
receptors. It is likely that different cellular targets are involved with distinct aspects 
of Notch regulation, including stem cell maintenance, progenitor cell proliferation, 
cell fate specification, and possibly cell maturation. Identification of signal-receiving 
cells by immunostaining for NICD or HES1 shows positive labeling in several 
epithelial cells in the crypts, suggesting that Notch signaling is primarily active in 
both stem and progenitor cells.164–166 However, other than CBC stem cells, the 
cellular identity of NICD- and HES1-positive cells have not yet been definitively 
established. Although Hes1 mRNA appears to be predominantly localized to the 
crypts,165 two reports have also shown nuclear HES1 protein expression in villus 
enterocytes of the developing intestine.164,167 Finally, NICD was also observed in 
scattered goblet cells in one report.168 Thus, Notch signaling may also be active in 
mature cells in the villus as well as progenitor cells. Further, although the focus of 
this chapter is on epithelial Notch signaling, it is worthwhile to note that Notch 
signaling components are also expressed in the intestinal mesenchyme,163 where 
they are important for the development of the enteric nervous, vasculature, and 
lymphatic systems,169–172 and likely play a role in inflammatory cell function in the 
gut.173,174  
  
 
26 
1.2.3 Intestinal Phenotypes of Notch Mutants  
Experimental disruption or activation of Notch signaling in mouse has a 
profound effect on the intestinal epithelium, resulting in changes in proliferation, 
cellular differentiation, and cell fate specification (Table 1.1). Collectively, these 
studies have demonstrated that Notch signaling is essential for intestinal epithelial 
cell proliferation, with a pronounced reduction in dividing cells observed upon 
Notch inhibition. Conversely, experimental models with constitutive activation of 
Notch signaling exhibit increased proliferation, although, compared to Notch 
inhibition, fewer studies have explored the effects of Notch activation. In addition to 
its important role in maintaining progenitor cell proliferation, Notch appears to be 
the key pathway regulating a binary cell fate decision directing epithelial cell 
differentiation, with Notch signaling inhibiting secretory cell fate through regulation 
of the critical transcriptional factors HES1 (and perhaps other HES family 
members) and ATOH1 (see Figure 1.5) to allow absorptive enterocyte 
differentiation. In most instances, complete disruption of Notch signaling in the 
intestine results in morbidity due to the extreme cellular remodeling that affects 
intestinal function, including barrier function. Thus, many of the mutant mice with 
Notch pathway alterations have been studied at perinatal stages. Analysis in 
adults is limited to short time periods following multiple days of Notch inhibition (~5 
days) due to the rapidity of cellular remodeling in the intestine, with significant 
morbidity, including death, commonly observed with Notch pathway inhibition. In 
some instances, adult viability can be maintained in genetic mouse studies through 
the use of mosaic Cre recombinase drivers to effect genetic changes in only a 
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fraction of the crypts. Intestinal effects over time following acute Notch inhibition 
have yet to be characterized. 
1.2.4 Mutations in Essential Notch Signaling Components  
Complete disruption of Notch signaling in the mouse intestinal epithelium by 
conditional knockout of the essential DNA-binding protein RBP-Jκ resulted in loss 
of proliferating cells and increased goblet cell number.175 This was also observed 
with intestine-specific activation of a dominant-negative form of the Notch 
transcriptional coactivator MAML.176 Conversely, constitutive activation of the 
Notch pathway using NICD transgenic mice, resulted in expansion of the 
proliferative zone and loss of secretory cells.177,178 Together, these genetic mouse 
models demonstrated that Notch signaling normally acts to promote proliferation 
and inhibit secretory cell differentiation in the intestinal epithelium (Table 1.1). 
Moreover, Notch signaling has been determined to be essential for maintenance of 
CBCs, with rapid stem cell loss observed after global Notch inhibition with γ-
secretase inhibitor treatment.35  
The Notch receptors Notch1 and Notch2 are both expressed in the crypt 
epithelium and were confirmed to be the key signaling receptors using mice 
genetically engineered with dual receptor deletion in the intestinal 
epithelium.163,165,179 Deletion of both receptors induced a phenotype similar to the 
intestine-specific RBP-Jκ knock-out mouse, suggesting that these receptors 
function redundantly, and together they likely transmit all of the epithelial Notch 
signal.165,179 Similarly, a study that used neutralizing antibodies specific for 
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NOTCH1 or NOTCH2 receptors showed that simultaneous treatment with both 
receptor antibodies induced intestinal epithelial cell phenotypes similar to the 
double receptor-deficient genetic model and to global Notch inhibition with γ-
secretase inhibitor.35,165 Individual Notch1 receptor deletion or blockade showed 
moderate goblet cell hyperplasia, but normal goblet cell numbers with Notch2 loss 
or blockade, suggesting that NOTCH1 is predominant for cell fate determination.179 
Lineage tracing studies confirmed active NOTCH1 receptor signaling in CBC stem 
cells,168 and Notch1 deletion resulted in reduced stem cell number and decreased 
expression of the stem cell marker Olfm4.179 Thus, NOTCH1 appears to be the 
primary receptor regulating ISC function, and NOTCH1 and NOTCH2 receptors 
together regulate epithelial cell proliferation, cell fate determination, and post-injury 
regeneration.  
In situ hybridization studies demonstrated that the Notch ligands Dll1, Dll4, 
and Jag1 are expressed in the crypt epithelium of the mouse intestine.163 In vivo 
function was assessed in mice with inducible, intestinal epithelial-specific deletion 
of Dll1, Dll4, and/or Jag1.180 Deletion of Jag1 or Dll4 had no apparent effect, while 
deletion of Dll1 resulted in a moderate increase in goblet cells, without affecting 
progenitor cell proliferation.180 Combined deletion of Dll1 and Dll4 showed marked 
goblet cell hyperplasia with reduced cell proliferation, and loss of stem cells, a 
phenotype consistent with complete Notch loss-of-function.180 These data 
demonstrate that DLL1 and DLL4 are the key ligands regulating intestinal epithelial 
cell homeostasis. Interestingly, gene expression profiling studies showed that 
Paneth cells contain Dll1 and Dll4 transcripts, suggesting a key signaling 
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relationship between Paneth cells and stem cells, with Paneth cells presenting 
Notch ligands DLL1 and DLL4 to adjacent stem cells expressing NOTCH1.61,181 
However, analysis of genetic mouse models with Paneth cell ablation showed that 
these cells are not required for stem cell maintenance, suggesting alternate or 
additional cellular sources of Notch ligand are possible.68,182,183 Indeed, Dll1 is also 
expressed in secretory progenitor cells, which could be positioned next to stem 
cells when Paneth cells are lost.12,184 The identity of Notch presenting cells and 
their roles in supporting the niche are still outstanding questions in the field. 
The ADAM proteases perform the first essential cleavage of the Notch 
receptor to activate signaling (Figure 1.6). Both ADAM10 and ADAM17 have been 
shown to cleave the Notch receptors in vitro;185–187 however, studies with genetic 
mouse models have determined that ADAM10 is the key protease performing this 
function in vivo. Mice with deletion of Adam10 in the intestinal epithelium exhibited 
a Notch inhibition phenotype, with loss of proliferation and increased secretory cell 
differentiation.176 In contrast, mice with intestine-specific deletion of Adam17 had 
apparently normal intestines.188  
The γ-secretase complex has the ability to cleave more than 60 types of 
transmembrane proteins, including the Notch receptor, Notch ligands DLL1 and 
JAG2, ERBB4, CD44, and E-cadherin.189–193 There does not appear to be a 
specific consensus sequence to determine whether a protein is cleaved by γ-
secretase; instead, the main prerequisite for a potential substrate appears to be 
prior removal of the ectodomain by sheddases, such as removal of the Notch 
receptor ectodomain by ADAM10.189 Rodents treated with the γ-secretase inhibitor 
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benzodiazepine, dibenzazepine (DBZ) or LY-411,575 exhibited intestinal goblet 
cell hyperplasia and epithelial degeneration reminiscent of the phenotype 
observed in Notch disruption models.35,175,194,195 The similarity of the phenotypes 
induced by γ-secretase treatment and by complete Notch disruption through 
genetic models demonstrates that Notch is the dominant γ-secretase substrate in 
the intestine.  
The Hes genes are classic transcriptional targets of canonical Notch 
signaling. The HES proteins are basic helix-loop-helix transcription factors that 
primarily function as transcriptional repressors.196 Multiple Hes genes are 
expressed in the intestine, including Hes1, Hes3, Hes5, Hes6, and Hes7.163,164,175 
HES1-deficient embryos exhibited intestinal phenotypes similar to complete Notch 
disruption models; however, the phenotype of HES1-deficient mice was not as 
severe as complete Notch loss-of-function mutants, and an effect on proliferation 
was not observed.164,197 A more complete loss-of-function phenotype was 
observed after combined inactivation of HES1, HES3, and HES5, with reduced cell 
proliferation and increased secretory cell formation, suggesting that these three 
Notch effectors cooperatively regulate intestinal homeostasis.197 A separate study 
of HES1-deficient embryos reported precocious differentiation of Paneth cells and 
increased expression of Paneth cell genes.198 Therefore, Notch signaling through 
HES1 may also play an important regulatory role in cellular maturation as well as 
differentiation.  
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1.2.5 Notch Signaling and Intestinal Stem and Progenitor 
Cells 
Notch signaling regulates several distinct processes in the intestine, 
including stem cell maintenance, progenitor cell proliferation, cell fate specification, 
and possibly cell maturation. Since mutations affecting Notch signaling result in 
altered proliferation, it is reasonable to hypothesize that stem or progenitor cells 
directly respond to Notch signals. Advances in stem cell research have brought 
renewed vigor into identification and characterization of ISC populations. Many 
new intestinal ISC markers have been identified, and methods for in vitro culture of 
ISCs have been developed, allowing for more detailed and mechanistic studies of 
these cells.116,199 Currently, there is continued debate about the identity of ISCs 
with evidence supporting the presence of both facultative and active stem cell 
populations, as described in previous sections (Figure 1.2 and 1.3). Notch 
signaling in active ISCs was first demonstrated by a lineage tracing experiment 
that marked a long-lived stem cell capable of undergoing sequential Notch 
processing and NICD production (Figure 1.5).168 Combined with the discovery that 
expression of the CBC stem cell marker Olfm4 is affected by Notch signaling,35 
and the numerous studies characterizing Notch gain-of-function and loss-of-
function, these reports demonstrate an essential role of Notch signaling in 
maintaining the ISC pool.200,201 They also show that Notch acts iteratively within 
TA cells to regulate cell fate specification.200,201 Further studies in this area are 
necessary to tease out which intestinal progenitor cells carry out distinct Notch-
regulated functions.  
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1.3. Intestinal Regeneration 
1.3.1 Methods of intestinal injury 
With the intestinal epithelium turning over approximately every 5 days, the 
intestine is amongst the most regenerative tissues in the human body. As such, a 
wealth of research has been aimed at understanding the remarkable regenerative 
capacity of this organ with the hope of using this knowledge to mitigate debilitating 
intestinal afflictions. Mice are the main animal model employed to study the 
intestinal regenerative response due to the wealth of genetic and technological 
tools available. Many methods of inducing a regenerative response in murine 
models have been employed, including: small bowel resection (SBR), 
chemotherapeutic drug administration, ionizing radiation and genetic ablation of 
CBCs. All three of these injury models stimulate a significant regenerative 
response.  
SBR is a well-established surgical procedure in which part, or the entirety of 
the small bowel, or intestine, is removed.202,203 Dynamic intestinal adaption 
subsequently ensues, manifesting as crypt cell hyperproliferation, and longer 
crypts and villi, resulting in a expanded mucosal surface area.204 How the post-
SBR environment in the remaining intestine and/or surrounding tissue adapts is an 
interesting avenue of study, especially given the model’s therapeutic relevance. 
Albeit the method of choice to study intestinal adaptation, SBR may not be the 
ideal model for studying the process of intestinal regeneration. The insult does not 
target stem cells, instead rousing a body-wide compensatory response to stimulate 
  
 
33 
mucosal growth in the undisturbed intestine. On the other hand, chemotherapy 
drugs (including 5-flurouracil, or 5-FU, and doxorubicin, among others) and 
ionizing radiation are DNA damage agents that target the proliferative 
stem/progenitor cell compartment.205 These models are more commonly used to 
study mechanisms of crypt regeneration.   
ISCs are quite sensitive to DNA damage. Ionizing, or γ-irradiation doses as 
low as 1 Gy can induce ISC apoptosis (Figure 1.3 and 1.7).205 While it is usually 
believed that a cell’s sensitivity to ionizing radiation is correlated with its 
proliferative status,206 in the intestinal crypt there has been some debate regarding 
this topic.205 Recently, the current dogma is that Lgr5-expressing CBCs are 
sensitive to irradiation, especially at high doses, and that FSCs (encompassing 
HopX-, Bmi1-, Dll1-, and Alpi-expressing cells) are more radioresistant.37 These 
nuances in crypt cell radiosensitivity are controversial. Nonetheless, the ablation of 
CBCs with high doses of γ-irradiation (>10 Gy) has been well documented, and is 
the most common method of inducing damage to investigate intestinal epithelial 
regeneration. Administration of 12 Gy γ-irradiation for example, has been shown to 
lead to an 86-99% depletion of CBCs.207  
Another method of ablating CBCs directly is to do so using a genetic mouse 
model containing a CBC-specific diphtheria toxin receptor (e.g. Lgr5-GFP-
DTR).54,208 Administration of diphtheria toxin will specifically target CBCs 
expressing the receptor, inducing rapid CBC death. CBC loss is associated with 
FSC activation to replenish the CBC stem cell population and return to 
homeostasis.54,208 Thus, γ-irradiation and targeted CBC ablation allow analysis of 
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mechanisms of crypt cell reprogramming to replace lost CBCs, mechanisms that 
have yet to be fully elucidated.  
1.3.2 The intestinal regenerative response post-irradiation 
 The damage from high dose γ-irradiation occurs rapidly, with apoptotic cells 
observed at the crypt base as early as 3-6 hours post-irradiation (HPI) (Figure 
1.7).52,208 By 2 days post-irradiation (DPI), studies have demonstrated that Lgr5- 
and Olfm4-expressing CBCs have been lost through apoptosis, and FSCs are 
activating.6,51,52 2 DPI, ~18% of Bmi1-positive FSCs are in S-phase, compared to 
~2% in unirradiated mice,6 a 9-fold increase. Additionally, HOPX-marked FSCs are 
increased 2.5-fold with a 3-fold increase in HOPX-positive cells in S-phase.51 FSC 
mobilization results in expanded lineage tracing by 4 DPI with a 5-fold increase in 
Bmi1 lineage traced cells, and a 9-fold increase in mTert lineage-traced crypts.526 
By 7 DPI, confluent Bmi1 lineage stripes can be seen, Lgr5-positive CBCs are 
returning, and intestinal homeostasis is being re-established.6 FSC generation of 
CBCs is critical to the regenerative response, as demonstrated by the impaired 
regenerative capacity in mice in which Lgr5-positive cells were genetically 
ablated.208 Figure 1.7 provides an illustrative summary of the regenerative 
response post-irradiation based on data compiled from previous studies. This 
response, which can vary slightly based on damage conditions employed, has yet 
to be fully characterized by a single study. 
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1.4 IGF/mTOR Signaling in the Intestine 
1.4.1 Growth factors in the intestine 
The intestine is home to myriad growth factors, polypeptides that bind to 
receptors on the cell surface to direct tissue growth, cellular proliferation and/or 
differentiation. They are produced from different cellular sources with different 
targets, which informs the mode of signaling, including exocrine, autocrine, 
juxtacrine, paracrine and endocrine (Figure 1.8).209 There are five primary 
intestinal growth factor families: epidermal growth factor (EGF), transforming 
growth factor beta (TGF-β), hepatocyte growth factor (HGF), fibroblast growth 
factor (FGF), and insulin-like growth factor (IGF). A summary of these growth 
factor families, and their main ligands and receptors, and intestinal expression 
pattern is found in Table 1.3.209 While all critical to intestinal development, 
homeostasis and repair, these growth factor families have varying importance in 
each of these different processes. The predominant role of TGF-β signaling is 
during intestinal development and in maintaining homeostasis.209 HGF is best 
understood to regulate development and liver regeneration, and FGF signaling is 
most commonly implicated in intestinal homeostasis.209 The most pertinent growth 
factor families to ISC regulation and intestinal regeneration are detailed in the 
following sections, and include EGF and IGF signaling.  
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1.4.2 EGF in the intestine 
 EGF family ligands are integral membrane proteins that signal via binding to 
ErbB receptor tyrosine kinases (RTKs). Receptors to these ligands include EGFR, 
ERBB3 and ERBB4, with ERBB2 capable of transducing signal without ligand 
binding.209 Different ligands bind receptors preferentially and induce 
homodimerization or heterodimerization in different combinations to elicit distinct 
cellular effects, including activation of ERK, MAPK, p38 MAPK, JNK and PI3K 
pathways, among others.209 
EGF has been reported to be important during development,209 and in 
mediating cellular proliferation, intestinal cell shedding, and nutrient and ion 
transport.209 Interestingly, genetic ablation of Egf does not perturb intestinal 
homeostasis,210,211 suggesting ligand family redundancy. However, an important 
role has been reported for this growth factor in regulating ISCs in vivo,55,212 and 
intestinal organoids, whose growth and formation are ISC-driven, require 
EGF.213,214 The role of EGF in ISC regulation could contribute to its predominant 
role in the intestine: mediating repair.  
One theory suggests that barrier breaches resulting from mucosal injury 
would allow luminal EGF to access basolaterally-located EGFR,209 as well as 
EGFR on the surface of infiltrated immune cells, hence promoting such epithelial 
wound repair mechanisms.215,216 This suggests EGF serves as a ‘first responder’ 
to injury. There is also data suggesting significant remodeling in the localization of 
EGF/EGFR production following injury that would allow EGF access to EGFR 
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without barrier dysfunction. It has been reported that Paneth cells61,217 and 
subepithelial myofibroblasts secrete EGF,218 and that intestinal injury results in 
elevated EGF levels, as well as EGFR redistribution to the apical surface of 
enterocytes.219 This evidence suggests there are other mechanisms by which EGF 
can access EGFR to promote signaling in response to intestinal injury.  
These studies were the foundation for the investigations into the functional 
role of EGF in repair. Research has shown that intraperitoneal (IP) EGF injections 
(resulting in EGF accessing basolateral EGFR) are protective to the intestinal 
mucosa following methotrexate injury in rats.220 EGF administration is also 
protective and/or healing in animals subjected to different damage methods 
(ranging from hydrochloric acid exposure in rabbits, and asphyxia and cold stress-
induced necrotizing enterocolitis in rats).221–223 Further, enhanced or depleted EGF 
signaling via employment of gain-of-function or loss-of-function EGFR mouse 
models have reported a protective or sensitizing effect to injury, respectively.224–226 
This in vivo work provides compelling evidence for the functional role of EGF in 
protecting against intestinal injury and/or enhancing repair.. 
1.4.3 IGF in the intestine 
1.4.3.1 IGF signaling 
IGF is synthesized by many cell types in the body. The main source of IGF 
ligands in the GI tract of infants is from breast milk,227–229 while in adults, intestinal 
mesenchymal cells are known to secrete IGF1, which signals to epithelial cells.209 
IGF1 binds IGF receptor 1 (IGFR1) and IGF receptor 2 (IGFR2), which mediates 
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the majority of intestinal effects.230 Ligand binding leads to IGFR1 auto-
phosphorylation, activation of insulin receptor substrate-1 (IRS-1), among other 
substrates (e.g. GI2 which activates ERK/MAPK signaling231), and downstream 
activation of RAS/ERK/MAPK and phosphoinositide 3-kinase (PI3K).232 Figure 1.9 
illustrates this mechanism.  
 IGF signaling is tightly regulated. IGF-binding proteins (IGFBP) 1 through 6 
can modulate IGF function, via transport through the body.233 In the intestine, 
IGFBPs 3 through 6 are expressed in stromal subepithelial populations and the 
lamina propria.234–236  
1.4.3.2 IGF functionality in the intestine 
 IGF signaling affects cell survival, metabolism and growth, directing 
intestinal epithelial proliferation and inhibiting apoptosis.209 The function of this 
growth factor has been mostly parsed out from pathway stimulation studies (e.g. 
via exogenous IGF1 administration), although a few studies have reported on the 
effects of depleting IGF1 signaling. Two studies showed that mice with constitutive 
deficiencies in IGFR1 and IGF1 are significantly smaller postnatally than controls, 
remain small throughout life and are designated as “failing to thrive into 
adulthood.”237,238 Interestingly, intestinal-specific deletion of Igf1r in uninjured mice 
led to no overt phenotype, suggesting another receptor (e.g. IGFR2, insulin 
receptor) can compensate for loss of IGF1 signaling through IGF1R.239–241 
In support of a developmental role for IGF signaling, a study in which pig 
neonates were fed IGF1 found that their small intestine weight was significantly 
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increased, with longer villi.242 In rats, 3 and 14-day daily IGF1 administration 
increased epithelial cell numbers across the crypt-villus axis,243 and led to 
significant growth of the GI tract respectively.244 In agreement, a mouse strain 
engineered to overexpress Igf1 under the control of the widely expressed 
metallothionein I promoter, showed larger small intestines (by length and weight) 
and increased villus height and crypt depth.245 These mice also demonstrated 
increased proliferation and reduced apoptosis at baseline and following irradiation, 
supporting a role of this signaling axis in inhibiting apoptosis and promoting cellular 
proliferation.245  
  Demonstrating a pro-proliferative and anti-apoptotic role for IGF suggests 
that IGF signaling would also be critical for preventing intestinal injury or 
enhancing repair. A 1998 study showed that damage ensuing from DSS-induced 
colitis in rats was partially attenuated by exogenous administration of IGF1.246 
Additional studies in rats have demonstrated that IGF enhances the adaptive 
response to SBR,247–251 and improves recovery from small intestinal transplant.252 
IGF1 administration also improved adaptation in zebrafish that had undergone 
SBR, and stimulated ISC regeneration.253 IGF1 was also able to blunt the small 
intestinal atrophy concomitant with chronic liver disease and sepsis.254,255 Despite 
all of this evidence, little is known about the mechanism by which IGF1 promotes 
intestinal regeneration following damage.  
A few studies have attempted to understand this mechanism, employing a 
rodent irradiation model of intestinal injury. Studies show that exogenous IGF1 
administration promotes crypt regeneration and reduces irradiation-induced 
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apoptosis,245,256,257 suggesting that IGF1 might function to both reduce injury and 
promote repair. A potential mechanism via IGF1 inhibition of pro-apoptotic p53 
target PUMA through the PI3K/AKT pathway has been proposed.256 This is 
thought to occur in CBCs at the crypt base.256 However, another study has 
suggested IGF1 may have differential effects on CBC and FSC populations.257 In 
this report, they found that IGF1 administration to uninjured mice increased 
intestinal epithelial growth, and activated different gene expression signatures in 
CBCs (Sox9-EGFPlow) and FSCs (Sox9-EGFPhigh). Further, IGF1 administration 
led to increased Sox9-EGFPlow CBC cycling and numbers, and Sox9-EGFPhigh 
FSC cycling, but did not yield changes to Sox9-EGFPhigh FSC numbers. Further, in 
vitro IGF1 treatment led to enhanced organoid formation of sorted Sox9-EGFPlow 
CBCs but not Sox9-EGFPhigh FSCs.257 Differential IGF1 regulation of CBCs and 
FSCs warrants further study. These data point to a protective and/or pro-
regenerative role for IGF signaling in the intestinal mucosa via epithelial-
mesenchymal interactions that have yet to be defined.  
1.4.3.3 Pathways engaged by IGF signaling  
 Ras/ERK/MAPK and PI3K/AKT are the two main pathways downstream of 
IGF signaling mediating its effects on cellular regulation (Figure 1.9).231 The IGF-
induced PI3K/AKT signaling axis upstream of mTORC1 signaling will be the focus 
of this section.  
 PI3K/AKT signaling is initiated by IGFR1-phosphorylation of IRS-1, which 
activates PI3K,258 thereby producing phosphatidylinositol (3,4,5) trisphosphate 
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(PIP3) by phosphorylation of phosphatidylinositol (4,5) biphosphate (PI4,5P2) 
(Figure 1.9). These PI3K lipid products serve as docking sites on the plasma 
membrane for proteins that have pleckstrin-homology (PH) domains (e.g. AKT). 
The tumor suppressor protein PTEN is a PIP3 phosphatase, converting PIP3 back 
to PI4,5P2, thus inhibiting downstream PI3K signaling. PIP3 binds the PH domain 
of the best characterized PI3K effector, AKT, thereby recruiting it to the plasma 
membrane and releasing its kinase domain, where it can be phosphorylated at 
T308 and S473 by PDK1 and mTOR complex 2 (mTORC2), respectively. Maximal 
activation of AKT is achieved when both residues are phosphorylated. Many 
additional sites of post-translational modifications have been mapped on AKT, and 
associated with enhanced or attenuated functionality. Kinase inactivation of AKT 
occurs via dephosphorylation of T308 by protein phosphatase 2A, and PH domain 
leucine-rich repeat protein phosphatases (PHLPP) is responsible for S473 
dephosphorylation.259  
Active AKT phosphorylates a range of protein targets, leading to myriad 
downstream effects, including promoting cell survival, proliferation, growth, and 
altering metabolism.258 The three most studied AKT targets include: glycogen 
synthase kinase 3 (GSK3; includes isoforms GSK3α and GSK3β), Forkhead Box 
O (FoxO) transcription factors, and tuberous sclerosis complex 2 (TSC2), a 
negative regulator of mTOR complex 1 (mTORC1) (Figure 1.9).259 
The primary anabolic effect of PI3K/AKT signaling downstream of IGF1, is 
mediated through mTORC1.259 The mTOR protein is a highly conserved 
serine/threonine kinase that nucleates two functionally distinct protein complexes: 
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mTORC1 and mTORC2. The latter was discussed earlier in this section in the 
context of its phosphorylation of AKT to augment its AKT activation. mTORC1 is 
responsible for stimulating processes responsible for cell, tissue and organismal 
growth. AKT is responsible for the inhibitory phosphorylation of TSC2, which is 
part of an inhibitory complex to mTORC1.260 AKT also regulates mTORC1 activity 
through its phosphorylation of proline-rich AKT substrate of 40 kDa (PRAS40), a 
non-essential protein component of mTORC1. AKT phosphorylation of PRAS40 at 
T246, relieves its inhibitory activity towards the complex.260 The exact mechanism 
by which this occurs is unclear, and the role of PRAS40 in this regard warrants 
further study. It remains that TSC inactivation is the dominant method by which 
AKT regulates mTORC1 activity.259  
1.4.3.4 The mTOR signaling network 
The discovery of mTOR signaling was a result of a cascade of discoveries 
originating from the collection of soil samples at Rapa Nui island (also known as 
Easter Island) in 1964, which contained the compound henceforth known as 
rapamycin (clinically known as sirolimus). Much of the mTOR signaling axis has 
been elucidated as a result of pioneering studies investigating the mechanism of 
action of rapamycin.260 
The protein complex mTORC1 is a master regulator of cellular 
homeostasis, controlling the balance between anabolism and catabolism (Figure 
1.10). The complex is made up of three core components: the catalytic subunit 
mTOR, the regulatory protein associated with mTOR (Raptor), and the mammalian 
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lethal with Sec13 protein 8 (mLST8). The function of Raptor is two-fold. It is 
required for the correct subcellular recruitment of mTORC1 to the lysosome for 
subsequent activation, and it binds the TOR signaling (TOS) motif on mTORC1 
substrates to facilitate substrate recruitment to the complex. Meanwhile mLST8 
binds to the mTOR kinase domain to stabilize the kinase activation loop of the 
complex. mTORC1 also contains two inhibitory components, the aforementioned, 
AKT substrate PRAS40, and DEP domain containing mTOR interacting protein 
(DEPTOR). To serve as contrast, mTORC2 contains mTOR and mLST8 similarly 
to mTORC1, however this complex contains rapamycin insensitive companion of 
mTOR (Rictor) in lieu of Raptor (Figure 1.11).260     
Rapamycin functions via formation of a gain-of-function complex with the 
petidyl-prolyl-isomerase FKBP12.261 The rapamycin-FKBP12 complex binds 
mTOR, thereby sterically hindering the catalytic cleft and blocking substrates from 
accessing the catalytic site of mTORC1.262 In contrast, mTORC2 is insensitive to 
acute rapamycin treatment. Interestingly, prolonged treatment can deplete 
mTORC2 signaling, which is suggested to result from rapamycin-bound mTOR 
being unable to incorporate into newly forming mTORC2 complexes.263,264  
Growth factors (e.g. IGF1), amino acids (e.g. leucine), oxygen, stress, and 
energy can all modulate mTORC1 activity, mediating changes to mRNA 
translation, metabolism and protein turnover (Figure 1. 9). To illustrate the 
upstream regulation of mTORC1 warrants describing the convergence of several 
growth factor-stimulated signaling pathways on TSC2 (Figure 1.11 and 1.12).260 
TSC2 is a GAP protein that is part of an inhibitory complex with TSC1 and 
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TBC1D7, known as the TSC complex. It is responsible for converting Rheb-GTP to 
Rheb-GDP.260 Rheb-GTP is essential to mTORC1 activation. Thus the TSC 
complex serves to maintain Rheb in its GDP-bound form, preventing mTORC1 
activation. In addition to growth factor stimulation, amino acid availability also 
controls complex localization via Rag/Ragulator/v-ATPase interaction at the 
lysosomal surface (Figure 1.12). Without growth factors, the TSC complex 
maintains Rheb in a GDP-bound form so that it cannot activate mTORC1.259 In the 
presence of growth factors, growth factor-stimulated kinases (e.g. AKT, ERK) 
inactivate the TSC complex by phosphorylating TSC2, allowing GTP-loaded Rheb 
to activate mTORC1 on the lysosomal surface.260 As mentioned with the case of 
PRAS40, mTORC1 can also be regulated independently of the TSC complex. An 
additional example is that of AMP-activated protein kinase (AMPK), which is 
capable of inhibitive phosphorylation of Raptor, blocking mTORC1 signaling.265  
mTORC1 targets include p70S6 Kinase 1 (S6K1) and eIF4E Binding 
Protein (4EBP), which are involved in regulating protein synthesis (Figure 1.13). 
mTORC1 phosphorylates S6K1 at Thr389, which then allows PDK1 to 
phosphorylate and activate S6K1.260 Activated S6K1 then phosphorylates and 
activates eIF4B, which promotes initiation of mRNA translation.266 It also 
phosphorylates PDCD4, an inhibitor of eIF4B, however rather than being 
activating, phosphorylation targets the substrate for degradation to enhance eIF4B 
activity.267 S6K1 also interacts with SKAR, which deposits S6K1 at the exon 
junction complex during mRNA splicing to enhance translation efficiency of spliced 
mRNAs.268 As for 4EBP, mTORC1 phosphorylation of 4EBP triggers 
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phosphorylated 4EBP dissociation from eIF4E. Unphosphorylated 4EBP normally 
functions to sequester eIF4E to prevent eIF4F complex assembly. eIF4E 
dissociation from the complex allows 5’ cap-dependent mRNA translation to 
proceed. Phosphorylation of these common mTORC1 downstream targets is a 
common method of assessing the status of mTORC1 activity. However, it is worth 
noting that it has been reported that mTORC1 inhibition can lead to inhibition of 
some of its downstream signaling elements and not others, by a mechanism that 
has yet to be characterized.260 The downstream effectors of mTORC1 involved in 
nucleotide and lipid synthesis, glucose metabolism and protein turnover (e.g. 
autophagy) are illustrated in Figure 1.13 and reviewed expertly by Saxton and 
Sabatini.260    
1.4.3.5 mTOR in intestinal pathogenesis 
Although critical to the regulation of many tissues throughout the body, the 
role of mTOR in the intestine has not been fully delineated. The pathway was first 
implicated in intestinal hyperplasia. A 2015 study demonstrated that mTORC1 
activity, specifically 4EBP1-mediated translational elongation, is essential for the 
proliferation of APC-deficient intestinal epithelial cells, a hallmark of early stage 
intestinal cancer.269 A 2007 study found that conditional widespread deletion of 
PTEN, a key node of the PI3K/AKT/mTORC1 inhibitory network, results in 
intestinal polyposis, a precancerous neoplasia that results from increased crypt 
fission stemming from increased ISC and progenitor proliferation.113 Additional 
studies support a role for mTORC1 in intestinal polyp formation,270 and the 
therapeutic potential of inhibiting the pathway to mitigate tumorigenesis of 
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colorectal cancer (e.g. rapamycin).271 These studies suggest mTORC1 plays a 
critical role in tumorigenic proliferation.  
Long-term pharmacologic mTORC1 inhibition via administration of 
rapamycin is well-tolerated by human patients and animal models alike, although it 
has been shown to lead to diarrhea in mice, rats and humans due to Na+/H+ 
exchanger 3 reduction.272 These gross observations suggest that elevated 
mTORC1 activity (above the activity that might remain following rapamycin 
administration) may be dispensable for homeostasis, although studies discussed 
in the subsequent section point to the contrary. Amidst some controversy 
potentially attributable to varying methods of manipulating mTORC1 activity, 
reports agree to a critical role for mTORC1 in regulating ISC function and 
differentiation during homeostasis.  
1.4.3.6 mTOR in intestinal homeostasis 
Although there is some debate on the mechanism of action, several studies 
support a role for mTORC1 in regulation of ISC function. A 2012 study out of the 
Sabatini lab controversially demonstrated via immunostaining for downstream 
mTORC1 target phosphorylated ribosomal protein S6 (p-S6) at S235/236, that 
mTORC1 is active in Paneth cells, but not neighboring CBCs.273 It is worth noting 
that unlike the S240/244 sites, phosphorylation of S6 at the S235/236 sites is not 
specific to mTORC1 signaling.274 mTORC1 activity was suppressed in mice by 
calorie restriction, which increased numbers of CBCs and Paneth cells, increased 
CBC proliferation, reduced transit amplifying progenitor cell proliferation, and 
  
 
47 
increased organoid forming efficiency. The increased CBC and Paneth cell 
numbers were also observed following rapamycin administration. The study 
posited that this effect was due to mTORC1 inhibition in Paneth cells resulting in 
increased bone stromal antigen 1 (Bst1) secretion of the paracrine product cyclic 
ADP ribose (cADPR), which results in increased CBC self-renewal over CBC 
differentiation.75 While some claims from this study were supported by subsequent 
reports, multiple labs have since challenged the claim that mTORC1 activity is 
absent from ISCs.275–277 These multiple labs have however agreed in a role for 
mTORC1 in the intestine. 
In seemingly direct response to the Sabatini lab report,273 Igarashi and 
Guarente showed that indeed, Paneth cells augment CBC function and number via 
cADPR secretion in response to calorie restriction in a mTORC1-dependent 
manner.276 This report did not wholly agree with the Sabatini report however, as it 
demonstrated that mTORC1 was active in CBCs as well as in Paneth cells. They 
however resolved this disagreement with the Sabatini report by showing that CBCs 
were shielded from sensing calorie restriction, observing increased mTORC1 
activity in these cells following reduced calorie intake. They proposed that Paneth 
cell signaling to CBCs mediated the increased mTORC1 activity and increased 
CBC number.276 
In 2013, a study that came out shortly after the Sabatini report that 
employed a Drosophila melanogaster model also supported a role for mTORC1 in 
ISC regulation.278 This study demonstrated that genetic deletion of TSC1 or TSC2, 
or overexpression of Rheb, which all lead to mTORC1 hyperactivity, led to rapid 
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ISC loss, and altered differentiation. Similarly to the Igarashi and Guarente report, 
this group also found that the role of mTORC1 in ISC maintenance is nutritional 
status-independent.278 In further agreement with the importance of mTOR in 
regulating ISC function, albeit disagreeing with previous reports regarding the 
nature of this role,273,279 a group from Cincinnati in 2015 found impaired organoid 
formation from crypts of mice in which they disrupted several of the genes that 
code for the components of mTORC1 and 2 using a Villin-Cre genetic mouse 
model to contain the depletion of mTOR signaling to the intestinal epithelium.280  
In this same 2015 report, the Cincinnati group also reported altered 
differentiation in their mouse models of mTOR depletion, observing reduced 
mature enterocyte marker alkaline phosphatase, reduced goblet cell number and 
size, fewer Paneth cells, and increased enteroendocrine cell numbers in 
responses to mTOR deletion.280 The Evers lab also proposed a role for mTORC1 
in intestinal differentiation, however their conclusions opposed those of the 
Cincinnati lab. The Evers lab employed a genetic mouse model constitutively 
expressing a dominant negative TSC2, resulting in increased mTORC1 activity.281 
They demonstrated that mTORC1 positively regulated Notch signaling to alter cell 
fate specification, observing decreased goblet and Paneth cell differentiation in 
their mTORC1 hyperactivation model.281 
Hence, although the literature agrees to an important role for mTORC1 in 
ISC regulation, also highlighted in the next section pertaining to mTORC1 activity 
in FSCs, further research is necessary to clarify the nature of this role, and to 
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understand how mTORC1 merges its signaling axis with other niche pathways, 
and the role of the pathway in regulating cellular differentiation in the intestine.  
1.4.3.7 mTOR in intestinal regeneration 
The literature proposes a pro-regenerative role for mTORC1 activity, 
involving the pathway in the transition of FSCs to a state capable of contributing to 
intestinal regeneration. The 2015 report from Cincinnati mentioned in the previous 
section, employed mouse models of mTOR depletion in the intestinal epithelium to 
demonstrate impaired organoid formation and cell differentiation at baseline, also 
investigated the role of the pathway post-injury.280 They administered 10 Gy 
irradiation and found mTOR to be critical to intestinal crypt recovery.280 In 
agreement with a pro-regenerative role of mTORC1, a 2017 study found 
rapamycin-treated mice had impaired intestinal adaptation following SBR.204 The 
report also found that TSC1-null mice, with hyperactive mTORC1 signaling, 
demonstrated enhanced adaptation.204  
A few studies have suggested a mechanism of action for the pro-
regenerative effect of mTORC1. The Breault lab at Harvard University published a 
study in 2015 that proposed that mTORC1 signaling could contribute to the 
intestinal regenerative/adaptive response via FSC activation.282 Following extreme 
nutrient deprivation (48h fast), they observed transient PTEN inhibitory 
phosphorylation in mTert-positive “dormant” FSCs, which they showed led to cell 
autonomous activation of mTORC1, and an increase in FSC number.282 They 
subsequently compared fasted FSC activity to the activity of FSCs in mice that had 
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been re-fed following fasting, and observed an enhanced propensity of re-fed 
FSCs to contribute to CBC lineage tracing.282 They also found that FSCs lacking 
PTEN had impaired contribution to intestinal regeneration following irradiation 
damage, and that this effect was PI3K signaling-dependent.282 The authors 
proposed a role for PTEN as a gatekeeper of the fasting/feeding transition in the 
intestine, which is reminiscent of a similar role for the phosphatase in adipose 
tissue.283 They propose that transient PTEN inactivation during fasting, results in 
an mTORC1-mediated change in FSC status from a dormant to a “poised” state 
capable of responding to injury by repopulating the CBC niche, or returning to a 
dormant FSC state.  
This proposed response is similar to that observed in muscle stem cells 
(satellite cells), which are normally mitotically dormant. Rodgers et al. described a 
mTORC1-dependent “Galert” transition state between G0 and G1 stages of the 
satellite cell cycle, in which satellite cells are functionally poised to respond to 
injury, or return to a dormant state.284 Additional research is needed to determine 
the existence of a parallel Galert state in FSCs, however, the Breault lab does 
suggest an FSC PTEN/PI3K/AKT/mTORC1-dependent transition state from 
dormancy in response to injury.  
In agreement, the Lengner lab published a study recently demonstrating the 
cell-autonomous regulation of FSCs by mTORC1 signaling during the regenerative 
response.277 In agreement with the Breault lab, the Lengner study first showed that 
calorie restriction increased FSC number and enhanced regenerative capacity. 
Subsequent data attributed this effect to mTORC1 activity, which was significantly 
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enhanced post-irradiation, and even further enhanced when combined with calorie 
restriction rather than ad libitum feeding. The lab also found that, in the absence of 
injury, mTORC1 inhibition via rapamycin administration reduced FSC lineage 
contribution and organoid formation, while mTORC1 activation, via amino acid 
(leucine) administration, enhanced both. This effect was found to be cell-
autonomous. Interestingly, the lab showed that activation of mTORC1 sensitized 
FSCs to irradiation injury, leading to failed regenerative capacity. These combined 
results were striking, suggesting two FSC states of mTORC1 activity: cycling, 
injury sensitive FSCs with high mTORC1 activity (FSCmTORC1high), and non-cycling, 
injury resistant FSCs with low mTORC1 activity (FSCmTORC1low). Combined data 
from the Breault and Lengner labs suggest that FSCmTORC1high and FSCmTORC1low 
differ in their response to different feeding/fasting conditions, resulting in different 
outcomes on regenerative capacity. Supplementary work is indispensable to 
enhancing our understanding of this mechanism.  
1.5 Dissertation Summary 
  Among the largest and most regenerative organs in the body, the intestine 
has been a source of fascination to scientists for centuries. Incredible leaps have 
been made to understand intestinal cellular composition and homeostasis thanks 
to the advent of genetic mouse models, three-dimensional culture systems and 
cutting edge molecular tools. It is only in the last two decades or so, however, that 
the scientific community has turned its attention to understanding how the cellular 
and molecular components of the intestine’s intricate environmental milieu direct 
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ISC-driven mucosal repair.285 My thesis work aims to advance our understanding 
of the intestinal regenerative response by exposing the roles of key niche factors 
IGF1/mTORC1 and Notch signaling in directing repair.  
 In Chapter II, I characterize the intestinal regenerative response following 
administration of a CBC-ablating dose of γ-irradiation into three phases: damage, 
regeneration and recovery. I go on to demonstrate increased secretion of growth 
factor IGF1, which signals via PI3K/Akt signaling to activate mTORC1. I show 
IGF1/mTORC1 signaling is crucial to the repair of the intestinal epithelium, and 
that mTORC1 activity directs FSC activation to contribute to crypt regeneration. I 
go on to suggest that IGF1 signaling from non-epithelial sources, such as 
pericryptal myofibroblasts or telocytes, stimulates mTORC1 signaling in FSCs, 
mobilizing them for regeneration.  
 In Chapter III, I present a discovery made while characterizing the intestinal 
response of genetic mouse models to damage, going on to advise proper control 
parameters in the scientific community’s usage of intestinal epithelial-specific 
genetic mouse strains in research. I find that mouse strains that express the Cre 
fusion protein CreERT2 in the intestinal epithelial (Villin-CreERT2) and CBC (Olfm4-
CreERT2 and Lgr5-CreERT2) compartments suffer from impaired regenerative 
capacity, and/or depleted organoid forming capacity. I also find that Villin-CreERT2 
mice demonstrate genotoxicity and increased DNA cleavage at cryptic loxP sites. 
Finally, I present experimental designs to minimize CreERT2 toxicity.  
 In my final data chapter, Chapter IV, I introduce a new method of inducing 
intestinal damage: acute pharmacological blockage of Notch signaling. My studies 
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find that administration of one dose of the Notch inhibitor DBZ induces dramatic 
Paneth cell loss, and significantly impairs CBC activity. The ensuing response is 
reminiscent of the regenerative response to irradiation damage, with a 
hyperproliferative surge and rapid return of the Paneth cell compartment. 
Interestingly, we found that Paneth cell regeneration is at least in part fuelled by 
Notch ligand Dll1-expressing cells, whose numbers are dramatically expanded 
following Paneth cell loss, and whom are imparted enhanced organoid forming 
capacity following acute Notch inhibition. HopX-positive FSCs are not found to 
contribute to this rapid return in Paneth cells, indicative of an interesting selectivity 
in the regenerative capacity of FSCs and further pointing to the heterogeneity of 
this population and the remarkable plasticity of the intestinal crypts.  
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1.6 Figures 
 
Figure 1.1 Cellular composition of developing and adult mouse intestine.  
(A) Hematoxylin and eosin stained paraffin sections of developing (embryonic day 18.5) and adult duodenum. 
Scale bars, 100 µm. (B) The major cell populations of the epithelium and mesenchyme are depicted 
schematically. In the adult intestine, stem cells, progenitor cells, and Paneth cells are anchored in the crypts, 
whereas mature enterocytes, goblet cells, endocrine cells, and tuft cells are primarily located on the villi. Stem 
cells give rise to the rapidly proliferating transit-amplifying progenitors located on the lateral sides of the crypts. 
Several crypts surround the base of each villus and provide the mature cell types that migrate onto the villi in 
organized columns where they eventually reach the villus tip in 3–5 days. In contrast to the other mature cell 
types, Paneth cells migrate to the base of the crypts where they reside for approximately 20 days. Crypts and 
Paneth cells do not arise until 2–3 weeks after birth. Proliferating cells in the developing intestine are clustered 
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together in the so-called “intervillus zone.” Cell types not shown include cells of the enteric nervous system 
and hematopoietic cells that are resident and likely regulated by Notch signaling. Follicle-associated 
epithelium, microfold M cells and pericryptal telocytes are also not depicted.286  
 
 
Figure 1.2 Stem cells in the adult small intestine.  
Notch signaling is concentrated in the crypts where there are numerous distinct progenitor cell types, including 
facultative and active stem cells, and transit-amplifying (TA) progenitor cells. The facultative, long-term label-
retaining stem cells are located at the “+4 position,” just above the Paneth cell compartment, and the active 
crypt base columnar (CBC) stem cells reside between the Paneth cells. These two stem cell populations and 
their possible relationship to each other are under extensive investigation. The current molecular markers for 
the active stem cell population include Lgr5, Ascl2, and Olfm4. Numerous progenitor cell populations, 
including secretory and enterocyte progenitors, can act as facultative stem cells, reflecting the considerable 
plasticity observed within the intestinal stem cell/progenitor compartment. The current molecular markers for 
facultative stem populations include Bmi1, mTert, Hopx, Sox9, Dll1, alkaline phosphatase (Api1), keratin 19 
(K19), doublecortin-like kinase 1 (Dclk1), Neurogenin 3 (Neurog3), NK2 homeobox 2 (Nkx2.2), and 
Tryptophan hydroxylase 1 (Tph1).286 
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Figure 1.3 Intestinal crypt plasticity. 
(A) During homeostasis, CBCs give rise to all differentiated intestinal epithelial cell types, via absorptive and 
secretory progenitors that go on to mature to enterocytes, goblet, enteroendocrine and tuft cells. FSCs make 
minimal contribution to homeostatic maintenance. (B) Following irradiation-induced CBC loss however, FSCs 
mediate regeneration. FSCs considered mitotically dormant during homeostasis at the ‘+4’ crypt position 
activate, secretory and absorptive progenitors in the mid-crypt region mobilize and Paneth cells de-
differentiate, all to the aim of regenerating CBCs, and returning to homeostasis. Note that CBC and FSC self-
renewal is excluded from this diagram, as are absorptive M cells, and the de-differentiation potential of 
enteroendocrine cells. Adapted from Figure 1.37 
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Figure 1.4 Facultative intestinal stem cell heterogeneity by marker expression. 
Expression patterns of some of the biomarkers mapped to FSCs, with  original marker specificity (dark blue) 
and expression patterns reported by follow-up studies (light blue). Expression reported by follow-up studies 
(light blue) also corresponds with lower expression than the expression originally reported (dark blue). LRC: 
label-retaining cell, see text for definition. Adapted from Figure 3.37  
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Figure 1.5 Model of intestinal epithelial cell differentiation. 
Notch acts iteratively in stem cell renewal and cell fate specification. Stem cell renewal is regulated by WNT 
and Notch signaling. Upon exiting the stem cell niche, daughter cells are converted into bipotential transit-
amplifying progenitor cells, which then undergo Notch-dependent cell fate specification. Notch signaling drives 
the absorptive cell fate over the default secretory cell fate. Notch signaling activates HES family transcription 
factors, including HES1, that function to inhibit expression of Atoh1 and thus promote enterocyte cell fate. 
RANKL-dependent induction of the transcription factor SpiB within the enterocyte lineage promotes the 
formation of M cells. In contrast, Atoh1 expression induces secretory cell differentiation. Atoh1 is expressed in 
all secretory pro- genitors and is essential for differentiation into goblet, endocrine, and Paneth cells. Atoh1 is 
also expressed in mature cells of these three secretory cell types. The involvement of Atoh1 in tuft cell 
specification is less clear. The identity of the secretory progenitor cell (red dashed box) is not well understood. 
Some studies suggest that there may not be a common secretory progenitor, and instead each secretory 
lineage may have its own committed progenitor cell. Critical transcription factors for lineage differentiation are 
listed in blue. See text for more details.286 
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Figure 1.6 The Notch signaling pathway 
Notch signaling is involved in short-range communication between juxtaposed cells with the signal-sending 
cell expressing ligand (Dll1 and Dll4 in intestinal crypts) and the signal-receiving cell expressing Notch 
receptor (Notch1 and Notch2 in intestinal crypts). Receptor activation is mediated by proteolytic cleavage 
events, but optimal Notch activity is dependent on posttranslational modifications and membrane trafficking of 
Notch receptors and ligands (see Table 1.2). In the signal-receiving cell, newly synthesized Notch receptor is 
O-fucosylated by Pofut1 within the endoplasmic reticulum (ER), which is essential for Notch activity. O-
glucosylation, which is required for efficient Notch proteolysis, also occurs at this time. Upon transit through 
the Golgi, fucose moities are further modified through the addition of N-acetylglucosamine by Fringe O-
glycosyltransferases, which can alter ligand-binding specificity. In the Golgi compartment, the Notch receptor 
is also cleaved within its ectodomain by furin-like proteases (S1 cleavage) to generate a heterodimer held 
together by noncovalent interactions. Mature Notch receptor is then delivered to the plasma membrane. At the 
cell surface, steady-state receptor levels needed for productive Notch signaling are regulated by protein 
interactions (e.g., Numb) and several distinct E3 ubiquitin ligases (e.g., Deltex, Itch/Nedd4), which control 
receptor trafficking, lysosomal degradation, and recycling. In the signal-sending cell, Notch ligand activity is 
enhanced through endocytic trafficking, which is also controlled by E3 ubiquitin ligases (e.g., Neuralized, 
Mindbomb). Upon ligand engagement, the Notch receptor is cleaved by the disintegrin-metalloproteinase 
ADAM10 (S2 cleavage), which releases the Notch receptor ectodomain and produces a membrane-anchored 
NEXT fragment. The released receptor ectodomain is trans-endocytosed into the signal-sending cell. 
Subsequent γ-secretase-dependent cleavage of NEXT (S3/S4 cleavage) releases the bioactive form of the 
Notch receptor, the Notch intracellular domain (NICD). In the absence of signaling, the DNA-binding protein 
RBP-Jκ interacts with corepressors (Co-R) to suppress transcription of Notch target genes. However, upon 
Notch activation, NICD is produced, and it translocates to the nucleus where it interacts with RBP-Jκ, 
mastermind (MAML) and other coactivators (Co-A) to activate transcription of target genes, including hairy and 
enhancer of split 1 (Hes1). NICD signaling is terminated by rapid phosphorylation of its C-terminal PEST 
domain and targeting for proteosomal degradation by E3 ubiquitin ligases such as F-box and WD-40 domain-
containing protein 7 (FBW7). Endocytic trafficking components that either reduce (−) or increase (+) the 
activity of ligands and receptors are noted.286 
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 Figure 1.7 The prototypical intestinal regenerative response to high dose irradiation injury  
A
dm
inistration of a high γ-irradiation dose (>10 G
y) is a dem
onstrated m
ethod of injuring the intestinal epithelium
 that results in a repair response that can be 
categorized into 3 phases: dam
age, regeneration and recovery. W
ithin 3-6 hours post-irradiation (H
P
I), crypt cells undergo m
assive apoptosis (denoted as faded 
cells), w
ith crypt base colum
nar cells (C
B
C
s; green at crypt base) being lost. B
y 48H
P
I, C
B
C
 loss, perhaps through signaling from
 pericryptal m
esenchym
al cells 
(purple flat cells underlying the crypt) and/or P
aneth cells (pink cells intercalated betw
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B
C
s) stim
ulates activation of facultative stem
 cells (FS
C
s; from
 gray 
inactive to orange active around +4 crypt position) to contribute to crypt repair. A
round 4 days post-irradiation (D
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I), a hyperpoliferative surge is noted (expansion 
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id-crypt progenitors in blue), w
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C
 lineage traces. A
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P
I, hom
eostasis is on 
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ay to being re-established, w
ith C
B
C
s having m
ostly returned, and proliferation returning to baseline levels. 
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Figure 1.8 Growth factor signaling routes 
Growth factors are synthesized from numerous different cellular sources, and have myriad targets throughout 
the intestine. There are three main modes by which growth factors signal to surrounding tissues: exocrine, 
autocrine/juxtacrine, paracrine and endocrine signaling. Exogenously derived growth factors, such as those 
produced in breast milk, employ an exocrine signaling route to affect change to target cells. Signaling from 
secreted growth factors acting on their own cell’s receptors, or on a same cell type locally, is referred to as 
autocrine and juxtacrine signaling respectively. Paracrine signaling is employed by growth factors secreted 
from one cell type and acting on another, such as that observed in epithelial to mesenchymal interactions. 
Growth factors produced in one area or organ, and acting on a distant target cell, often travelling via the 
circulatory system, are known as signaling via an endocrine route. Adapted from Figure 3.1 of the Sixth 
Edition of the Physiology of the Gastrointestinal Tract.209 
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Figure 1.9 Insulin-like growth factor 1 (IGF1) signaling 
IGF1 signals via two main signaling axis, the PI3K/AKT and the Ras/ERK/MAPK signaling pathways. In the 
former pathway, upon IGF1 binding, IGFR1 is activated via autophosphorylation, and proceeds to 
phosphorylate and activate IRS. IRS promotes PI3K-mediated PIP3 production, leading to AKT 
phosphorylation by PDK1 at T308 and mTORC2 at S473. In this phosphorylated active form, AKT proceeds to 
inhibit the repressive function of the TSC complex on mTORC1. Activated IGFR1 also phosphorylates SHC, 
which stimulates Raf through the Ras GTPase. Raf triggers a kinase cascade including activation of 
MAPK/ERK. ERK goes on to inhibit TSC complex activity on mTORC1, and phosphorylate and activate 
transcription factor ELK1, promoting expression of target genes.  
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Figure 1.10 mTORC1-dependent catabolic/anabolic balance 
In response to nutrient availability (e.g. amino acids, growth factors, energy), mTORC1 maintains tight control 
over the precarious balance between catabolism and anabolism. Adapted from Figure 4A of Saxton and 
Sabatini review.260 
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Figure 1.11 mTORC1 versus mTORC2 
The mTOR protein is the catalytic subunit of two functionally distinct protein complexes: mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2). In mTORC1, Raptor binds mTOR through its HEAT repeats. In 
mTORC2, Raptor is replaced by Rictor. The subunit DEPTOR binds both Raptor and Rictor to inhibit complex 
activity. mTORC1 has an additional Raptor-bound inhibitory subunit: PRAS40. On the other hand, Rictor in 
mTORC2 is bound by regulatory subunits mSin1, and Protor1/2. Both complexes are also comprised of 
mLST8, which is thought to stabilize complex activity. mTORC1 is rapamycin-sensitive, while mTORC2 is 
not*. Rapamycin binds FKBP12, and together the complex binds the FRB domain of mTOR, leading to 
narrowing of the catalytic cleft and substrate occlusion from the active site. These subunit differences result in 
functional differences between the two complexes. While growth factors promote the activity of both 
complexes, mTORC1 activity is also controlled by amino acid availability, energy, oxygen and stress. 
mTORC1 is involved in anabolic pathways (i.e. protein synthesis, lipid and nucleotide synthesis, glucose 
metabolism and autophagy), and mTORC1 in pro-survival mechanisms via modulation of Akt signaling.  
*Extended rapamycin treatment does affect mTORC2 activity. See text for additional detail. Adapted from 
Figure 1 of Saxton and Sabatini review.260 
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Figure 1.12 Upstream mTORC1 signaling pathways 
mTORC1 is regulated by myriad environmental cues including amino acids, growth factors, energy, stress and 
oxygen. Some of these regulatory axes are illustrated and described here. [AMINO ACIDS] The subcellular 
localization of mTORC1, critical to its activity, is regulated by cytosolic and lysosomal amino acid availability. 
The active RagAGTP/RagCGDP heterodimers tether mTORC1 to the lysosome where it can interact with 
stores of lysosomal membrane-bound Rheb. Active, GTP-bound Rheb activates mTORC1. Lysosomal amino 
acid content works in part through lysosomal v-ATPase interacting with the Ragulator-Rag heterodimers 
complex, serving to enhance to the GEF activity of Ragulator to RagA, and in part through the lysosomal 
amino acid sensor SLC38A9 and its interaction with the Rag-Ragulator-v-ATPase complex. Cytosolic amino 
acid content on the other hand works through the GATOR1 and GATOR2 complexes. GATOR1 serves as a 
GAP to RagA, maintaining it in its inactive GDP-bound form. GATOR1 is tethered to the lysosomal membrane 
surface, in close proximity to the active RagA/C heterodimers, via interaction with KICSTOR. The activity of 
this negative mTORC1 regulator is inhibited by GATOR2. Cytosolic amino acids work to enhance mTORC1 
activity by inhibiting the activity of two negative regulators of GATOR2 and mTORC1 activity, Sestrin2 and 
CASTOR1. [GROWTH FACTORS] Insulin/IGF signal to mTORC1 via PI3K/AKT signaling. PI3K produces 
PIP3, which subsequently activates AKT. AKT, whose activity can be enhanced by mTORC2, is a negative 
regulator of the TSC complex. When active, the TSC complex works as a GAP to GTP-bound Rheb, thereby 
inactivating it. TSC complex activity is also inhibited by Erk, part of the Ras/Erk signaling cascade stimulated 
by EGF activity on its receptor EGFR. [OTHERS] mTORC1 activity can also be suppressed via energy and 
stress-responsive AMPK, a negative regulator of mTORC1, and hypoxia-responsive REDD1, which promotes 
TSC complex activity. Adapted from Figure 2A of Saxton and Sabatini review.260 
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Figure 1.13 Downstream mTORC1 signaling pathways 
mTORC1 is involved in promoting mRNA translation, lipid and nucleotide synthesis, glucose metabolism, 
autophagy and other protein turnover mechanisms. See text for detailed explanation of the downstream 
mTORC1 pathways involved in mRNA translation. mTORC1 activity leads to enhanced ATF4-dependent 
expression of the key component to the mitochondrial tetrahydrofolate cycle involved in purine nucleotide 
synthesis: MTHFD2. Through its phosphorylation and activation of S6K1, mTORC1 also activates carbamoyl-
phosphate synthetase (CAD), taking part in pyrimidine synthesis. mTORC1 signaling leads to increased 
expression of HIF1α (also hypoxia driven), which drives glycolysis over oxidative phosphorylation. mTORC1 
activates SREBP (via releasing its inhibition by Lipin1) to promote lipid synthesis and glucose metabolism. 
mTORC1 also controls autophagy by suppressing protein catabolism. ULK1 activation via AMPK 
phosphorylation is a key part of autophagy, as it leads to the formation of a complex that drives 
autophagosome formation. mTORC1 phosphorylates ULK1 in lieu of AMPK to inhibit this process. mTORC1 
also phosphorylates the nuclear translocation factor EB (TFEB), thereby inactivating it and preventing its 
driving lysosome biogenesis and autophagy machinery gene expression. Some studies have also reported a 
role for mTORC1 in the repression of protein ubiquitylation, and some have found the complex inhibits Erk5, 
which normally increases the abundance of proteasomal chaperones. Adapted from Figure 2B of Saxton and 
Sabatini review.260 
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1.7 Tables 
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D
ll1; 5-28 days after 
induction 
 
 
é
A
toh1, m
oderate 
secretory cell 
hyperplasia 
 
D
ll4 
4 w
ks 
LO
F; V
il-C
reE
R
T2 x 
floxed D
ll4; 14 days after 
C
re induction 
N
orm
al 
 
N
orm
al 
 
Jag1 
4 w
ks 
LO
F; V
il-C
reE
R
T2 x 
floxed Jag1; 14 days after 
C
re induction 
N
orm
al 
 
N
orm
al 
 
D
ll1 and 
D
ll4 
4 w
ks 
LO
F; V
il-C
reE
R
T2 x 
floxed D
ll1/D
ll4; 3-5 days 
after C
re induction 
D
ecreased 
 
ê
H
es1; goblet cell 
hyperplasia; stem
 cell 
loss 
N
uclear E
ffector 
R
B
P
-Jκ 
36 w
ks 
LO
F; P
450-C
re x floxed 
R
B
P
-J; 4-5 days after C
re 
induction 
D
ecreased 
N
orm
al 
ê
H
es1, é
A
toh1; goblet 
cell hyperplasia but no 
change in other 
secretory cell types 
R
B
P
-Jκ 
4-5 w
ks 
LO
F; V
il-C
reE
R
T2 x 
floxed R
B
P
-J; 6 and 12 
days after C
re induction 
D
ecreased 
 
ê
H
es1, é
A
toh1; 
secretory cell 
hyperplasia; stem
 cell 
loss 
 
M
A
M
L 
P
0 
LO
F; 9kbV
il-C
re x floxed 
"S
TO
P
" dnM
A
M
L 
D
ecreased 
 
S
ecretory cell 
hyperplasia 
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N
IC
D
 
P
0 
G
O
F; 9kbV
il-C
re x 
R
O
S
A
26-floxed "S
TO
P
" 
N
IC
D
 
Increased 
Increased 
é
H
es1, ê
A
toh1; 
decreased goblet and 
endocrine cells 
N
IC
D
 
A
dult 
G
O
F; Fabpl-C
re x 
R
O
S
A
26-floxed "S
TO
P
" 
N
IC
D
 x Z/A
P
 reporter 
m
ouse 
Increased 
N
orm
al 
D
ecreased goblet and 
endocrine cells 
R
eceptor P
roteolysis 
A
dam
10 
P
0, A
dult 
LO
F; 9kbV
il-C
re (or V
il-
C
reE
R
T2) x floxed 
A
D
A
M
10 
D
ecreased 
  
é
A
toh1; secretory cell 
hyperplasia; stem
 cell 
loss 
A
dam
17 
P
0, A
dult 
LO
F; 9kbV
il-C
re x floxed 
A
D
A
M
17 
N
orm
al 
 
N
orm
al 
A
dam
17 
A
dult 
LO
F; hypom
orphic allele 
N
orm
al w
hen 
unchallenged 
 
N
orm
al w
hen 
unchallenged 
 
γ-secretase
 
7-8 w
ks 
LO
F; pharm
acological 
inhibitors (D
B
Z, B
Z); 1-5 
day treatm
ent in rats 
 
 
ê
H
es1, é
A
toh1; 
increased goblet and 
endocrine cells 
γ-secretase
 
6 w
ks 
LO
F; pharm
acological 
inhibitor (LY
-411,575); 5 
or 15 day treatm
ent in 
TgC
R
N
D
8 m
ice 
 
 
G
oblet cell hyperplasia 
γ-secretase
 
A
dult 
LO
F; pharm
acological 
inhibitor (D
B
Z); 5 day 
treatm
ent in m
ice 
D
ecreased 
S
tem
 cell 
apoptosis 
é
A
toh1; secretory cell 
hyperplasia; stem
 cell 
loss 
G
lycosyl-transferase 
M
odifier 
P
ofut1 
4 w
ks, 
36 w
ks 
LO
F; 12.4kbV
il-C
re x 
floxed P
ofut-1 
D
ecreased w
ith 
dispacem
ent 
tow
ards top of 
crypt 
  
ê
H
es1 and H
es5, 
é
A
toh1; secretory cell 
hyperplasia (restricted to 
crypts) 
M
em
brane and 
E
ndosom
al 
Trafficking M
odifer 
M
ib1 
2-4 w
ks 
LO
F; 12.4kbV
il-C
re x 
floxed M
ib1 
D
ecreased 
  
Increased secretory 
cells, m
islocated P
aneth 
cells on villi, only 20%
 of 
m
utants are viable past 
4 w
eeks of age 
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Fbxw
7 
A
dult 
G
O
F; 9kbV
il-C
re x floxed 
Fbxw
7 
Increased 
Increased 
é
N
IC
D
1, é
H
es1, 
é
H
es5, ê
A
toh1; 
decreased secretory 
cells 
C
anonical bH
LH
 
E
ffector 
H
es1 
E
14-E
19 
LO
F; H
es1 knock-out 
N
orm
al 
Increased 
in 
intervillus 
zone 
é
H
es5, é
A
toh1, 
increased goblet and 
endocrine cells 
H
es1 
P
0 
LO
F; H
es1 knock-out 
A
ltered 
distribution 
along the crypt-
villus axis 
 
P
recocious 
differentiation of P
aneth 
cells 
 
 
H
es1 
P
2.5 
LO
F; V
il-C
re x floxed 
H
es1 
N
orm
al 
Increased 
M
oderate goblet and 
endocrine cell 
hyperplasia;  
 
 
H
es1 
A
dult 
LO
F; V
il-C
re x floxed 
H
es1 
N
orm
al 
N
orm
al 
N
orm
al 
 
H
es1, H
es3, 
H
es5 
P
2.5,  
2 m
o, 
1 yr 
LO
F; V
il-C
re x H
es1
f/-, 
H
es3
-/- and H
es5
-/- 
D
ecreased 
Increased 
S
ecretory cell 
hyperplasia; P
aneth 
cells m
islocalized; 
expanded colonic crypts 
 
 
H
es5 
A
dult 
LO
F; H
es5 knock-out 
 
 
é
D
ll1, é
Fbxw
7, 
m
oderate goblet cell 
hyperplasia  
LO
F, loss-of-function; G
O
F, gain-of-function. 
aA
ge of A
nalysis. 
bS
ee references for detailed description of each m
odel.    
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Table 1.2 M
am
m
alian N
otch Pathw
ay: C
ore C
om
ponents and M
odulators. 286  
C
om
ponent/A
ctivity 
G
ene(s) a 
P
rotein type/A
ctivity 
M
odulatory function 
R
eceptor 
N
otch1, N
otch2, N
otch3 and 
N
otch4 
Type 1 transm
em
brane protein 
 
Ligand 
D
ll1, Jag1 and Jag2 
D
S
L and D
O
S
 dom
ain-containing 
 
D
ll3 and D
ll4 
D
S
L only 
 
P
roteolysis 
Furin-like convertase 
P
roprotein convertase (receptor S
1 
cleavage) 
H
eterodim
er form
ation 
A
dam
10 
M
etalloproteinase (receptor S
2 
cleavage) 
Initiates receptor signaling
b 
TspanC
8s
c 
M
etalloproteinase 
trafficking/substrate  presentation 
(receptor S
2 cleavage) 
P
ositive and negative 
regulators 
P
sen(1 or 2), N
cstn, P
senen, 
A
ph1(a, b or c) 
g-S
ecretase com
plex: 1:1:1:1 
stoichiom
etry (receptor S
3/4 
cleavage) 
N
IC
D
 generation 
A
dam
9, A
dam
10, A
dam
12, 
A
dam
17 
M
etalloproteinase (ligand) 
E
ctodom
ain shedding 
G
lycosyltransferase 
P
ofut1 
O
-fucosyltransferase (receptor)  
E
ssential for N
otch activity 
Fringe fam
ily: Lfng, M
fng, R
fng 
b1,3-G
lnN
A
ctransferase (receptor) 
O
ptim
al N
otch activity/ligand 
specificity 
P
oglut1 
O
-glucosyltransferase (receptor)  
E
ssential for N
otch activity  
P
rom
otes extracellular 
cleavage 
G
xylt1, G
xylt12 and X
xylt1 
O
-xylosyltransferase (receptor) 
N
egative regulator 
E
ogt1 
O
-G
lcN
A
c transferase (receptor)  
Im
paired N
otch signaling 
R
educed D
LL1/D
LL4 binding 
M
em
brane/endosom
al trafficking 
M
ib1 
R
ing finger E
3 ubiquitin ligase (ligand 
endocytosis) 
O
ptim
al ligand activity 
 
Itch/N
edd4 fam
ily 
H
E
C
T dom
ain E
3 ubiquitin ligase 
(receptor endocytosis) 
R
educes N
otch activity; 
lysosom
al 
trafficking/degradation 
 
D
eltex1, 2, 3 and 4 
R
ing finger E
3 ubiquitin ligase 
(receptor endocytosis) 
O
ptim
al receptor activity 
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N
um
b 
R
eceptor binding partner (asym
m
etric 
partitioning during cell division) 
N
egative regulator 
 
Fbxw
7 
F-B
ox ubiquitin ligase (N
IC
D
 
degradation) 
R
educes N
otch activity; 
proteosom
al 
trafficking/degradation 
 
C
rum
bs 
R
eceptor binding partner (inhibits 
ligand-independent N
otch 
endocytosis/activation) 
N
egative regulator 
 
C
om
m
d99 
R
egulator of endosom
al trafficking 
and N
otch recylcling to the cell 
surface 
P
ositive regulator 
U
biquitin-specific proteases 
U
sp28 and U
sp12 
C
ounteracts Fbxw
7 
 
P
roductive N
otch signaling is dependent on the cell surface presentation and activity of m
em
brane bound ligands and receptors, processes that 
are controlled by a num
ber of different structural and m
odifying com
ponents. 
aM
ouse gene sym
bols are listed; see text for gene definitions and protein activity. 
bR
ate-lim
iting step for initiation of a N
otch signaling event. 
cTspan5, 10 and 14 (positive regulators) and Tspan15 and 33 (negative regulators). 
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      Table 1.3 O
verview
 of M
ajor G
row
th Factors, R
eceptors, and Targets. 
G
row
th Factor Fam
ily 
R
eceptors 
Ligands 
Target C
ell Types 
E
piderm
al grow
th factor 
E
G
FR
/E
rbB
1 
E
G
F, TG
Fα, N
R
G
-1-4, H
B
-
E
G
F, am
phiregulin, 
betcellulin, epiregulin, 
epigen 
E
pithelium
 
E
rbB
2 
E
ndothelium
 
E
rbB
3 
Im
m
une 
E
rbB
4 
? 
Transform
ing grow
th factor-β 
TβR
-I 
TG
Fβ, B
M
P
2-7, A
ctivin, 
inhibin, nodal 
E
pithelium
 
TβR
-II 
E
ndothelium
 
Im
m
une 
Insulin-like grow
th factor 
IG
FR
1 
IG
F1 
E
pithelium
 
IG
FR
2 
IG
F2 
E
ndothelium
 
H
epatocyte grow
th factor 
c-M
et 
H
G
F 
E
pithelium
 
C
o-receptors (C
D
44) 
E
ndothelium
 
M
esenchym
e 
Im
m
une 
Fibroblast grow
th factor 
FG
FR
1-4 
FG
F1, 2, 4, 7, 9, 10, 15/19, 
18, 21, 20 (in cancer), 23 
E
pithelium
 
C
o-receptors (α/β-klotho) 
M
esenchym
e 
Trefoil factor 
C
X
C
R
4 
TFF1, TFF2, TFF3 
E
pithelium
 
U
nidentified others 
Im
m
une 
H
edgehog 
P
tch1-2 
S
hh, Ihh, D
hh 
E
pithelium
 
Im
m
une 
      A
dapted from
 Table 3.1 of the S
ixth E
dition of the P
hysiology of the G
astrointestinal Tract. 209 
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Chapter II: IGF1/mTORC1 Signaling Directs 
the Intestinal Regenerative Response2 
2.1 Summary 
Background & Aims: Intestinal stem cells responsible for intestinal epithelial 
maintenance, known as crypt base columnar cells (CBCs), die following 12 Gy γ-
irradiation, and facultative stem cells (FSCs) drive the ensuing regenerative 
response. Our aim was to assess the role and mechanism of the growth factor 
IGF1 in mediating FSC contribution to the regenerative response.  
Methods: IGF1 and mTORC1 signaling were pharmacologically modulated 
by administering mice BMS-754807 or rapamycin, respectively. Genetic mouse 
models were also employed, using tamoxifen-inducible deletion of Raptor to 
inhibit, or TSC1 to increase mTORC1 signaling in the intestinal epithelium. A 
genetic mouse model to lineage trace from Bmi1-positive FSCs was also 
employed. 
Results: We observed increased growth factor expression, including IGF1, 
with the onset of the regenerative response 2 days post-irradiation. Inhibition of 
IGF1 signaling via BMS-754807 treatment impaired crypt regeneration, and      
                                            
2 Note this chapter is adapted from the following article in preparation: 
Bohin, N., McGowan, K. P., Carlson, E. A., Keeley, T. M., Samuelson, L. C. IGF1/mTORC1 
Signaling Directs the Intestinal Regenerative Response. CMGH. (2019). [In Preparation]. 
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decreased the activity of downstream mTORC1. Coincident with increased IGF1 
expression, mTORC1 activity surged concomitantly with the regenerative phase.  
Inhibition of mTORC1 mirrored the regenerative impairments observed with BMS-
754807 treatment. Pharmacologic mTORC1 inhibition with rapamycin blocked 
FSC mobilization 1-2 DPI. We confirmed in genetic models using Villin-
CreERT2;RaptorF/F mice, that depletion of mTORC1 activity impaired regeneration 
and activated a feedback mechanism by upregulating IGF1 expression. 
Conclusions: Our study shows that IGF1 signaling through mTORC1 drives 
crypt regeneration. We propose that IGF1 secretion from pericryptal mesenchymal 
cells stimulates mTORC1 in FSCs, resulting in their activation to regenerate lost 
CBCs.  
2.2 Introduction 
The intestinal epithelium is continually renewed throughout life by adult 
stem cells. Two intestinal stem cell (ISC) populations have been identified by their 
distinct roles during homeostasis and following intestinal damage. Active stem 
cells, also termed crypt base columnar (CBC) cells, maintain the epithelial cell 
population during homeostasis, fueling cell renewal every 5-7 days.1 Facultative 
stem cells (FSCs) on the other hand, which are also termed quiescent or reserve 
stem cells, repopulate the CBC niche following stem cell loss. Many different cells 
in the crypt are capable of reprogramming to function as FSCs, including quiescent 
cells,2–5 progenitor cells,6–8 as well as differentiated cells.9–11 Administration of a 
lethal dose of γ-irradiation (e.g. 12 Gy) is a common way of inducing CBC loss and 
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FSC mobilization to replenish the intestinal epithelium.2,3,6,7,12,13 Little is known 
about the mechanism of FCS activation to regenerate the intestinal epithelium 
after radiation injury. 
Intestinal homeostasis and mucosal repair are tightly regulated by the stem 
cell niche, the crypt/pericryptal microenvironment that consists of signaling factors 
and cell-to-cell interactions that direct stem cell function. Previously identified niche 
factors include developmental factors, such as Wnt, Notch and BMP, and growth 
factors, including epidermal growth factor (EGF), and insulin-like growth factor 1 
(IGF1).14 While the focus of the literature has predominantly been on 
characterizing niche factors that control CBC-driven homeostasis, fewer studies 
have sought to define niche factor control of intestinal mucosal repair.  
IGF1 has in recent years been proposed to be a critical niche factor in the 
intestinal regenerative response. Exogenous administration or transgenic 
overexpression of IGF1 has been shown to promote intestinal epithelial growth 
and healing under gut injury conditions.15–19 In one of these studies, IGF1 
enhanced stem cell proliferation and crypt regeneration after injury induced by 14 
Gy abdominal irradiation.19 This study also showed that IGF1 administration 
enhanced the potential for FSCs to form organoids, suggesting that IGF1 can 
enhance FSC activation post irradiation to promote crypt repair. The mechanism 
by which IGF1 functions to regulate crypt cell plasticity during intestinal repair 
remains a gap in our understanding.  
The mammalian Target of Rapamycin Complex 1 (mTORC1) signaling 
complex is regulated by IGF1 via PI3K/Akt signaling. The active mTORC1 complex 
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is regulates cellular homeostasis through integration of molecular pathways and 
environmental cues.20 However, the role of mTORC1 in regulating ISCs is 
controversial and not well understood, perhaps due to studies employing varying 
means to modulate its activity, from nutritional challenges to genetic approaches, 
which could differentially affect other pathways.21–26 Some studies suggest that 
mTORC1 may function in crypt repair.25,27 Mice with intestinal epithelial deletion of 
mTOR (which would disrupt both mTORC1 and mTORC2) using Villin-Cre mice, 
were more sensitive to 10 Gy γ-irradiation, with reduced capacity to regenerate 
crypts and CBCs.25 Interestingly, this study showed that deletion of the mTORC2 
complex gene Rictor had no effect on crypt regeneration, suggesting that 
mTORC1 is the key pathway mediating the mTOR effect, although mTORC1 was 
not tested directly.25 Another study examined the function of mTORC1 for 
intestinal adaptation after small bowel resection, showing that mTORC1 
inactivation via treatment with the mTORC1 inhibitor rapamycin diminished 
adaptation, while pathway activation via deletion of the negative regulator TSC1 
enhanced crypt cell proliferation and adaptation.27 Interestingly, these studies 
showed no effects of mTOR gene deletion or rapamycin treatment on crypt 
proliferation during homeostasis.  
Two additional studies have recently proposed a mechanism by which 
mTORC1 and/or PTEN activity, as regulated by nutrient exposure, in FSCs 
informs FSC contribution to intestinal epithelial repopulation post-injury.24,28 
Collectively the findings suggest that mTORC1 plays a key role in crypt 
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regeneration, although, the mechanism by which mTORC1 becomes activated, 
and the direct role of this pathway in FSC mobilization still requires investigation.  
Our study investigated the mechanism of IGF1 induction of regeneration of 
the intestinal crypts after 12 Gy γ-irradiation. Our findings suggest that 
mesenchymal IGF1 secretion promotes intestinal crypt repair by stimulating 
mTORC1 activity in FSCs. 
2.3 Experimental Procedures 
2.3.1 Mice  
Mouse use was approved by the Institutional Animal Care & Use Committee 
at the University of Michigan. Mice were housed in ventilated and automated 
watering cages with a 12-hour light/dark cycle under specific pathogen-free 
conditions. The following mouse strains were employed: Villin-CreERT2 (gift from 
Robine lab),29 RaptorF/F (JAX 013188),30,31 TSC1F/F (JAX 05680),32 Bmi1-CreERT2 
(JAX 010531),3 ROSA26-lacZ (JAX 003474).33 Mice were maintained on a 
C57BL/6 strain background. Mice of both sexes aged 1.5-4 months were used.  
To activate CreERT2-mediated recombination, mice were injected 
intraperitoneally with tamoxifen (Sigma; 100 mg/kg; 10 mg/mL in 5% ethanol and 
95% corn oil) or vehicle (5% ethanol, 95% corn oil) once per day for the number of 
days indicated, and tissue was collected as indicated. To inhibit mTORC1 activity, 
mice were injected intraperitoneally with rapamycin (LC Laboratories; 4mg/kg; 
25mg/mL in 5% Tween80, 5% polyethylene glycol 400 in saline) or vehicle (5% 
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Tween80 and 5% polyethylene glycol 400 in saline) daily for 5 or 7 days, as 
indicated, prior to tissue collection. To inhibit IGF1 signaling, mice were injected 
with BMS-754807 (MedChemExpress; 25mg/kg; 100mM in 80% polyethylene 
glycol 400 and 20% water) or vehicle (80% polyethylene glycol 400, 20% water) 
daily for 5 days, as indicated, prior to tissue collection. To induce intestinal injury, 
mice were exposed to 1 dose of 12 Gy whole-body irradiation from a 137Cs source. 
Animals were injected intraperitoneally with 5-ethynyl-2’-deoxyuridine (EdU; Life 
Technologies; 25 mg/kg) 2h prior to tissue collection.  
2.3.2 Tissue Collection 
Intestinal tissue was harvested following ad libitum feeding and fixed in 4% 
paraformaldehyde in 1X PBS overnight before paraffin processing, or flash frozen 
for subsequent RNA or protein extraction as previously described,34 and as 
illustrated in Figure 2.1. 
2.3.3 Histological Analysis 
Duodenal paraffin sections (5µm) were stained with H&E to assess 
intestinal morphology. The EdU-Click-it kit (Life Technologies) was used to identify 
proliferating cells. Regeneration was assessed using the adapted crypt 
microcolony survival assay method.35 Regenerating crypts were measured as the 
number of well-oriented crypts with 4 or more EdU-positive cells divided by the 
total number of well-oriented crypts. Well-oriented crypts were identified from 
images of adjacent H&E-stained sections. Immunostaining with rabbit antibodies to 
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γ-H2AX (1:50, Cell Signaling 9718) and phospho-S6 (S240/244) (1:300, Cell 
Signaling 5364) was performed as described.36 A goat anti-rabbit IgG Alexa Fluor 
488 polyclonal secondary antibody was used (1:400, Invitrogen A27034). Images 
were captured on a Nikon E800 microscope with Olympus DP controller software.  
2.3.4 Western Blot Analysis  
Full thickness duodenal tissue was homogenized and lysed in RIPA buffer 
(Thermo, 89900) containing protease and phosphatase inhibitor cocktail (Thermo 
Scientific, 78440). Cell lysates (40 µg protein) were mixed with NuPAGE LDS 
Sample Buffer (Thermo, NP0007) and separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis using NuPAGE MOPS SDS Running Buffer 
(Thermo, NP0001) and NuPAGE 4-12% Bis-Tris gels (Thermo, NP0335), following 
manufacturer recommendations. Protein transfer onto 0.45µm pore size 
nitrocellulose membrane (GE Healthcare) at 100V for 45 min preceded blocking in 
Odyssey Blocking Buffer (Li-COR, 927-40000) for 1 hour at room temperature.  
Immunoblotting with rabbit antibodies to phospho-S6 (S240/244) (1:500, 
Cell Signaling 5364) and phospho-4EBP1 (1:200, Cell Signaling 2855), and mouse 
antibodies to S6 total (1:200, Cell Signaling 2317), 4EBP1 (1:200, Cell Signaling 
9644), and GAPDH (1:10,000, Thermo Scientific MA5-15738) was performed on a 
rocking platform overnight at 4°C. Subsequent to rinsing the membrane in TBST 
(Tris-buffered saline, 0.1% Tween 20), IRDye 800CW Goat α-rabbit (1:10,000, LI-
COR 925-32211) and IRDye 680RD Goat α-mouse (1:10,000, LI-COR 925-68070) 
secondary antibodies were used to visualize probed proteins. Membrane was 
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scanned on an Odyssey Imager (LI-COR). Western blot analysis was performed 
using the free Image Studio Lite software (LI-COR).  
2.3.5 Gene Expression Analysis 
RNA from full-thickness duodenal tissue segments was isolated as 
previously described.37 mRNA abundance was measured by quantitative reverse 
transcriptase polymerase chain reaction (qPCR) as previously described,36 using 
IGF1 primers with sequences: CAACTCCCAGCTGTGCAATT (forward) and 
GCCGAGGTGAACACAAAACT (reverse), which yielded a 151 bp amplified 
product. Assays for each sample were run in triplicate and normalized to Gapdh or 
Hprt as indicated, as an internal control, with Gapdh primer sequences: TCA AGA 
AGG TGG TGA AGC AGG (forward) and TAT TAT GGG GGT CTG GGA TGG 
(reverse), which yielded a 350 bp amplified product, and Hprt primer sequences: 
AGG ACC TCT CGA AGT GTT GGA TAC (forward) and AAC TTG CGC TCA TCT 
TAG GCT TTG (reverse). 
For growth factor array analysis, RNAs from unirradiated, 48 hours post 
irradiation (HPI), 4 days post irradiation (DPI) and 6 DPI were submitted to the 
University of Michigan DNA Sequencing Core who performed quality control 
analysis of the samples, ran RT2 Profiler™ PCR Mouse Growth Factor Arrays 
(Qiagen; PAMM-041Z) and analyzed the data (Figure 2.3 and Appendix Tables 
2.1, 2.2. and 2.3). Three independent biological samples were assessed for each 
time point. 
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2.3.6 Statistical Analysis 
All experiments were performed with at least 3 biological replicates per 
group. Quantitative data are presented as mean ± SEM. Comparisons between 2 
groups were conducted with unpaired two-tailed Student t tests using the Prism 
software (Graphpad). Significance is reported as *(P<0.05), **(P<0.01), 
***(P<0.001), and ***P<0.0001).  
2.4 Results 
2.4.1 The Intestinal Regenerative Response has Three 
Phases  
We characterized the intestinal response following damage induced by 12 
Gy whole body γ-irradiation. Histological analysis revealed gross morphological 
changes, particularly apparent in the crypt compartment, which allowed 
categorization of the post-damage response into three distinct phases: damage, 
regeneration and recovery (Figure 2.2A). The damage phase is characterized by 
rapid cellular injury, followed by crypt collapse. At 3 HPI, DNA double-strand 
breaks were demonstrated throughout the epithelium by γ-H2AX staining (Figure 
2.2B). This DNA damage appears largely resolved by 12 HPI (Figure 2.2B), but 
cell proliferation is almost totally lost at this time, as demonstrated by EdU 
incorporation (Figure 2.2C). By 48 HPI, crypt architecture is destroyed, with de-
cellularization and crypt loss (Figure 2.2A). The regenerative phase, which is 
apparent at 3 days post-irradiation (DPI), is characterized by crypt recovery 
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(Figure 2.2A). The hallmark of this phase of the post-damage response is the 
hyperproliferative surge and expanded crypts that occurs 3-5 DPI (Figure 2.2C-D). 
We denote 6 DPI as the beginning of the recovery phase, where the regenerative 
response is resolving, and crypt structure and the intestinal epithelium are 
returning to baseline.  
2.4.2 Surge of IGF1 Signaling During the Regenerative Phase 
We next sought to identify growth factors that might play a role in mediating 
the response to radiation injury. We assessed growth factor expression signatures 
using a Qiagen qPCR based array designed to measure 84 mouse growth factor 
mRNAs. We analyzed time points across the three phases of the regenerative 
response, and compared to unirradiated (UNIRR) baseline (Figure 2.2A). Several 
growth factors showed a coordinate increase in mRNA abundance with damage 
(48 HPI) and regeneration (4 DPI), with a return towards baseline during the 
recovery phase (6 DPI; Figures 2.2A and 2.3A). IGF1 was amongst the growth 
factors with the most dramatic changes in expression in response to damage. We 
confirmed the dynamic expression of IGF1 mRNA abundance by qPCR analysis, 
which revealed a 6-fold increase at 48HPI (Figure 2.3B). To identify the cellular 
source of IGF1 we used the RNAscope in situ hybridization method, which 
demonstrated expression in pericryptal mesenchymal cells (Figure 2.3C). In light 
of a previous study demonstrating intestinal pro-regenerative properties of IGF1 in 
vivo,19 and an in vitro study showing that IGF1 promoted growth of human 
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intestinal stem cells, we focused the rest of our study on the role of this signaling 
axis.  
2.4.3 Inhibition of IGF1/mTORC1 Signaling Impairs Intestinal 
Regeneration 
We tested the effect of pharmacological inhibition of IGF1 using the 
reversible IGF1 receptor (IGF1R) inhibitor BMS-754807 (BMS). Mice were 
administered a 12 Gy dose of γ-irradiation, and treated immediately after, and daily 
thereafter, with BMS (25mg/kg) or vehicle, with tissue harvest at 5 DPI (Figure 
2.4A). At baseline, inhibition of this pathway had no discernible effect on intestinal 
homeostasis; tissue architecture and cellular proliferation did not differ from 
controls (Figure 2.5). Marked differences were however noted at 5 DPI between 
BMS and vehicle-treated mice challenged with 12 Gy γ-irradiation (Figure 2.4A-E). 
BMS-treated mice had a more pronounced post-irradiation weight loss compared 
to controls (Figure 2.4A) and histological analysis showed more extensive 
intestinal damage, with blunted villi (Figure 2.4B). BMS-treated mice had 20% 
fewer regenerating crypts, consistent with impaired regeneration (Figure 2.4C-D).  
IGF1 signaling is known to activate the PI3K/AKT pathway, which releases 
inhibition of mTORC1 signaling,38,39 so we next aimed to assess changes to 
mTORC1 activity. We confirmed inhibition of downstream mTORC1 signaling with 
BMS treatment by immunostaining for mTORC1 target p-S6(S240/244) (Figure 
2.4E). Thus, pharmacological inhibition of IGF1 signaling results in impaired 
intestinal regeneration, and decreased mTORC1 activity.  
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2.4.4 Elevated mTORC1 Activity in Intestinal Crypts Post 
Irradiation 
We next asked whether the compromised intestinal regenerative capacity in 
response to IGF1 inhibition is due to depleted mTORC1 activity. We first assessed 
changes to mTORC1 activity post-irradiation by Western blot analysis, with 
increased phosphorylation of mTORC1 targets, ribosomal protein S6 and 4EBP1, 
coincident with the regenerative phase (Figure 2.6A-C) and the surge in IGF1 
expression (Figure 2.3A-B). Immunohistological analysis confirmed changes in S6 
phosphorylation status (S240/244), which were most pronounced in the crypts, 
alluding to a role for increased mTORC1 signaling in the crypts following damage 
(Figure 2.6D).  
2.4.5 Inhibition of mTORC1 Signaling Impairs Intestinal 
Regeneration 
We next tested whether mTORC1 inhibition would mirror the impaired 
intestinal regeneration observed with inhibition of IGF1 signaling. To inhibit 
mTORC1 activity, we treated mice with rapamycin or vehicle daily, starting 
immediately following exposure to 12 Gy γ-irradiation (Figure 2.7A). Similar to 
BMS, rapamycin administration to non-irradiated mice did not affect intestinal 
tissue morphology, cellular proliferation, or mRNA abundance of markers of stem 
cells (Lgr5, Olfm4) or differentiated cells (Mmp7, Chga, Muc2) (Figure 2.8). In 
contrast, inhibition of the pathway in irradiated mice impaired intestinal 
regeneration (Figure 2.7A-H), similar to the effect of IGF1 inhibition (Figure 2.4A-
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D). At 3 DPI, the intestines of vehicle-treated mice began to recover with a typical 
regenerative response, characterized by expanded crypts and increased 
proliferation (Figure 2.7C, E). In contrast, rapamycin-treated mice had fewer, and 
smaller crypts (Figure 2.7C). We measured a 43.4% decrease in regenerating 
crypts in rapamycin-treated mice (Figure 2.7G). Further, at 5 DPI, the villi of 
rapamycin-treated mice were blunted, similarly to BMS-treated mice, consistent 
with impaired regeneration at 3 DPI (Figure 2.7D). Crypt regeneration at this time 
point was still compromised in mTORC1-inhibited intestine, with about 33.2% 
fewer regenerating crypts (Figure 2.7F, H). These results suggest that IGF1 
signaling works via mTORC1 to support the intestinal regenerative response.  
2.4.6 mTORC1 Inhibition Blocks FSC Contribution to 
Regeneration 
To identify the key timing for mTORC1 function in crypt repair, we varied the 
inhibitor treatment by delaying rapamycin administration to 24 and 48 HPI (Figure 
2.9A-E). Mice initiating rapamycin treatment at 24 HPI had a similar effect on 
regeneration as observed in our previous experiment, in which mice started 
rapamycin treatment at the time of radiation. Both groups of rapamycin-treated 
mice exhibited enhanced weight loss and reduced numbers of regenerating crypts 
(Figure 2.9A, C-E compared to Figure 2.7C, E, G). In contrast, mice initiating 
rapamycin treatment at 48 HPI exhibited a normal crypt regeneration response 
(Figure 2.9B, C-E). These findings suggest that the key window for mTORC1 
action is 24-48 HPI. Importantly this timing corresponds to the timing for 
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mobilization of facultative intestinal stem cells (FSCs), suggesting that mTORC1 
might play a role in the mobilization and/or proliferation of these cells following 
radiation injury.12,40   
To test whether mTORC1 is important to FSC contribution to the 
regenerative response, we assessed FSC activity post-irradiation in an mTORC1-
depleted context. Bmi1-CreERT2;ROSA26-lacZ mice were irradiated, and 
immediately treated with tamoxifen, to induce lineage tracing from Bmi1-positive 
FSCs, along with rapamycin or vehicle. Rapamycin or vehicle treatment was 
continued daily thereafter. We observed fewer lineage traces from rapamycin-
treated FSCs compared to vehicle-treated counterparts (Figure 2.9F). This data 
indicates that mTORC1 is critical to FSC mobilization following intestinal injury.  
2.4.7 Genetic Depletion of mTORC1 Results in Impaired 
Regeneration 
 Given the potential off-target effects common to pharmacological inhibitors, 
we used genetic models to validate our finding that mTORC1 activity is crucial to 
the intestinal regenerative response following injury. Villin-CreERT2;RaptorF/F mice 
were treated with 100mg/kg tamoxifen daily for 4 days to induce deletion of 
Raptor, which encodes a mTORC1 protein subunit essential to the activity of the 
complex, and irradiated 24 hours following the last injection of tamoxifen (Figure 
2.10A). Villin-CreERT2 mice were used as controls to account for any effects of 
CreERT2 toxicity.41 We first confirmed depleted mTORC1 activity in Villin-
CreERT2;RaptorF/F mice by immunostaining for the downstream mTORC1 target p-
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S6(S240/244) (Figure 2.10B). Consistent with impaired regeneration, we 
observed that at 3 DPI, Villin-CreERT2;RaptorF/F mice had lost significantly more 
weight post-irradiation than Villin-CreERT2 controls (Figure 2.10A). Histological 
analysis of Villin-CreERT2;RaptorF/F also revealed significant impairment in crypt 
regeneration (Figure 2.10C-E compared to Figure 2.7C, E, G). At 3DPI, Villin-
CreERT2;RaptorF/F crypts appeared few, small and de-cellularized compared to 
controls (Figure 2.10C). Proliferation was dramatically reduced in the Raptor-
deleted intestine (Figure 2.10D), with a 3-fold decrease in regenerating crypts 
compared to Villin-CreERT2 controls (Figure 2.10E). Notably, the reduced 
regenerative capacity was almost twice that observed in rapamycin-treated mice 
(Figure 2.10E compared to 2.7G). These findings demonstrate that the impaired 
regeneration observed with rapamycin administration is attributable to the 
importance of mTORC1 in this response.  
Given the reported enhancement in regeneration following in vivo IGF1 
administration post-irradiation,19 and our findings suggesting that IGF1 works via 
mTORC1 to contribute to intestinal regeneration, we sought to determine if 
increased mTORC1 activity might enhance regeneration. To this aim, we irradiated 
tamoxifen-treated Villin-CreERT2;Tsc1F/F mice, to activate mTORC1 by deletion of 
a negative regulator. Interestingly, we did not observe body weight differences, 
histological changes, or variations in proliferation or regenerative capacity in these 
animals compared to Villin-CreERT2 controls (Figure 2.10A, C-E). Thus, we find 
that genetic mTORC1 depletion results in impaired intestinal regeneration, but that 
activation of the pathway does not lead to an improved regenerative capacity. 
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We finally sought to understand how genetic modulation of mTORC1 
activity might affect IGF1. We assessed IGF1 expression by qPCR in our Villin-
CreERT2;RaptorF/F and Villin-CreERT2;Tsc1F/F animals, compared to Villin-CreERT2 
controls at baseline and post-irradiation. At baseline, there were no changes in 
IGF1 expression between these genetic models of varying mTORC1 activity levels 
(Figure 2.10F). Following irradiation, IGF1 expression was increased in all animal 
models (Figure 2.10F), as expected from our data indicating a surge of IGF1 
expression concomitant with the regenerative phase (Figure 2.3B). However, 
surprisingly, the induction in IGF1 expression in Villin-CreERT2;RaptorF/F, 
mTORC1-depleted mice post-irradiation was almost doubled compared to the 
surge observed in Villin-CreERT2 controls (Figure 2.10F). This data suggests a 
potential feedback mechanism is at play in enhancing IGF1 induction in response 
to mTORC1 depletion following injury.  
2.5 Discussion 
Our study shows that the intestinal response to crypt damage induced by 12 
Gy whole body irradiation is characterized by 3 phases: damage (3-48 HPI), 
regeneration (3-5 DPI) and recovery (6+ DPI). Cellular injury preferentially targets 
CBCs, with rapid stem cell depletion and crypt collapse followed by mobilization of 
FSCs and crypt regeneration.5,40,42 The irradiation damage stimulates expression 
of IGF1, which our work suggests promotes mTORC1 activity in the regenerating 
crypts during the regeneration phase. Inhibition of either IGF1 or mTORC1 
signaling results in a severe impairment in crypt regeneration and enhanced body 
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weight loss, compared to uninhibited controls. Our findings indicate that 
IGF1/mTORC1 signaling is particularly important 24-48 HPI, coincident with the 
timing of FSC mobilization, with impaired FSC contribution to regeneration when 
mTORC1 activity is depleted. Further, in agreement with previous reports,43–47 we 
show that IGF1 production is localized to pericryptal mesenchymal cells, which 
have been reported to serve a stem cell niche-supporting function via paracrine 
signaling.48–51 Pericryptal mesenchymal cell to crypt cell IGF1 communication is 
also supported by evidence showing expression of the IGF receptor 1 (IGFR1) on 
the basolateral membrane of crypt cells.44,52 Thus, our studies propose a 
mechanism by which CBC loss induces mesenchymally-secreted IGF1 signaling to 
intestinal crypt cells to elevate mTORC1 activity, stimulating FSC contribution to 
regeneration (Figure 2.11).  
The study of IGF1 signaling in the intestine has mostly been parsed out 
from pathway stimulation studies, including a 2015 report employing exogenous 
IGF1 administration to demonstrate a pro-regenerative role for this growth factor.19 
Based on their data showing IGF1 administration enhanced the organoid forming 
potential of FSCs, this report suggested that IGF1 administration enhanced FSC 
potential by an unknown mechanism.19 Our work aimed to remediate this gap in 
knowledge, and to contribute to the body of literature seeking to understand the 
role of IGF1 signaling in the intestine given how few studies have reported on the 
effects of depleting IGF1 in the intestine.53–57 In agreement with the 
aforementioned 2015 study, our data proposes that IGF1 is indeed involved in 
controlling FSC contribution to the intestinal epithelium, working through mTORC1.  
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The literature is in agreement with our data implicating mTORC1 in 
intestinal mucosal repair. A 2015 report from Cincinnati employing mouse models 
of mTOR depletion in the intestinal epithelium demonstrated that mTOR was 
critical to intestinal crypt recovery from 10 Gy irradiation.25 However the group did 
not specify whether the activity of mTORC1 and mTORC2 combined or mTORC1 
alone was implicated. A few studies have however suggested a mechanism of 
action for the regenerative role of mTORC1.  
The Breault lab proposed that transient inactivation of the negative 
mTORC1 regulator PTEN during extreme nutrient deprivation (48h fast), results in 
a change in FSC status that is mTORC1-dependent from a “dormant” to a “poised” 
state capable of repopulating the intestinal epithelium.26,58 Interestingly, the 
Lengner lab showed that calorie restriction led to an mTORC1-dependent 
enhancement in regenerative capacity post-injury.24 This data was initially counter-
intuitive, calorie restriction leads to depleted mTORC1 activity in uninjured 
intestine,26,59 and our data demonstrated reduced regeneration following mTORC1 
depletion (Figure 2.7). However, while the Lengner lab showed that mTORC1 
activity was enhanced post-irradiation (in agreement with our data in Figure 2.6), 
they found mTORC1 activity was further enhanced by calorie restriction compared 
to ad libitum feeding. The Lengner lab also showed that mTORC1 activation via 
leucine administration sensitized FSCs to irradiation injury, leading to reduced 
regenerative capacity. These results combined with our data showing reduced 
Bmi1-positive FSC contribution to intestinal repair in rapamycin-treated mice 
(Figure 2.9) and the Breault lab report implicating mTORC1 in mobilizing FSCs to 
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contribute to repair, suggest that mTORC1 is responsible for transitioning FSCs 
into a “poised” state that is capable of responding to repair, but is also more 
sensitive to DNA damage. This is in agreement with the Rodgers group’s 
observation of a mTORC1-dependent muscle stem cell (satellite cell; normally 
mitotically dormant) transition state from dormancy to functionally poised in 
response to muscle injury.28 
 Surprisingly, our genetic study leading to increased mTORC1 activity in 
Villin-CreERT2;Tsc1F/F mice yielded unexpected outcomes. Because our data 
intimates mTORC1 as the mechanism through which IGF1 regulates the 
regenerative response, we expected that increased mTORC1 activity resulting 
from Tsc1 deletion would increase crypt regeneration. A previous study found that 
IGF1 administration to mice enhanced regenerative capacity after irradiation 
injury.19 Our observation that increased mTORC1 activity did not enhance 
regeneration suggests that the regenerative response, including increases in 
multiple growth factors, has effectively maximally activated mTORC1 to stimulate 
crypt cell repair. Barron et al. reported that tamoxifen-activated Villin-
CreERT2;Tsc1F/F mice had enhanced adaptation to small bowel resection, with 
proliferation and normal weight gain when compared to controls.27 This finding 
suggested that increased mTORC1 signaling due to Tsc1 deletion enhanced crypt 
regeneration in this injury context. The enhanced adaptation described by Barron 
et al. was small however, and differences between our two studies using Villin-
CreERT2;Tsc1F/F mice could be attributed to differences in the nature of intestinal 
injury. Further, the difference between our data indicating IGF1/mTORC1 signaling 
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is critical to intestinal regeneration and our findings that Tsc1-deleted mice do not 
have enhanced regenerative capacity may be the result of differences in acute 
versus long term stem cell and crypt remodeling to achieve homeostasis. 
  One query arising from our findings is the identity of the cells secreting 
IGF1. Several studies have emerged in recent years identifying a non-epithelial, 
pericryptal niche cell that supports CBC function by secreting critical factors to 
support epithelial cell function, including intestinal stem cells.48–51 Although the 
cellular localization of IGF1 had not previously been defined, our studies show 
IGF1 mRNA localization to pericryptal mesenchymal cells (Figure 2.3C). Notably, 
IGF1 receptors are preferentially expressed in epithelial stem/progenitor cells and 
one study showed stem cell expansion after IGF1 treatment.19 Although future 
studies are warranted, we propose that IGF1 is secreted by pericryptal pericryptal 
cells after epithelial injury. Further, we propose that IGF1 signals to FSCs by 
binding surface IGF receptors to promote downstream mTORC1 activity, to 
activate FSCs to repopulate the damaged crypt compartment (Figure 2.11). 
Future directions should be targeted to further understand the mesenchymal stem 
cell population expressing IGF1 as a niche cell for ISCs.  
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2.8 Figures 
 
Figure 2.1 Intestinal tissue collection.  
Diagram illustrating how the sections of mouse intestine are allocated to different analysis, including paraffin 
processing, cryogenic (cryo) embedding, RNA and protein extraction, and organoid formation (Chapters III 
and IV).  
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Figure 2.2 Three phases of the intestinal regenerative response post-irradiation.  
Mice were unirradiated or administered 12 Gy γ-irradiation, and intestinal tissue was collected at various times 
points, including 3 hours post-irradiation (HPI), 12 HPI, 48 HPI, 3 days post irradiation (DPI), 4 DPI, 5 DPI, and 
6 DPI. (A) Duodenal histology was assessed by H&E staining. (B) DNA damage was assessed by 
immunostaining for γ-H2AX.  (C) Cellular proliferation was assessed by EdU incorporation (green) with 
nuclear counterstain DAPI (red). (D) The number of Edu+ cells was counted at the various time points post 
irradiation. Proliferating cell number is presented as EdU-positive cells per crypt (mean +/- SEM, n=3-6 
mice/group). Scale bars = 100µm. 
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Figure 2.3 IGF1 growth factor expression increases during the regenerative response.  
Duodenal tissue from unirradiated (UNIRR) and irradiated mice harvested at 48 hours post-irradiation (HPI), 4 
days post-irradiation (DPI) and 6 DPI was analyzed for expression of 84 growth factors by qPCR array 
analysis. (A) Heatmap of growth factor expression after irradiation injury, with red meaning more and blue 
meaning less expressed, relative to UNIRR control (n=3 mice/group). (B) qPCR analysis of Igf1 mRNA 
abundance normalized to Gapdh displayed as mean +/- SEM (n=3-4 mice/group; **p<0.01 by Student’s t-test). 
(C) In situ hybridization (ISH) for Igf1 on UNIRR tissue.  
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Figure 2.4 IGFR1 inhibition impairs intestinal regeneration.  
Mice administered 12 Gy γ-irradiation were treated within an hour of challenge, and daily thereafter, with BMS-
754807 (BMS; 25mg/kg) or vehicle (Veh). (A) Mouse body weight relative to weight at the initiation of 
treatment (n=5-6 mice/group). (B-D) Duodenal crypt regeneration was assessed at 5 DPI by (B) H&E staining, 
and (C) EdU incorporation. (D) Crypt regeneration was measured (n=5-6 mice/group). (E) Immunofluorescent 
images of duodenal tissue stained for mTORC1 target p-S6(S240/244). Quantitative data are presented as 
mean +/- SEM (**P<0.01, ***P<0.001 by Student’s t- test). Scale bars = 100µm.  
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Figure 2.5 IGFR1 inhibition does not perturb intestinal homeostasis. 
Duodenal tissue was harvested from mice 24 hours following administration of BMS or Veh daily for five days. 
(A) Mouse body weight relative to weight at the initiation of treatment (n=5 mice/group). Assessment of 
disruption of intestinal homeostasis was examined via (B) H&E staining, and (C) EdU incorporation. 
Quantitative data are presented as mean +/- SEM. Scale bars = 100µm. 
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Figure 2.6 mTORC1 activity increases during the regenerative response. 
(A-D) Protein levels of mTORC1 signaling components in UNIRR duodenum compared to samples collected 
48 HPI, 4 DPI and 6 DPI, as assessed by western blotting and immunostaining. (A) Western blot analysis for 
p-S6(S240/244), total S6, p-4EBP1, total 4EBP1, and loading control GAPDH. (B) p-S6 and (C) p-4EBP1 
band signal was quantified and displayed as mean +/- SEM (n=3 mice/group; **p<0.01 by Student’s t-test). (D) 
Immunofluorescent images of p-S6-stained duodenal tissue at various time points post-irradiation compared to 
unirradiated control. Scale bars = 100µm. 
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Figure 2.7 mTORC1 inhibition leads to impaired intestinal regeneration. 
(A-H) Mice administered 12 Gy γ-irradiation were treated within an hour of challenge, and daily thereafter, with 
rapamycin (Rap; 4mg/kg) or Veh, and euthanized 3 and 5 DPI, as indicated by arrowheads. (A) Mouse body 
weight relative to weight at the initiation of treatment (n=16-25 mice/group). (B) Immunofluorescent images of 
p-S6-stained duodenal tissue harvested 3 and 5 DPI from Veh- and Rap-treated animals. (C-H) Duodenal 
crypt regeneration was assessed at (C, E, G) 3 DPI and (D, F, H) 5 DPI by (C-D) H&E staining, and (E-F) EdU 
incorporation. (G-H) Crypt regeneration was measured (n=4-6 mice/group). Quantitative data are presented as 
mean +/- SEM (*P<0.05, **P<0.01, ***P<0.001 by Student’s t-test). Scale bars = 100µm.  
  
  
 
141 
 
Figure 2.8 mTORC1 inhibition does not perturb intestinal homeostasis. 
(A-G) Mice were administered Rap or Veh daily over 7 days and duodenal tissue was harvested 24 hours 
following the last injection. (A) Mouse body weight relative to weight at the initiation of treatment. Intestinal 
homeostasis was assessed by (B) H&E staining, (C-D) EdU incorporation, (E-F) and expression of intestinal 
stem and differentiated cell markers. (E-F) qPCR analysis from full thickness duodenum for markers of 
intestinal (E) stem (Lgr5, Olfm4), and (F) differentiated cells (Mmp7, Chga, Muc2) normalized to Gapdh. 
Quantitative data are presented as mean +/- SEM. Scale bars = 100µm. 
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Figure 2.9 Rapamycin impairs facultative stem cell contribution to intestinal regeneration. 
(A-E) Mice administered were treated with Rap or Veh starting 24 HPI (Rap 24) or 48 HPI (Rap 48) after 12 
Gy γ-irradiation, and analyzed at 3 DPI. (A-B) Mouse body weight relative to weight at the initiation of the 
experiment (n=4 mice/group). (C-E) Duodenal crypt regeneration was assessed by (C) H&E staining, and (D) 
EdU incorporation, with (E) crypt regeneration quantitated (n=4 mice/group). (F) Bmi1-CreERT2;ROSA26-lacZ 
mice 12 Gy γ-irradiation were injected with a single dose of tamoxifen (TX; 100mg/kg), and daily thereafter, 
with Rap or Veh for 5 days. (G) 5 DPI duodenal sections were stained for X-gal to visualize lineage traces 
(n=2-3 mice/group). Quantitative data are presented as mean +/- SEM (**P<0.01, ***P<0.001 by Student’s t-
test). Scale bars = 100µm. 
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Figure 2.10 Genetic mTORC1 depletion leads to impaired intestinal regeneration. 
(A-F) Villin-CreERT2, Villin-CreERT2;RaptorF/F and Villin-CreERT2;Tsc1F/F mice were treated daily with TX over 
4 days, irradiated 24 hours following the last TX injection and the intestine was analyzed 3 DPI. (A) Mouse 
body weight relative to weight at the initiation of the experiment (n=3-4 mice/group). (B) Genetic modulation of 
mTORC1 activity was confirmed by p-S6(S240/244) immunostaining. (C-E) Duodenal crypt regeneration was 
assessed by (C) H&E staining, and (D) EdU incorporation. (E) Crypt regeneration was measured (n=3-4 
mice/group). (F) qPCR analysis of Igf1 mRNA abundance in unirradiated and 3DPI normalized to Hprt (n=3-4 
mice/group). Quantitative data are presented as mean +/- SEM (*p<0.05, **p<0.01, ***p<0.001 by Student’s t-
test). Scale bars = 100µm. 
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Figure 2.11 Pericryptal IGF1 secretion stimulates mTORC1-mediated FSC mobilization. 
(A-B) Our model proposes that increased IGF1 secretion in response to irradiation results in mTORC1 
activation in FSCs, and their mobilization to contribute to intestinal regeneration.   
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A
 
N
A
 
N
M
_0
0777
8 
C
sf
1 
C
olony stim
ulating factor 
1 (m
acrophage) 
-
0.8963
53467 
7.640
046867 
-
3.0953
73286 
0.010
997186 
0.035
740853 
8.377
1456 
7.294
1266 
7.506
8442 
6.530
1614 
6.755
8028 
7.203
0918 
8.259
4312 
7.986
0486 
7.905
5856 
7.903
1236 
7.973
6514 
7.985
5496 
N
M
_1
7340
4 
B
m
p3 
B
one 
m
orphogenetic 
protein 3 
0.9908
942 
6.965
816283 
3.0267
739 
0.012
381408 
0.035
768511 
6.957
0366 
6.140
5106 
7.254
0622 
7.643
5534 
7.699
0748 
7.981
6638 
6.032
8112 
7.051
6706 
6.404
4526 
6.852
2316 
6.613
2294 
6.959
4986 
N
M
_1
7709
9 
Left
y2 
Left-right 
determ
ination 
factor 2 
-
3.4432
986 
17.96
781106 
-
3.7593
99992 
0.011
93627 
0.035
768511 
N
A
 
18.64
55386 
17.57
09482 
N
A
 
14.66
49448 
N
A
 
18.59
73272 
16.63
62926 
N
A
 
N
A
 
19.58
21354 
20.07
74906 
N
M
_0
0936
7 
Tgf
b2 
Transform
ing 
grow
th 
factor, beta 2 
-
0.8476
42133 
8.858
1462 
-
3.0669
0057 
0.011
551543 
0.035
768511 
9.253
1686 
8.720
6876 
8.967
0022 
7.902
9814 
8.331
8368 
8.163
1138 
8.969
3952 
8.702
2676 
9.291
2276 
9.819
8056 
8.882
4324 
9.293
8356 
  
 
157 
N
M
_0
0850
1 
Lif 
Leukem
ia 
inhibitory 
factor 
-
0.6475
608 
8.660
766617 
-
2.8561
12886 
0.016
642419 
0.046
361025 
9.022
9606 
8.393
1566 
8.882
7652 
8.251
0534 
7.895
9628 
8.209
1838 
9.040
7282 
8.565
3426 
8.976
3926 
9.007
2956 
8.943
8284 
8.740
5296 
N
M
_0
0882
7 
P
gf 
P
lacental grow
th factor 
-
1.0246
31467 
9.671
740617 
-
2.7981
81457 
0.018
403127 
0.049
498065 
10.57
62326 
9.684
7136 
9.949
5492 
9.001
6854 
8.974
2118 
9.160
7038 
9.411
5592 
9.688
6466 
9.564
8726 
10.83
22756 
9.970
8834 
9.245
5536 
N
M
_0
1360
9 
N
gf 
N
erve grow
th factor 
-
1.0770
93567 
12.25
852698 
-
2.6045
29305 
0.027
860182 
0.072
436474 
N
A
 
12.81
77566 
13.08
10692 
11.48
23524 
11.59
30088 
12.54
15968 
12.38
88372 
11.83
25566 
12.06
11146 
12.10
17856 
11.91
66754 
13.02
70436 
N
M
_0
0755
4 
B
m
p4 
B
one 
m
orphogenetic 
protein 4 
-
0.5022
44133 
5.530
883367 
-
2.4346
4192 
0.034
571663 
0.086
986765 
5.618
5626 
5.201
3416 
5.422
3182 
4.816
9994 
4.839
5038 
5.078
9868 
6.235
9032 
5.667
8986 
5.724
1876 
5.886
8996 
5.903
6954 
5.974
3036 
N
M
_0
0800
8 
Fgf
7 
Fibroblast grow
th factor 
7 
-
0.7552
76467 
8.584
481283 
-
2.4069
15063 
0.036
267728 
0.088
402587 
9.056
8086 
7.982
0726 
8.303
5972 
7.983
2504 
7.694
9148 
7.398
4838 
9.074
3702 
9.207
0506 
9.212
1256 
9.107
3166 
8.554
6434 
9.439
1416 
N
M
_0
1021
6 
Figf 
C
-fos 
induced 
grow
th 
factor 
-
0.7022
17467 
8.766
61645 
-
2.3092
6491 
0.042
912965 
0.101
430645 
9.480
2056 
8.465
8226 
9.118
5672 
8.276
7854 
8.278
6518 
8.402
5058 
8.182
3392 
8.200
0076 
8.934
7606 
8.948
2096 
9.553
5864 
9.357
9556 
N
M
_0
0755
6 
B
m
p6 
B
one 
m
orphogenetic 
protein 6 
-
0.6662
60133 
8.844
636783 
-
2.1971
31107 
0.052
004475 
0.119
304384 
9.318
0386 
8.320
3026 
8.915
4822 
8.228
5124 
8.099
5148 
8.227
0158 
9.024
5412 
9.116
3086 
8.952
1426 
8.889
7776 
9.137
4064 
9.906
5986 
N
M
_0
0800
Fgf
10 
Fibroblast grow
th factor 
10 
-
1.0445
9.978
68278
-
2.1600
0.055
39920
0.123
46108
11.25
7404
9.585
9006 
9.868
7822 
8.899
9644 
9.021
0428 
9.657
5158 
8.897
8812 
10.24
6737
9.854
4136 
10.72
5312
10.43
4852
11.29
4385
  
 
158 
2 
21467 
3 
53796 
6 
8 
6 
6 
6 
4 
6 
N
M
_0
0975
5 
B
m
p1 
B
one 
m
orphogenetic 
protein 1 
-
0.5712
648 
6.876
9237 
-
2.1344
69369 
0.057
864287 
0.125
372623 
7.060
3256 
6.323
6306 
7.082
9282 
6.412
8564 
6.467
7518 
5.872
4818 
7.225
9722 
7.202
3166 
7.544
9766 
7.309
6286 
6.844
6454 
7.175
5706 
N
M
_0
5300
9 
Zfp
91 
Zinc finger protein 91 
0.3820
752 
2.985
7062 
2.0696
06434 
0.064
59112 
0.136
165064 
3.198
2956 
2.673
8356 
2.985
2802 
3.425
2724 
3.391
9728 
3.186
3918 
2.692
4792 
2.718
2496 
2.690
5246 
2.879
3976 
3.085
9634 
2.900
8116 
N
M
_0
1011
3 
E
gf 
E
piderm
al grow
th factor 
-
0.7274
21467 
10.77
793162 
-
2.0070
3274 
0.071
778059 
0.137
082977 
11.14
42206 
10.81
36886 
11.22
50072 
10.24
68084 
9.751
2268 
11.00
26168 
11.15
37882 
10.18
76056 
11.12
57056 
11.15
77716 
10.53
95234 
10.98
72166 
N
M
_0
1051
4 
Igf2 
Insulin-like grow
th factor 
2 
-
0.4219
33233 
10.18
495798 
-
2.0519
64277 
0.069
474205 
0.137
082977 
N
A
 
9.774
4106 
9.880
0972 
9.398
3774 
9.548
4328 
9.269
1518 
10.35
65112 
10.79
32386 
10.64
34416 
10.77
98226 
10.77
44304 
10.81
66236 
N
M
_0
1055
4 
Il1a 
Interleukin 1 alpha 
-
1.0938
37467 
8.893
557367 
-
2.0047
29826 
0.072
056436 
0.137
082977 
9.356
3216 
9.169
7366 
9.061
6982 
9.334
4714 
6.911
8398 
8.059
9328 
8.108
0942 
8.930
2776 
8.933
6586 
9.206
1936 
9.290
5634 
10.35
99006 
N
M
_0
3116
8 
Il6 
Interleukin 6 
-
1.4175
554 
11.67
697153 
-
2.0501
39571 
0.069
681673 
0.137
082977 
N
A
 
12.26
04506 
12.07
21942 
11.47
19134 
10.15
21388 
10.62
22488 
10.80
82452 
11.52
56046 
10.57
98546 
13.68
40956 
13.83
08854 
11.43
90556 
N
M
_0
0926
3 
S
p
p1 
S
ecreted 
phosphoprotein 1 
-
1.8386
458 
7.855
4667 
-
1.9863
54432 
0.074
31431 
0.138
01229 
9.968
0006 
8.465
7956 
9.125
8262 
6.427
4564 
6.627
1578 
8.989
0708 
5.630
2102 
6.973
1796 
7.335
0926 
7.671
9986 
6.855
0944 
10.19
67176 
N
M
_0
Tgf
Transform
ing 
grow
th 
-
5.655
-
0.079
0.144
6.135
5.232
5.302
4.926
5.068
5.249
5.580
5.768
5.679
6.401
6.218
6.298
  
 
159 
1157
7 
b1 
factor, beta 1 
0.4749
818 
222283 
1.9454
93249 
57516 
345639 
3986 
2026 
0142 
7414 
0148 
9138 
5612 
7156 
9486 
9866 
2094 
9606 
N
M
_0
0836
0 
Il18 
Interleukin 18 
0.4745
45533 
1.433
462283 
1.7266
12455 
0.114
132454 
0.202
325714 
1.335
0986 
0.584
1806 
1.094
0462 
1.545
8234 
1.834
9368 
1.056
2018 
2.493
8802 
1.925
7836 
2.154
3916 
0.931
5356 
0.971
1224 
1.274
5466 
N
M
_0
0997
1 
C
sf
3 
C
olony stim
ulating factor 
3 (granulocyte) 
-
2.4318
558 
13.82
481198 
-
1.7103
32265 
0.120
376205 
0.208
652089 
16.37
07856 
14.79
68256 
13.59
58202 
12.01
05824 
12.19
54358 
13.26
18458 
12.50
78762 
15.59
37986 
12.86
75186 
N
A
 
17.37
85454 
11.49
38976 
N
M
_0
1009
4 
Left
y1 
Left 
right 
determ
ination 
factor 1 
0.3869
38867 
8.523
2862 
1.5535
10902 
0.150
542284 
0.255
267351 
8.541
8916 
8.126
2766 
7.889
6622 
8.748
9894 
8.589
8948 
8.379
7628 
8.409
0092 
8.223
7096 
8.386
7696 
9.456
6356 
8.730
0824 
8.796
7506 
N
M
_0
0755
3 
B
m
p2 
B
one 
m
orphogenetic 
protein 2 
-
0.4586
37133 
6.189
48745 
-
1.5010
63428 
0.163
433135 
0.271
229458 
5.553
8156 
5.597
1856 
6.564
0362 
5.344
1494 
5.345
6048 
5.649
3718 
6.209
6512 
6.439
8186 
6.167
9706 
7.524
7016 
6.687
4354 
7.190
1086 
N
M
_0
0880
8 
P
d
gfa 
P
latelet 
derived 
grow
th 
factor, alpha 
-
0.4179
13133 
6.653
06195 
-
1.4318
1896 
0.181
909254 
0.295
602538 
7.191
1226 
6.319
0366 
6.352
4622 
6.171
4654 
6.297
3168 
6.140
0998 
7.136
6162 
7.061
6176 
7.472
6136 
6.852
3856 
6.057
3784 
6.784
6286 
N
M
_0
0936
2 
Tff1 
Trefoil factor 1 
-
1.7639
448 
10.93
600145 
-
1.3779
80704 
0.197
48101 
0.302
02978 
11.30
64826 
12.32
40246 
15.40
74662 
11.08
44234 
11.52
27018 
11.13
90138 
7.250
5392 
9.023
0736 
8.136
3506 
9.215
1176 
14.32
30554 
10.49
97686 
N
M
_0
3119
9 
Tgf
a 
Transform
ing 
grow
th 
factor alpha 
-
0.2318
69133 
7.220
880617 
-
1.3834
01853 
0.195
863676 
0.302
02978 
7.494
1846 
7.369
7266 
7.451
1782 
7.063
2814 
7.362
4548 
7.193
7458 
7.175
2852 
7.081
2556 
7.031
7686 
7.200
1316 
6.975
8984 
7.251
6566 
  
 
160 
N
M
_0
0950
5 
V
e
gfa 
V
ascular 
endothelial 
grow
th factor A
 
-
0.3139
14467 
3.838
946117 
-
1.3929
13708 
0.193
052919 
0.302
02978 
3.984
7886 
3.374
6376 
3.795
7642 
3.201
7734 
3.313
6438 
3.698
0298 
4.813
4282 
4.453
8636 
4.547
9126 
3.517
8586 
3.544
8954 
3.820
7576 
N
M
_0
1027
2 
G
df
11 
G
row
th 
differentiation 
factor 11 
0.3868
84933 
9.077
986527 
1.2703
68584 
0.234
899428 
0.352
349142 
N
A
 
8.662
9276 
8.539
7232 
8.740
9024 
9.029
5648 
9.194
1638 
8.897
9592 
8.820
9826 
9.137
2376 
9.018
5216 
9.833
2594 
9.982
6096 
N
M
_0
0755
5 
B
m
p5 
B
one 
m
orphogenetic 
protein 5 
-
0.2813
15467 
5.813
9917 
-
1.1844
51902 
0.262
91307 
0.372
858536 
5.805
1126 
5.078
2476 
5.609
8372 
5.355
7534 
5.291
0168 
5.002
4808 
6.279
3652 
6.277
6876 
6.267
5416 
6.534
9666 
5.931
2304 
6.334
6606 
N
M
_0
1019
7 
Fgf
1 
Fibroblast grow
th factor 
1 
-
0.3872
65133 
8.064
896117 
-
1.1907
76959 
0.260
527869 
0.372
858536 
8.698
8466 
7.421
1386 
8.253
1592 
7.376
3644 
7.895
3218 
7.939
6628 
7.979
2952 
7.960
1316 
8.311
3806 
8.088
7406 
8.190
9234 
8.663
7886 
N
M
_0
1027
5 
G
d
nf 
G
lial 
cell 
line 
derived 
neurotrophic factor 
-
0.5609
32133 
9.856
8922 
-
1.1980
575 
0.257
803716 
0.372
858536 
10.99
95856 
9.019
6806 
9.331
0132 
9.115
4124 
9.500
6268 
9.051
4438 
10.20
32612 
9.669
0566 
9.591
5506 
10.79
66326 
10.06
23354 
10.94
21076 
N
M
_0
2170
4 
C
xc
l12 
C
hem
okine 
(C
-X
-C
 
m
otif) ligand 12 
-
0.2458
019 
5.654
867982 
-
1.1426
44924 
0.281
828702 
0.392
54712 
N
A
 
5.417
3466 
5.909
4592 
5.411
8524 
5.423
8348 
5.417
1158 
5.486
4912 
5.791
9026 
5.557
8886 
5.838
5386 
5.929
2004 
6.019
9176 
N
M
_0
0810
9 
G
df
5 
G
row
th 
differentiation 
factor 5 
-
0.7064
928 
14.50
696255 
-
1.3186
06439 
0.304
427919 
0.416
585574 
N
A
 
14.34
33456 
N
A
 
N
A
 
13.63
68528 
N
A
 
14.54
13882 
N
A
 
N
A
 
N
A
 
N
A
 
15.50
62636 
N
M
_0
1020
Fgf
4 
Fibroblast grow
th factor 
4 
-
0.9922
13.15
84667
-
1.0666
0.313
13225
0.421
10889 
15.75
8705
12.08
3528
11.98
4543
12.24
5068
12.52
5683
12.07
9238
14.69
9778
13.13
4535
12.92
3776
13.16
7399
14.14
0875
N
A
 
  
 
161 
2 
62133 
1 
01688 
1 
6 
6 
2 
4 
8 
8 
2 
6 
6 
6 
4 
N
M
_0
1078
4 
M
d
k 
M
idkine 
-
0.2771
218 
7.141
73445 
-
1.0396
85235 
0.322
336803 
0.426
14018 
7.299
3646 
6.712
1356 
7.391
8062 
7.120
8794 
6.791
8078 
6.659
2538 
7.093
7162 
7.206
5206 
7.312
4536 
7.461
8416 
6.908
7254 
7.742
3086 
N
M
_0
1020
5 
Fgf
8 
Fibroblast grow
th factor 
8 
-
0.6770
95133 
15.13
678162 
-
1.0116
53614 
0.334
937242 
0.435
418414 
14.45
13626 
14.02
75456 
16.56
23042 
14.11
72294 
14.14
58168 
14.74
68808 
14.59
30202 
16.22
53366 
15.96
28156 
14.88
26856 
16.36
44554 
15.56
19266 
N
M
_0
1361
1 
N
o
dal 
N
odal 
-
0.4304
644 
13.95
672689 
-
0.7703
77969 
0.465
358723 
0.595
048859 
N
A
 
15.02
32966 
13.49
18702 
14.42
12614 
13.56
50798 
13.49
50158 
N
A
 
13.23
25276 
14.37
21586 
13.85
49916 
14.15
43404 
N
A
 
N
M
_0
0996
9 
C
sf
2 
C
olony stim
ulating factor 
2 
-
0.3278
36133 
11.28
337253 
-
0.7208
69648 
0.487
069673 
0.603
692874 
11.09
47516 
9.892
2346 
11.62
19092 
10.75
93044 
10.47
18948 
10.39
41878 
11.85
80392 
12.26
37966 
13.14
43116 
11.77
46856 
10.98
46794 
11.14
06756 
N
M
_0
1020
3 
Fgf
5 
Fibroblast grow
th factor 
5 
-
0.9662
417 
15.40
041338 
-
0.7310
99527 
0.487
598091 
0.603
692874 
15.43
13276 
18.85
08646 
13.64
15922 
14.42
10674 
15.59
56388 
N
A
 
15.56
36512 
15.53
77796 
N
A
 
15.11
08086 
14.45
09904 
N
A
 
N
M
_0
0755
8 
B
m
p8a 
B
one 
m
orphogenetic 
protein 8a 
-
0.1614
51467 
7.019
420283 
-
0.6486
77419 
0.530
779268 
0.643
98441 
6.450
8076 
6.082
5956 
6.875
0462 
6.258
9254 
6.407
2528 
6.257
9168 
8.027
2492 
7.541
7696 
8.073
5886 
7.679
8226 
7.180
2404 
7.397
8286 
N
M
_0
0874
2 
N
tf
3 
N
eurotrophin 3 
-
0.2027
40467 
8.184
056367 
-
0.6392
48794 
0.536
653675 
0.643
98441 
8.067
5716 
7.157
3656 
7.933
6382 
7.563
3794 
7.402
4378 
7.584
5368 
9.578
1922 
8.574
8416 
8.870
6166 
8.644
2026 
8.137
9654 
8.693
9286 
  
 
162 
N
M
_0
0837
1 
Il7 
Interleukin 7 
0.1403
27433 
8.091
0868 
0.5760
41435 
0.578
297736 
0.683
442778 
N
A
 
8.338
8656 
7.909
4442 
8.224
3494 
8.364
1568 
8.204
9408 
8.052
8512 
7.979
8646 
7.962
9436 
8.230
8096 
7.608
0954 
8.125
6336 
N
M
_0
1940
0 
R
a
bep
1 
R
abaptin, R
A
B
 G
TP
ase 
binding effector protein 1 
0.0930
39533 
5.600
5022 
0.4830
77241 
0.639
170686 
0.744
109156 
5.496
0156 
5.174
1256 
5.767
8192 
5.433
5124 
5.731
4028 
5.552
1638 
5.573
2922 
5.624
3156 
5.656
3066 
5.809
8056 
5.618
8614 
5.768
4056 
N
M
_0
0744
5 
A
m
h 
A
nti-M
ullerian horm
one 
-
0.4063
938 
17.11
161137 
-
0.4417
37054 
0.667
83286 
0.750
731565 
15.58
12986 
18.21
67106 
19.06
45092 
18.55
23234 
17.19
21968 
15.89
88168 
15.39
06752 
17.37
73566 
16.17
20286 
17.43
80716 
16.69
70154 
17.75
83336 
N
M
_0
0800
4 
Fgf
17 
Fibroblast grow
th factor 
17 
-
0.3828
441 
16.06
200877 
-
0.4652
88617 
0.664
455207 
0.750
731565 
N
A
 
N
A
 
16.00
67922 
14.88
32524 
16.36
46438 
N
A
 
16.77
68552 
N
A
 
N
A
 
15.66
76786 
16.67
28304 
N
A
 
N
M
_0
0835
1 
Il12
a 
Interleukin 12A
 
0.4620
65533 
13.99
847037 
0.4333
28814 
0.673
733456 
0.750
731565 
14.10
11056 
11.82
19306 
12.28
02152 
13.17
41414 
12.34
59328 
14.06
93738 
13.92
37282 
18.35
90996 
14.11
51886 
14.77
33856 
14.20
66094 
14.81
09336 
N
M
_0
1019
8 
Fgf
11 
Fibroblast grow
th factor 
11 
0.1015
44867 
8.684
428533 
0.3097
55191 
0.762
939187 
0.838
158543 
8.357
8896 
7.928
1556 
8.022
5572 
7.834
9984 
8.297
2308 
8.481
0078 
10.05
98112 
9.247
6296 
9.308
9466 
8.816
7476 
8.386
5424 
9.471
6256 
N
M
_0
0950
6 
V
e
gfc 
V
ascular 
endothelial 
grow
th factor C
 
-
0.0512
79467 
9.746
123117 
-
0.2357
66265 
0.818
247834 
0.886
435154 
9.703
5556 
9.396
3526 
9.564
7672 
9.397
1664 
9.530
4628 
9.583
2078 
10.33
53682 
9.648
1926 
9.965
3606 
9.840
7256 
9.788
3484 
10.19
99696 
N
M
_0
2128
Il4 
Interleukin 4 
-
0.1704
12.05
33028 
-
0.2176
0.832
44792 
0.889
4649 
N
A
 
11.40
4266
11.43
5452
11.41
5841
12.12
3139
10.20
9253
12.24
3512
11.55
6168
13.34
1214
12.49
0359
14.34
2415
12.02
4706
  
 
163 
3 
47733 
0744 
6 
2 
4 
8 
8 
2 
6 
6 
6 
4 
6 
N
M
_0
1056
4 
Inh
a 
Inhibin alpha 
-
0.0570
694 
11.07
142589 
-
0.1391
70392 
0.892
29121 
0.934
919022 
N
A
 
10.72
89126 
10.41
56122 
9.818
5994 
10.51
56168 
11.21
13628 
11.49
94912 
11.21
07796 
11.48
64026 
12.18
87256 
11.42
40184 
11.28
61636 
N
M
_0
1359
8 
K
itl 
K
it ligand 
0.0586
592 
3.753
494867 
0.1301
50508 
0.898
960598 
0.934
919022 
3.791
1376 
3.288
3876 
3.680
8272 
3.478
8894 
3.608
1468 
3.849
2938 
2.493
1232 
4.188
8146 
4.310
4306 
4.284
0666 
3.540
5324 
4.528
2886 
N
M
_0
1351
8 
Fgf
9 
Fibroblast grow
th factor 
9 
0.0268
22867 
11.11
44902 
0.0982
84028 
0.923
598046 
0.935
592826 
10.43
35766 
10.52
19786 
10.48
36972 
10.72
45544 
10.70
38828 
10.09
12838 
12.81
34372 
12.20
57716 
12.46
48796 
11.05
46566 
10.51
17104 
11.36
44536 
N
M
_1
4574
1 
G
df
10 
G
row
th 
differentiation 
factor 10 
0.0848
592 
12.08
812053 
0.1054
27995 
0.918
066384 
0.935
592826 
13.09
36396 
10.62
53356 
10.82
01742 
11.41
58844 
12.19
02938 
11.18
75488 
11.46
64242 
13.27
16326 
14.58
41306 
11.70
14536 
12.63
07694 
12.07
01596 
N
M
_0
1020
1 
Fgf
14 
Fibroblast grow
th factor 
14 
-
0.0185
60467 
9.910
584867 
-
0.0662
2786 
0.948
467583 
0.948
467583 
10.61
79506 
10.17
17016 
10.41
41682 
10.09
98634 
11.05
42688 
9.994
0068 
8.972
3922 
9.302
1976 
9.202
8116 
9.527
7386 
9.765
4754 
9.804
4436 
N
M
_0
0975
6 
B
m
p10 
B
one 
m
orphogenetic 
protein 10 
N
A
 
14.33
55976 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.21
54598 
N
A
 
N
A
 
N
A
 
N
A
 
14.45
57354 
N
A
 
N
M
_0
1020
4 
Fgf
6 
Fibroblast grow
th factor 
6 
N
A
 
17.35
00847 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
19.97
00298 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.73
01396 
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N
M
_0
0836
6 
Il2 
Interleukin 2 
N
A
 
14.61
257653 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.43
39402 
N
A
 
13.59
79628 
13.72
41438 
14.91
01972 
15.77
39666 
15.23
52486 
N
A
 
N
A
 
N
A
 
N
M
_0
1055
6 
Il3 
Interleukin 3 
N
A
 
14.34
337152 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.52
31272 
15.19
48744 
14.70
29568 
14.53
63838 
N
A
 
N
A
 
N
A
 
N
A
 
12.75
95154 
N
A
 
N
M
_0
0849
3 
Lep 
Leptin 
N
A
 
19.76
42197 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
19.09
65168 
N
A
 
N
A
 
20.43
19226 
N
A
 
N
A
 
N
A
 
N
A
 
N
M
_0
1083
4 
M
st
n 
M
yostatin 
N
A
 
15.62
76996 
N
A
 
N
A
 
N
A
 
N
A
 
16.31
17006 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.94
36986 
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A
ppendix Table 2.2 Table show
ing the com
parison betw
een the norm
alized cycle threshold (C
t) values of 84 grow
th factor genes from
 U
N
IR
R
 and 4 D
PI 
sam
ples. 
 
 
 
 
 
 
 
 
M
ock Irradiated 
48 H
ours 
4 D
ays 
6 D
ays 
G
ene
B
ank 
S
y
m
b
ol 
D
escription 
logFC
 
A
veE
x
pr 
t 
P
.V
al
ue 
adj.P
.
V
al 
P
A
M
M
041 
P
late
1 
P
A
M
M
041 
P
late
2 
P
A
M
M
041 
P
late
3 
P
A
M
M
041 
P
late
1 
P
A
M
M
041 
P
late
2 
P
A
M
M
041 
P
late
3 
P
A
M
M
041 
P
late
1 
P
A
M
M
041 
P
late
2 
P
A
M
M
041 
P
late
3 
P
A
M
M
041 
P
late
1 
P
A
M
M
041 
P
late
2 
P
A
M
M
041 
P
late
3 
N
M
_0
1131
3 
S
1
00a
6 
S
100 
calcium
 
binding 
protein A
6 (calcyclin) 
-
3.56087 
1.070
665867 
-
15.039
56865 
2.50E
-08 
1.95E
-06 
3.063
0376 
2.984
1846 
3.066
4342 
-
0.148
8696 
0.111
2968 
0.582
3288 
-
0.799
4798 
-
0.300
2294 
-
0.469
2444 
1.484
3786 
1.875
8174 
1.398
3356 
N
M
_0
0795
0 
E
re
g 
E
piregulin 
-
3.6993
59667 
4.985
225867 
-
9.6418
52653 
1.81E
-06 
7.05E
-05 
7.876
6046 
6.486
7596 
6.901
1292 
3.354
9354 
3.295
3638 
3.650
7718 
3.073
4792 
3.842
0966 
3.250
8386 
5.624
9286 
6.607
7654 
5.858
0376 
N
M
_0
1351
8 
Fgf
9 
Fibroblast grow
th factor 9 
2.0149
45333 
11.11
44902 
7.3831
38667 
2.03E
-05 
0.000
396755 
10.43
35766 
10.52
19786 
10.48
36972 
10.72
45544 
10.70
38828 
10.09
12838 
12.81
34372 
12.20
57716 
12.46
48796 
11.05
46566 
10.51
17104 
11.36
44536 
N
M
_0
1051
2 
Igf1 
Insulin-like grow
th factor 1 
-
2.0662
326 
5.169
512527 
-
7.9360
63215 
1.98E
-05 
0.000
396755 
N
A
 
6.258
9006 
6.658
7702 
4.344
6264 
4.411
2368 
4.872
4378 
4.162
8152 
4.365
7296 
4.649
2636 
5.510
4536 
5.842
9084 
5.787
4956 
N
M
_0
0755
9 
B
m
p8b 
B
one 
m
orphogenetic 
protein 8b 
-
2.3086
34667 
9.759
587367 
-
7.0826
89049 
2.92E
-05 
0.000
455986 
10.62
43746 
10.32
65996 
11.56
22702 
8.137
6504 
7.746
0718 
8.237
0848 
8.392
4532 
8.693
6286 
8.501
2586 
12.07
37586 
11.36
42844 
11.45
56136 
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N
M
_1
9819
0 
N
tf
5 
N
eurotrophin 5 
-
2.5473
95333 
12.30
53502 
-
6.4997
56898 
6.09E
-05 
0.000
791702 
14.41
48456 
13.79
42406 
12.83
95372 
10.93
08274 
11.11
66828 
11.52
43198 
10.87
61622 
11.57
32326 
10.95
70426 
13.60
30856 
13.21
37994 
12.82
04266 
N
M
_0
0755
8 
B
m
p8a 
B
one 
m
orphogenetic 
protein 8a 
1.411386 
7.019
420283 
5.6706
46706 
0.000
186652 
0.002
079834 
6.450
8076 
6.082
5956 
6.875
0462 
6.258
9254 
6.407
2528 
6.257
9168 
8.027
2492 
7.541
7696 
8.073
5886 
7.679
8226 
7.180
2404 
7.397
8286 
N
M
_0
1019
8 
Fgf
11 
Fibroblast 
grow
th 
factor 
11 
1.4359
28333 
8.684
428533 
4.3801
94393 
0.001
291551 
0.011
115048 
8.357
8896 
7.928
1556 
8.022
5572 
7.834
9984 
8.297
2308 
8.481
0078 
10.05
98112 
9.247
6296 
9.308
9466 
8.816
7476 
8.386
5424 
9.471
6256 
N
M
_0
1020
1 
Fgf
14 
Fibroblast 
grow
th 
factor 
14 
-
1.2421
39667 
9.910
584867 
-
4.4322
29742 
0.001
189207 
0.011
115048 
10.61
7950
6 
10.17
17016 
10.41
41682 
10.09
98634 
11.05
42688 
9.994
0068 
8.972
3922 
9.302
1976 
9.202
8116 
9.527
7386 
9.765
4754 
9.804
4436 
N
M
_0
0836
0 
Il18 
Interleukin 18 
1.18691 
1.433
462283 
4.3185
18341 
0.001
425006 
0.011
115048 
1.335
0986 
0.584
1806 
1.094
0462 
1.545
8234 
1.834
9368 
1.056
2018 
2.493
8802 
1.925
7836 
2.154
3916 
0.931
5356 
0.971
1224 
1.274
5466 
N
M
_0
1042
7 
H
gf 
H
epatocyte grow
th factor 
-
1.2790
99267 
7.523
043345 
-
4.4053
6134 
0.001
587992 
0.011
260308 
N
A
 
7.695
3736 
8.484
1492 
6.515
9764 
6.787
9898 
6.734
2108 
6.615
5292 
7.131
8486 
6.684
6086 
8.710
7716 
8.922
3204 
8.470
6986 
N
M
_0
0874
2 
N
tf
3 
N
eurotrophin 3 
1.2883
58333 
8.184
056367 
4.0622
45317 
0.002
155889 
0.014
013281 
8.067
5716 
7.157
3656 
7.933
6382 
7.563
3794 
7.402
4378 
7.584
5368 
9.578
1922 
8.574
8416 
8.870
6166 
8.644
2026 
8.137
9654 
8.693
9286 
N
M
_0
0950
V
e
gfa 
V
ascular 
endothelial 
grow
th factor A
 
0.8866
71333 
3.838
94611
3.9343
73168 
0.002
65901
0.015
95406
3.984
7886 
3.374
6376 
3.795
7642 
3.201
7734 
3.313
6438 
3.698
0298 
4.813
4282 
4.453
8636 
4.547
9126 
3.517
8586 
3.544
8954 
3.820
7576 
  
 
167 
5 
7 
1 
4 
N
M
_0
0754
0 
B
d
nf 
B
rain derived neurotrophic 
factor 
-
2.2278
17667 
11.88
260395 
-
3.7741
32593 
0.003
468084 
0.016
90691 
12.61
53106 
13.58
28136 
13.13
13542 
9.696
0704 
10.72
25598 
12.16
06368 
9.943
7452 
11.64
44996 
11.05
77806 
12.68
69316 
12.58
42984 
12.76
52466 
N
M
_0
0817
6 
C
xc
l1 
C
hem
okine (C
-X
-C
 m
otif) 
ligand 1 
-
2.438001 
10.74
938437 
-
3.7956
87826 
0.003
345757 
0.016
90691 
13.39
40856 
12.15
14456 
12.04
77552 
8.539
9404 
8.978
8668 
10.32
91468 
10.20
97712 
10.78
34386 
9.286
0736 
11.04
68096 
12.11
89434 
10.10
63356 
N
M
_0
0936
2 
Tff1 
Trefoil factor 1 
-
4.8760
03333 
10.93
600145 
-
3.8090
97941 
0.003
271928 
0.016
90691 
11.30
64826 
12.32
40246 
15.40
74662 
11.08
44234 
11.52
27018 
11.13
90138 
7.250
5392 
9.023
0736 
8.136
3506 
9.215
1176 
14.32
30554 
10.49
97686 
N
M
_0
0835
0 
Il11 
Interleukin 11 
-
2.0017
33333 
11.42
749745 
-
3.6841
26077 
0.004
031387 
0.018
496954 
13.48
14356 
12.04
62936 
11.69
78712 
10.84
53724 
9.635
6288 
10.97
17178 
9.698
2872 
11.17
44726 
10.34
76406 
12.81
98886 
12.22
92994 
12.18
20616 
N
M
_0
1051
4 
Igf2 
Insulin-like grow
th factor 2 
0.7704
76567 
10.18
495798 
3.7470
15561 
0.004
339918 
0.018
806309 
N
A
 
9.774
4106 
9.880
0972 
9.398
3774 
9.548
4328 
9.269
1518 
10.35
65112 
10.79
32386 
10.64
34416 
10.77
98226 
10.77
44304 
10.81
66236 
N
M
_0
0800
6 
Fgf
2 
Fibroblast grow
th factor 2 
-
1.240967 
8.787
76095 
-
3.5430
44459 
0.005
112921 
0.020
989885 
10.18
83416 
9.203
5826 
9.171
1342 
7.471
4824 
7.573
7088 
8.400
6138 
8.059
7152 
8.406
7146 
8.373
7276 
9.642
2596 
9.102
9214 
9.858
9296 
N
M
_0
0755
7 
B
m
p7 
B
one 
m
orphogenetic 
protein 7 
-
0.6575
57667 
7.304
668867 
-
3.3581
42884 
0.007
001808 
0.024
824593 
7.922
3216 
7.329
7156 
7.722
7622 
6.427
1424 
6.560
5168 
6.438
7908 
6.799
9652 
7.071
3926 
7.130
7686 
8.064
7806 
8.026
7554 
8.161
1146 
N
M
_0
C
sf
C
olony stim
ulating factor 2 
1.5524
11.28
3.4135
0.006
0.024
11.09
9.892
11.62
10.75
10.47
10.39
11.85
12.26
13.14
11.77
10.98
11.14
  
 
168 
0996
9 
2 
(granulocyte-m
acrophage) 
17333 
337253 
6679 
370047 
824593 
47516 
2346 
19092 
93044 
18948 
41878 
80392 
37966 
43116 
46856 
46794 
06756 
N
M
_0
0838
1 
Inh
bb 
Inhibin beta-B
 
-
1.312911 
9.220
747617 
-
3.3669
72657 
0.006
896997 
0.024
824593 
10.56
52196 
9.991
6646 
9.980
4662 
8.017
6224 
8.235
2518 
9.090
8038 
8.840
2092 
9.569
4896 
8.188
9186 
9.735
8436 
9.127
8434 
9.305
6386 
N
M
_0
0800
3 
Fgf
15 
Fibroblast 
grow
th 
factor 
15 
-
3.1132
43333 
15.90
422212 
-
3.3296
30081 
0.007
351579 
0.024
931441 
18.83
27256 
15.20
81336 
18.76
83662 
14.30
71594 
14.29
59838 
14.00
81458 
13.52
7632
2 
14.63
96726 
15.30
21906 
16.94
04786 
16.35
7240
4 
18.66
2936
6 
N
M
_0
0755
5 
B
m
p5 
B
one 
m
orphogenetic 
protein 5 
0.7771
32333 
5.813
9917 
3.2720
4146 
0.008
113797 
0.026
36984 
5.805
1126 
5.078
2476 
5.609
8372 
5.355
7534 
5.291
0168 
5.002
4808 
6.279
3652 
6.277
6876 
6.267
5416 
6.534
9666 
5.931
2304 
6.334
6606 
N
M
_0
0926
3 
S
p
p1 
S
ecreted 
phosphoprotein 
1 
-
2.54038 
7.855
4667 
-
2.7444
62838 
0.020
202488 
0.063
031763 
9.968
0006 
8.465
7956 
9.125
8262 
6.427
4564 
6.627
1578 
8.989
0708 
5.630
2102 
6.973
1796 
7.335
0926 
7.671
9986 
6.855
0944 
10.19
67176 
N
M
_0
1156
2 
Tdg
f1 
Teratocarcinom
a-derived 
grow
th factor 1 
-
3.6323
252 
16.71
278144 
-
2.9005
10811 
0.022
023535 
0.066
070604 
20.30
8368
6 
19.86
10076 
N
A
 
14.52
3699
4 
14.88
77538 
13.92
8123
8 
18.46
12072 
14.44
35186 
N
A
 
N
A
 
18.10
51684 
15.89
61856 
N
M
_0
0835
1 
Il12
a 
Interleukin 12A
 
2.7315
88333 
13.99
847037 
2.5617
05749 
0.027
744613 
0.080
151105 
14.10
11056 
11.82
19306 
12.28
02152 
13.17
41414 
12.34
59328 
14.06
93738 
13.92
37282 
18.35
90996 
14.11
51886 
14.77
33856 
14.20
66094 
14.81
09336 
N
M
_0
0838
0 
Inh
ba 
Inhibin beta-A
 
-
1.193691 
9.123
83295 
-
2.4473
43736 
0.033
820885 
0.094
215322 
10.52
11856 
8.730
7816 
11.06
67442 
7.787
7774 
7.855
1908 
8.233
5698 
9.024
1422 
9.057
7156 
8.655
7806 
9.299
5316 
9.444
0984 
9.809
4776 
  
 
169 
N
M
_0
0800
8 
Fgf
7 
Fibroblast grow
th factor 7 
0.7170
22667 
8.584
481283 
2.2850
07853 
0.044
739046 
0.120
332606 
9.056
8086 
7.982
0726 
8.303
5972 
7.983
2504 
7.694
9148 
7.398
4838 
9.074
3702 
9.207
0506 
9.212
1256 
9.107
3166 
8.554
6434 
9.439
1416 
N
M
_0
0755
4 
B
m
p4 
B
one 
m
orphogenetic 
protein 4 
0.4619
22333 
5.530
883367 
2.2391
80912 
0.048
39627 
0.121
771259 
5.618
5626 
5.201
3416 
5.422
3182 
4.816
9994 
4.839
5038 
5.078
9868 
6.235
9032 
5.667
8986 
5.724
1876 
5.886
8996 
5.903
6954 
5.974
3036 
N
M
_0
0936
8 
Tgf
b3 
Transform
ing 
grow
th 
factor, beta 3 
-
0.458053 
8.327
371783 
-
2.2451
85143 
0.047
90116 
0.121
771259 
9.014
8256 
8.524
2746 
8.661
2152 
7.723
6964 
7.685
6888 
8.172
4258 
8.163
4182 
8.240
5996 
8.422
1386 
8.394
2066 
8.494
2254 
8.431
7466 
N
M
_0
1360
9 
N
gf 
N
erve grow
th factor 
-
0.8552
43433 
12.25
852698 
-
2.0680
71571 
0.067
668282 
0.155
244389 
N
A
 
12.81
77566 
13.08
10692 
11.48
23524 
11.59
30088 
12.54
15968 
12.38
88372 
11.83
25566 
12.06
11146 
12.10
17856 
11.91
66754 
13.02
70436 
N
M
_0
0880
8 
P
d
gfa 
P
latelet 
derived 
grow
th 
factor, alpha 
0.602742 
6.653
06195 
2.0650
64136 
0.065
089021 
0.155
244389 
7.191
1226 
6.319
0366 
6.352
4622 
6.171
4654 
6.297
3168 
6.140
0998 
7.136
6162 
7.061
6176 
7.472
6136 
6.852
3856 
6.057
3784 
6.784
6286 
N
M
_0
3119
9 
Tgf
a 
Transform
ing 
grow
th 
factor alpha 
-
0.34226 
7.220
880617 
-
2.0420
27377 
0.067
670631 
0.155
244389 
7.494
1846 
7.369
7266 
7.451
1782 
7.063
2814 
7.362
4548 
7.193
7458 
7.175
2852 
7.081
2556 
7.031
7686 
7.200
1316 
6.975
8984 
7.251
6566 
N
M
_1
4574
1 
G
df
10 
G
row
th 
differentiation 
factor 10 
1.594346 
12.08
812053 
1.9807
95275 
0.075
010377 
0.161
507455 
13.09
36396 
10.62
53356 
10.82
01742 
11.41
58844 
12.19
02938 
11.18
75488 
11.46
64242 
13.27
16326 
14.58
41306 
11.70
14536 
12.63
07694 
12.07
01596 
N
M
_0
1056
Inh
a 
Inhibin alpha 
0.8266
28733 
11.07
14258
2.0158
3063 
0.073
69454
0.161
50745
N
A
 
10.72
8912
10.41
5612
9.818
5994 
10.51
5616
11.21
1362
11.49
9491
11.21
0779
11.48
6402
12.18
8725
11.42
4018
11.28
6163
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4 
9 
3 
5 
6 
2 
8 
8 
2 
6 
6 
6 
4 
6 
N
M
_0
0950
6 
V
e
gfc 
V
ascular 
endothelial 
grow
th factor C
 
0.428082 
9.746
123117 
1.9681
81432 
0.076
612511 
0.161
507455 
9.703
5556 
9.396
3526 
9.564
7672 
9.397
1664 
9.530
4628 
9.583
2078 
10.33
53682 
9.648
1926 
9.965
3606 
9.840
7256 
9.788
3484 
10.19
99696 
N
M
_0
1021
6 
Figf 
C
-fos 
induced 
grow
th 
factor 
-
0.582496 
8.766
61645 
-
1.9155
56985 
0.083
648132 
0.171
698798 
9.480
2056 
8.465
8226 
9.118
5672 
8.276
7854 
8.278
6518 
8.402
5058 
8.182
3392 
8.200
0076 
8.934
7606 
8.948
2096 
9.553
5864 
9.357
9556 
N
M
_0
0975
5 
B
m
p1 
B
one 
m
orphogenetic 
protein 1 
0.502127 
6.876
9237 
1.8761
43429 
0.089
306511 
0.178
613021 
7.060
3256 
6.323
6306 
7.082
9282 
6.412
8564 
6.467
7518 
5.872
4818 
7.225
9722 
7.202
3166 
7.544
9766 
7.309
6286 
6.844
6454 
7.175
5706 
N
M
_0
3116
8 
Il6 
Interleukin 6 
-
1.1950
876 
11.67
697153 
-
1.7283
95504 
0.116
989607 
0.228
129734 
N
A
 
12.26
04506 
12.07
21942 
11.47
19134 
10.15
21388 
10.62
22488 
10.80
82452 
11.52
56046 
10.57
98546 
13.68
40956 
13.83
08854 
11.43
90556 
N
M
_0
0971
1 
A
rt
n 
A
rtem
in 
-
0.3735
06667 
9.520
28395 
-
1.4556
83696 
0.175
348747 
0.333
5903 
10.26
3923
6 
9.604
9026 
9.928
1242 
8.876
4214 
8.842
0558 
8.839
2028 
9.407
5852 
9.406
3476 
9.862
4976 
9.271
4256 
9.915
2904 
10.02
56306 
N
M
_0
0744
5 
A
m
h 
A
nti-M
ullerian horm
one 
-
1.307486 
17.11
161137 
-
1.4211
95435 
0.184
896454 
0.342
856345 
15.58
12986 
18.21
67106 
19.06
45092 
18.55
23234 
17.19
21968 
15.89
88168 
15.39
06752 
17.37
73566 
16.17
20286 
17.43
80716 
16.69
70154 
17.75
83336 
N
M
_0
0882
7 
P
gf 
P
lacental grow
th factor 
-
0.515139 
9.671
740617 
-
1.4068
0083 
0.189
010549 
0.342
856345 
10.57
62326 
9.684
7136 
9.949
5492 
9.001
6854 
8.974
2118 
9.160
7038 
9.411
5592 
9.688
6466 
9.564
8726 
10.83
22756 
9.970
8834 
9.245
5536 
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N
M
_0
5300
9 
Zfp
91 
Zinc finger protein 91 
-
0.2520
52667 
2.985
7062 
-
1.3653
06674 
0.201
306047 
0.356
86072 
3.198
2956 
2.673
8356 
2.985
2802 
3.425
2724 
3.391
9728 
3.186
3918 
2.692
4792 
2.718
2496 
2.690
5246 
2.879
3976 
3.085
9634 
2.900
8116 
N
M
_0
0755
3 
B
m
p2 
B
one 
m
orphogenetic 
protein 2 
0.3674
67667 
6.189
48745 
1.2026
76877 
0.256
087107 
0.429
449304 
5.553
8156 
5.597
1856 
6.564
0362 
5.344
1494 
5.345
6048 
5.649
3718 
6.209
6512 
6.439
8186 
6.167
9706 
7.524
7016 
6.687
4354 
7.190
1086 
N
M
_0
0800
2 
Fgf
10 
Fibroblast 
grow
th 
factor 
10 
-
0.5710
18333 
9.978
682783 
-
1.1808
5684 
0.264
276495 
0.429
449304 
11.25
74046 
9.585
9006 
9.868
7822 
8.899
9644 
9.021
0428 
9.657
5158 
8.897
8812 
10.24
67376 
9.854
4136 
10.72
53126 
10.43
48524 
11.29
43856 
N
M
_0
0800
5 
Fgf
18 
Fibroblast 
grow
th 
factor 
18 
-
0.5319
74333 
12.19
765912 
-
1.1830
80074 
0.263
432674 
0.429
449304 
13.34
01656 
12.85
39406 
12.09
33502 
10.55
37974 
11.32
14388 
10.88
83698 
12.33
15842 
12.08
80246 
12.27
19246 
13.19
29956 
11.84
61584 
13.59
01596 
N
M
_0
2128
3 
Il4 
Interleukin 4 
0.9604
39067 
12.05
33028 
1.2261
7463 
0.250
357571 
0.429
449304 
N
A
 
11.40
42666 
11.43
54522 
11.41
58414 
12.12
31398 
10.20
92538 
12.24
35122 
11.55
61686 
13.34
12146 
12.49
03596 
14.34
24154 
12.02
47066 
N
M
_0
1027
2 
G
df
11 
G
row
th 
differentiation 
factor 11 
0.3507
344 
9.077
986527 
1.1516
65327 
0.278
285075 
0.442
984405 
N
A
 
8.662
9276 
8.539
7232 
8.740
9024 
9.029
5648 
9.194
1638 
8.897
9592 
8.820
9826 
9.137
2376 
9.018
5216 
9.833
2594 
9.982
6096 
N
M
_0
0777
8 
C
sf
1 
C
olony stim
ulating factor 1 
(m
acrophage) 
0.3243
16333 
7.640
046867 
1.1199
60096 
0.288
230693 
0.449
639882 
8.377
1456 
7.294
1266 
7.506
8442 
6.530
1614 
6.755
8028 
7.203
0918 
8.259
4312 
7.986
0486 
7.905
5856 
7.903
1236 
7.973
6514 
7.985
5496 
N
M
_0
1169
V
e
gfb 
V
ascular 
endothelial 
grow
th factor B
 
-
0.2003
7.473
3892 
-
1.0074
0.336
85224
0.515
18578
7.371
2026 
7.505
5296 
6.979
3652 
8.142
2794 
8.051
3108 
7.991
9638 
7.175
8832 
6.958
1246 
7.121
0306 
7.250
7166 
7.444
1144 
7.689
1496 
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7 
53 
62431 
2 
2 
N
M
_0
1055
4 
Il1a 
Interleukin 1 alpha 
-
0.5385
75333 
8.893
557367 
-
0.9870
73552 
0.346
283707 
0.519
425561 
9.356
3216 
9.169
7366 
9.061
6982 
9.334
4714 
6.911
8398 
8.059
9328 
8.108
0942 
8.930
2776 
8.933
6586 
9.206
1936 
9.290
5634 
10.35
99006 
N
M
_0
0800
7 
Fgf
3 
Fibroblast grow
th factor 3 
-
0.4431
38867 
13.86
97248 
-
0.9538
41308 
0.370
782401 
0.545
679761 
14.09
30906 
15.33
98366 
14.45
87422 
12.76
79754 
13.10
79838 
13.40
85238 
N
A
 
13.67
23226 
14.70
25126 
13.27
65356 
N
A
 
N
A
 
N
M
_1
7340
4 
B
m
p3 
B
one 
m
orphogenetic 
protein 3 
-
0.2875
58333 
6.965
816283 
-
0.8783
72341 
0.399
819076 
0.565
452207 
6.957
0366 
6.140
5106 
7.254
0622 
7.643
5534 
7.699
0748 
7.981
6638 
6.032
8112 
7.051
6706 
6.404
4526 
6.852
2316 
6.613
2294 
6.959
4986 
N
M
_0
0997
1 
C
sf
3 
C
olony stim
ulating factor 3 
(granulocyte) 
-
1.264746 
13.82
481198 
-
0.8895
00064 
0.396
22286 
0.565
452207 
16.37
07856 
14.79
68256 
13.59
58202 
12.01
05824 
12.19
54358 
13.26
18458 
12.50
78762 
15.59
37986 
12.86
75186 
N
A
 
17.37
85454 
11.49
38976 
N
M
_0
1020
5 
Fgf
8 
Fibroblast grow
th factor 8 
0.5799
86667 
15.13
678162 
0.8665
63026 
0.405
965687 
0.565
452207 
14.45
1362
6 
14.02
75456 
16.56
23042 
14.11
72294 
14.14
58168 
14.74
68808 
14.59
30202 
16.22
53366 
15.96
28156 
14.88
26856 
16.36
44554 
15.56
19266 
N
M
_0
0800
4 
Fgf
17 
Fibroblast 
grow
th 
factor 
17 
0.770063 
16.06
200877 
0.8105
08097 
0.460
378977 
0.629
992284 
N
A
 
N
A
 
16.00
6792
2 
14.88
3252
4 
16.36
46438 
N
A
 
16.77
68552 
N
A
 
N
A
 
15.66
7678
6 
16.67
2830
4 
N
A
 
N
M
_0
1361
1 
N
o
dal 
N
odal 
-
0.4552
403 
13.95
672689 
-
0.7437
32384 
0.480
369938 
0.644
677566 
N
A
 
15.02
32966 
13.49
18702 
14.42
12614 
13.56
50798 
13.49
50158 
N
A
 
13.23
25276 
14.37
21586 
13.85
49916 
14.15
43404 
N
A
 
N
M
_0
R
a
R
abaptin, 
R
A
B
 
G
TP
ase 
0.1386
5.600
0.7199
0.487
0.644
5.496
5.174
5.767
5.433
5.731
5.552
5.573
5.624
5.656
5.809
5.618
5.768
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1940
0 
bep
1 
binding effector protein 1 
51333 
5022 
01542 
640723 
677566 
0156 
1256 
8192 
5124 
4028 
1638 
2922 
3156 
3066 
8056 
8614 
4056 
N
M
_0
1011
3 
E
gf 
E
piderm
al grow
th factor 
-
0.2386
05667 
10.77
793162 
-
0.6583
38263 
0.524
79934 
0.682
239142 
11.14
42206 
10.81
36886 
11.22
50072 
10.24
68084 
9.751
2268 
11.00
26168 
11.15
37882 
10.18
76056 
11.12
57056 
11.15
77716 
10.53
95234 
10.98
72166 
N
M
_1
7709
9 
Left
y2 
Left-right 
determ
ination 
factor 2 
-
0.4914
335 
17.96
781106 
-
0.6571
34453 
0.538
692991 
0.688
820546 
N
A
 
18.64
55386 
17.57
09482 
N
A
 
14.66
49448 
N
A
 
18.59
7327
2 
16.63
62926 
N
A
 
N
A
 
19.58
21354 
20.07
7490
6 
N
M
_0
1009
4 
Left
y1 
Left 
right 
determ
ination 
factor 1 
0.153886 
8.523
2862 
0.6178
32943 
0.550
135428 
0.692
105861 
8.541
8916 
8.126
2766 
7.889
6622 
8.748
9894 
8.589
8948 
8.379
7628 
8.409
0092 
8.223
7096 
8.386
7696 
9.456
6356 
8.730
0824 
8.796
7506 
N
M
_0
0755
6 
B
m
p6 
B
one 
m
orphogenetic 
protein 6 
0.179723 
8.844
636783 
0.5926
73904 
0.566
216118 
0.701
029479 
9.318
0386 
8.320
3026 
8.915
4822 
8.228
5124 
8.099
5148 
8.227
0158 
9.024
5412 
9.116
3086 
8.952
1426 
8.889
7776 
9.137
4064 
9.906
5986 
N
M
_0
0837
1 
Il7 
Interleukin 7 
-
0.1256
01767 
8.091
0868 
-
0.5155
92854 
0.618
205348 
0.753
437768 
N
A
 
8.338
8656 
7.909
4442 
8.224
3494 
8.364
1568 
8.204
9408 
8.052
8512 
7.979
8646 
7.962
9436 
8.230
8096 
7.608
0954 
8.125
6336 
N
M
_0
1157
7 
Tgf
b1 
Transform
ing 
grow
th 
factor, beta 1 
0.11987 
5.655
222283 
0.4909
79393 
0.633
759967 
0.760
511961 
6.135
3986 
5.232
2026 
5.302
0142 
4.926
7414 
5.068
0148 
5.249
9138 
5.580
5612 
5.768
7156 
5.679
9486 
6.401
9866 
6.218
2094 
6.298
9606 
N
M
_0
0836
1 
Il1b 
Interleukin 1 beta 
0.2145
14333 
8.015
2477 
0.4269
38686 
0.678
233358 
0.797
831134 
9.140
3526 
7.244
4306 
7.965
0722 
6.127
7164 
5.702
4638 
6.734
4988 
8.393
7792 
8.732
9756 
7.866
6436 
10.15
29236 
8.965
3674 
9.156
7486 
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N
M
_0
0850
1 
Lif 
Leukem
ia inhibitory factor 
0.094527 
8.660
766617 
0.4169
18045 
0.685
316487 
0.797
831134 
9.022
9606 
8.393
1566 
8.882
7652 
8.251
0534 
7.895
9628 
8.209
1838 
9.040
7282 
8.565
3426 
8.976
3926 
9.007
2956 
8.943
8284 
8.740
5296 
N
M
_0
1020
2 
Fgf
4 
Fibroblast grow
th factor 4 
0.3104
37667 
13.15
846671 
0.3336
9543 
0.746
031573 
0.843
340039 
15.75
87056 
12.08
35286 
11.98
45432 
12.24
50684 
12.52
56838 
12.07
92388 
14.69
97782 
13.13
45356 
12.92
37766 
13.16
73996 
14.14
08754 
N
A
 
N
M
_0
0810
9 
G
df
5 
G
row
th 
differentiation 
factor 5 
0.1980
426 
14.50
696255 
0.3696
29029 
0.743
298899 
0.843
340039 
N
A
 
14.34
3345
6 
N
A
 
N
A
 
13.63
68528 
N
A
 
14.54
13882 
N
A
 
N
A
 
N
A
 
N
A
 
15.50
6263
6 
N
M
_0
1020
3 
Fgf
5 
Fibroblast grow
th factor 5 
-
0.4238
794 
15.40
041338 
-
0.3207
25165 
0.757
437972 
0.844
002311 
15.43
13276 
18.85
08646 
13.64
15922 
14.42
10674 
15.59
56388 
N
A
 
15.56
36512 
15.53
77796 
N
A
 
15.11
08086 
14.45
09904 
N
A
 
N
M
_0
1078
4 
M
d
k 
M
idkine 
0.0697
94667 
7.141
73445 
0.2618
50509 
0.798
612104 
0.877
348509 
7.299
3646 
6.712
1356 
7.391
8062 
7.120
8794 
6.791
8078 
6.659
2538 
7.093
7162 
7.206
5206 
7.312
4536 
7.461
8416 
6.908
7254 
7.742
3086 
N
M
_0
2170
4 
C
xc
l12 
C
hem
okine (C
-X
-C
 m
otif) 
ligand 12 
-
0.0513
08767 
5.654
867982 
-
0.2385
16064 
0.816
668381 
0.884
72408 
N
A
 
5.417
3466 
5.909
4592 
5.411
8524 
5.423
8348 
5.417
1158 
5.486
4912 
5.791
9026 
5.557
8886 
5.838
5386 
5.929
2004 
6.019
9176 
N
M
_0
1359
8 
K
itl 
K
it ligand 
0.0773
38667 
3.753
494867 
0.1715
95704 
0.867
08846 
0.926
478081 
3.791
1376 
3.288
3876 
3.680
8272 
3.478
8894 
3.608
1468 
3.849
2938 
2.493
1232 
4.188
8146 
4.310
4306 
4.284
0666 
3.540
5324 
4.528
2886 
N
M
_0
1019
Fgf
1 
Fibroblast grow
th factor 1 
-
0.0407
8.064
89611
-
0.1253
0.902
63568
0.951
4268 
8.698
8466 
7.421
1386 
8.253
1592 
7.376
3644 
7.895
3218 
7.939
6628 
7.979
2952 
7.960
1316 
8.311
3806 
8.088
7406 
8.190
9234 
8.663
7886 
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7 
79 
7 
88757 
2 
N
M
_0
1020
0 
Fgf
13 
Fibroblast 
grow
th 
factor 
13 
0.0188
01333 
8.592
814033 
0.0715
85439 
0.944
306322 
0.956
570041 
8.875
1626 
8.533
6686 
8.812
2092 
7.525
0804 
7.643
1268 
7.981
5008 
8.782
3912 
8.374
5446 
9.120
5086 
9.039
5006 
8.852
9884 
9.573
0866 
N
M
_0
2330
4 
Fgf
22 
Fibroblast 
grow
th 
factor 
22 
0.0332
72667 
11.97
653078 
0.0930
9604 
0.927
617856 
0.956
570041 
12.72
42316 
12.81
26376 
11.68
22042 
10.70
65134 
11.78
46838 
11.11
83528 
12.68
12432 
12.16
61746 
12.47
14736 
12.06
32416 
11.57
83384 
11.92
92746 
N
M
_0
1027
5 
G
d
nf 
G
lial 
cell 
line 
derived 
neurotrophic factor 
0.037863 
9.856
8922 
0.0808
69054 
0.937
099907 
0.956
570041 
10.99
95856 
9.019
6806 
9.331
0132 
9.115
4124 
9.500
6268 
9.051
4438 
10.20
32612 
9.669
0566 
9.591
5506 
10.79
66326 
10.06
23354 
10.94
21076 
N
M
_0
0936
7 
Tgf
b2 
Transform
ing 
grow
th 
factor, beta 2 
0.007344 
8.858
1462 
0.0265
7173 
0.979
310415 
0.979
310415 
9.253
1686 
8.720
6876 
8.967
0022 
7.902
9814 
8.331
8368 
8.163
1138 
8.969
3952 
8.702
2676 
9.291
2276 
9.819
8056 
8.882
4324 
9.293
8356 
N
M
_0
0975
6 
B
m
p10 
B
one 
m
orphogenetic 
protein 10 
N
A
 
14.33
55976 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.21
54598 
N
A
 
N
A
 
N
A
 
N
A
 
14.45
57354 
N
A
 
N
M
_0
1020
4 
Fgf
6 
Fibroblast grow
th factor 6 
N
A
 
17.35
00847 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
19.97
00298 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.73
01396 
N
M
_0
0836
6 
Il2 
Interleukin 2 
N
A
 
14.61
257653 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.43
39402 
N
A
 
13.59
79628 
13.72
41438 
14.91
01972 
15.77
39666 
15.23
52486 
N
A
 
N
A
 
N
A
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N
M
_0
1055
6 
Il3 
Interleukin 3 
N
A
 
14.34
337152 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.52
31272 
15.19
48744 
14.70
29568 
14.53
63838 
N
A
 
N
A
 
N
A
 
N
A
 
12.75
95154 
N
A
 
N
M
_0
0849
3 
Lep 
Leptin 
N
A
 
19.76
42197 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
19.09
65168 
N
A
 
N
A
 
20.43
19226 
N
A
 
N
A
 
N
A
 
N
A
 
N
M
_0
1083
4 
M
st
n 
M
yostatin 
N
A
 
15.62
76996 
N
A
 
N
A
 
N
A
 
N
A
 
16.31
17006 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
N
A
 
14.94
36986 
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A
ppendix Table 2.3 Table show
ing the com
parison betw
een the norm
alized cycle threshold (C
t) values of 84 grow
th factor genes from
 U
N
IR
R
 and 6 D
PI 
sam
ples. 
 
 
 
 
 
 
 
 
M
ock Irradiated 
48 H
ours 
4 D
ays 
6 D
ays 
G
ene
B
ank 
S
y
m
b
ol 
D
escription 
logFC
 
A
veE
x
pr 
t 
P
.V
al
ue 
adj.P
.
V
al 
P
A
M
M
041 
P
late
1 
P
A
M
M
041 
P
late
2 
P
A
M
M
041 
P
late
3 
P
A
M
M
041 
P
late
1 
P
A
M
M
041 
P
late
2 
P
A
M
M
041 
P
late
3 
P
A
M
M
041 
P
late
1 
P
A
M
M
041 
P
late
2 
P
A
M
M
041 
P
late
3 
P
A
M
M
041 
P
late
1 
P
A
M
M
041 
P
late
2 
P
A
M
M
041 
P
late
3 
N
M
_0
1131
3 
S
1
00a
6 
S
100 
calcium
 
binding 
protein A
6 (calcyclin) 
-
1.4517
08267 
1.070
665867 
-
6.1313
85346 
9.90E
-05 
0.007
724514 
3.063
0376 
2.984
1846 
3.066
4342 
-
0.148
8696 
0.111
2968 
0.582
3288 
-
0.799
4798 
-
0.300
2294 
-
0.469
2444 
1.484
3786 
1.875
8174 
1.398
3356 
N
M
_0
1051
4 
Igf2 
Insulin-like grow
th factor 2 
0.9630
383 
10.18
495798 
4.6834
90261 
0.001
057654 
0.041
248493 
N
A
 
9.774
4106 
9.880
0972 
9.398
3774 
9.548
4328 
9.269
1518 
10.35
65112 
10.79
32386 
10.64
34416 
10.77
98226 
10.77
44304 
10.81
66236 
N
M
_0
0755
3 
B
m
p2 
B
one 
m
orphogenetic 
protein 2 
1.2290
694 
6.189
48745 
4.0225
94318 
0.002
300266 
0.059
806905 
5.553
8156 
5.597
1856 
6.564
0362 
5.344
1494 
5.345
6048 
5.649
3718 
6.209
6512 
6.439
8186 
6.167
9706 
7.524
7016 
6.687
4354 
7.190
1086 
N
M
_0
0755
8 
B
m
p8a 
B
one 
m
orphogenetic 
protein 8a 
0.9498
14067 
7.019
420283 
3.8161
49521 
0.003
233789 
0.063
058894 
6.450
8076 
6.082
5956 
6.875
0462 
6.258
9254 
6.407
2528 
6.257
9168 
8.027
2492 
7.541
7696 
8.073
5886 
7.679
8226 
7.180
2404 
7.397
8286 
N
M
_0
0755
5 
B
m
p5 
B
one 
m
orphogenetic 
protein 5 
0.7692
20067 
5.813
9917 
3.2387
27617 
0.008
591268 
0.096
098009 
5.805
1126 
5.078
2476 
5.609
8372 
5.355
7534 
5.291
0168 
5.002
4808 
6.279
3652 
6.277
6876 
6.267
5416 
6.534
9666 
5.931
2304 
6.334
6606 
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N
M
_0
1027
2 
G
df
11 
G
row
th 
differentiation 
factor 11 
1.0101
38133 
9.077
986527 
3.3168
71865 
0.008
62418 
0.096
098009 
N
A
 
8.662
9276 
8.539
7232 
8.740
9024 
9.029
5648 
9.194
1638 
8.897
9592 
8.820
9826 
9.137
2376 
9.018
5216 
9.833
2594 
9.982
6096 
N
M
_0
1009
4 
Left
y1 
Left 
right 
determ
ination 
factor 1 
0.8085
46067 
8.523
2862 
3.2462
10803 
0.008
481567 
0.096
098009 
8.541
8916 
8.126
2766 
7.889
6622 
8.748
9894 
8.589
8948 
8.379
7628 
8.409
0092 
8.223
7096 
8.386
7696 
9.456
6356 
8.730
0824 
8.796
7506 
N
M
_0
1157
7 
Tgf
b1 
Transform
ing 
grow
th 
factor, beta 1 
0.7498
47067 
5.655
222283 
3.0713
22745 
0.011
463614 
0.111
770239 
6.135
3986 
5.232
2026 
5.302
0142 
4.926
7414 
5.068
0148 
5.249
9138 
5.580
5612 
5.768
7156 
5.679
9486 
6.401
9866 
6.218
2094 
6.298
9606 
N
M
_0
0795
0 
E
re
g 
E
piregulin 
-
1.0579
206 
4.985
225867 
-
2.7573
18959 
0.019
75643 
0.154
100157 
7.876
6046 
6.486
7596 
6.901
1292 
3.354
9354 
3.295
3638 
3.650
7718 
3.073
4792 
3.842
0966 
3.250
8386 
5.624
9286 
6.607
7654 
5.858
0376 
N
M
_0
1051
2 
Igf1 
Insulin-like grow
th factor 1 
-
0.7452
162 
5.169
512527 
-
2.8622
54168 
0.018
168152 
0.154
100157 
N
A
 
6.258
9006 
6.658
7702 
4.344
6264 
4.411
2368 
4.872
4378 
4.162
8152 
4.365
7296 
4.649
2636 
5.510
4536 
5.842
9084 
5.787
4956 
N
M
_0
0755
4 
B
m
p4 
B
one 
m
orphogenetic 
protein 4 
0.5075
58733 
5.530
883367 
2.4604
04586 
0.033
065571 
0.166
642512 
5.618
5626 
5.201
3416 
5.422
3182 
4.816
9994 
4.839
5038 
5.078
9868 
6.235
9032 
5.667
8986 
5.724
1876 
5.886
8996 
5.903
6954 
5.974
3036 
N
M
_0
0755
9 
B
m
p8b 
B
one 
m
orphogenetic 
protein 8b 
0.7934
70733 
9.759
587367 
2.4342
98746 
0.034
592172 
0.166
642512 
10.62
43746 
10.32
65996 
11.56
2270
2 
8.137
6504 
7.746
0718 
8.237
0848 
8.392
4532 
8.693
6286 
8.501
2586 
12.07
3758
6 
11.36
42844 
11.45
56136 
N
M
_0
1019
Fgf
11 
Fibroblast 
grow
th 
factor 
11 
0.7887
71067 
8.684
42853
2.4060
88468 
0.036
31952
0.166
64251
8.357
8896 
7.928
1556 
8.022
5572 
7.834
9984 
8.297
2308 
8.481
0078 
10.05
9811
9.247
6296 
9.308
9466 
8.816
7476 
8.386
5424 
9.471
6256 
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8 
3 
2 
2 
2 
N
M
_0
1020
1 
Fgf
14 
Fibroblast 
grow
th 
factor 
14 
-
0.7020
54267 
9.910
584867 
-
2.5050
85285 
0.030
604934 
0.166
642512 
10.61
79506 
10.17
17016 
10.41
41682 
10.09
98634 
11.05
42688 
9.994
0068 
8.972
3922 
9.302
1976 
9.202
8116 
9.527
7386 
9.765
4754 
9.804
4436 
N
M
_0
0836
1 
Il1b 
Interleukin 1 beta 
1.3083
94733 
8.015
2477 
2.6040
41976 
0.025
780184 
0.166
642512 
9.140
3526 
7.244
4306 
7.965
0722 
6.127
7164 
5.702
4638 
6.734
4988 
8.393
7792 
8.732
9756 
7.866
6436 
10.15
29236 
8.965
3674 
9.156
7486 
N
M
_0
1056
4 
Inh
a 
Inhibin alpha 
1.0607
068 
11.07
142589 
2.5866
57311 
0.028
700018 
0.166
642512 
N
A
 
10.72
89126 
10.41
56122 
9.818
5994 
10.51
56168 
11.21
13628 
11.49
94912 
11.21
07796 
11.48
64026 
12.18
87256 
11.42
40184 
11.28
61636 
N
M
_0
0874
2 
N
tf
3 
N
eurotrophin 3 
0.7725
07067 
8.184
056367 
2.4357
45656 
0.034
50578 
0.166
642512 
8.067
5716 
7.157
3656 
7.933
6382 
7.563
3794 
7.402
4378 
7.584
5368 
9.578
1922 
8.574
8416 
8.870
6166 
8.644
2026 
8.137
9654 
8.693
9286 
N
M
_0
1156
2 
Tdg
f1 
Teratocarcinom
a-derived 
grow
th factor 1 
-
3.0840
111 
16.71
278144 
-
2.4626
67037 
0.042
042057 
0.182
182247 
20.30
83686 
19.86
10076 
N
A
 
14.52
36994 
14.88
77538 
13.92
81238 
18.46
12072 
14.44
35186 
N
A
 
N
A
 
18.10
51684 
15.89
61856 
N
M
_0
0817
6 
C
xc
l1 
C
hem
okine (C
-X
-C
 m
otif) 
ligand 1 
-
1.4403
99267 
10.74
938437 
-
2.2425
3639 
0.048
118971 
0.197
541038 
13.39
40856 
12.15
14456 
12.04
77552 
8.539
9404 
8.978
8668 
10.32
91468 
10.20
97712 
10.78
34386 
9.286
0736 
11.04
68096 
12.11
89434 
10.10
63356 
N
M
_0
0755
7 
B
m
p7 
B
one 
m
orphogenetic 
protein 7 
0.4259
504 
7.304
668867 
2.1753
26024 
0.053
975943 
0.200
482073 
7.922
3216 
7.329
7156 
7.722
7622 
6.427
1424 
6.560
5168 
6.438
7908 
6.799
9652 
7.071
3926 
7.130
7686 
8.064
7806 
8.026
7554 
8.161
1146 
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N
M
_0
0800
7 
Fgf
3 
Fibroblast grow
th factor 3 
-
1.3540
20867 
13.86
97248 
-
2.3041
01728 
0.053
297573 
0.200
482073 
14.09
30906 
15.33
98366 
14.45
87422 
12.76
79754 
13.10
79838 
13.40
85238 
N
A
 
13.67
23226 
14.70
25126 
13.27
65356 
N
A
 
N
A
 
N
M
_0
1042
7 
H
gf 
H
epatocyte grow
th factor 
0.6115
02133 
7.523
043345 
2.1060
81934 
0.063
583371 
0.225
431951 
N
A
 
7.695
3736 
8.484
1492 
6.515
9764 
6.787
9898 
6.734
2108 
6.615
5292 
7.131
8486 
6.684
6086 
8.710
7716 
8.922
3204 
8.470
6986 
N
M
_0
0838
1 
Inh
bb 
Inhibin beta-B
 
-
0.7893
416 
9.220
747617 
-
2.0242
73987 
0.069
725874 
0.226
609089 
10.56
52196 
9.991
6646 
9.980
4662 
8.017
6224 
8.235
2518 
9.090
8038 
8.840
2092 
9.569
4896 
8.188
9186 
9.735
8436 
9.127
8434 
9.305
6386 
N
M
_1
7709
9 
Left
y2 
Left-right 
determ
ination 
factor 2 
1.7215
696 
17.96
781106 
2.3020
46357 
0.066
887954 
0.226
609089 
N
A
 
18.64
55386 
17.57
09482 
N
A
 
14.66
49448 
N
A
 
18.59
73272 
16.63
62926 
N
A
 
N
A
 
19.58
21354 
20.07
74906 
N
M
_0
2128
3 
Il4 
Interleukin 4 
1.5326
34467 
12.05
33028 
1.9566
85817 
0.081
133671 
0.253
137053 
N
A
 
11.40
42666 
11.43
54522 
11.41
58414 
12.12
31398 
10.20
92538 
12.24
35122 
11.55
61686 
13.34
12146 
12.49
03596 
14.34
24154 
12.02
47066 
N
M
_0
0800
8 
Fgf
7 
Fibroblast grow
th factor 7 
0.5862
07733 
8.584
481283 
1.8681
2682 
0.090
499973 
0.271
499918 
9.056
8086 
7.982
0726 
8.303
5972 
7.983
2504 
7.694
9148 
7.398
4838 
9.074
3702 
9.207
0506 
9.212
1256 
9.107
3166 
8.554
6434 
9.439
1416 
N
M
_0
1351
8 
Fgf
9 
Fibroblast grow
th factor 9 
0.4971
894 
11.11
44902 
1.8217
95472 
0.097
69076 
0.278
794636 
10.43
35766 
10.52
19786 
10.48
36972 
10.72
45544 
10.70
38828 
10.09
12838 
12.81
34372 
12.20
57716 
12.46
48796 
11.05
46566 
10.51
17104 
11.36
44536 
N
M
_0
1027
G
d
nf 
G
lial 
cell 
line 
derived 
neurotrophic factor 
0.8169
32067 
9.856
8922 
1.7448
30669 
0.110
80299
0.278
79463
10.99
9585
9.019
6806 
9.331
0132 
9.115
4124 
9.500
6268 
9.051
4438 
10.20
3261
9.669
0566 
9.591
5506 
10.79
6632
10.06
2335
10.94
2107
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5 
6 
6 
6 
2 
6 
4 
6 
N
M
_0
0835
1 
Il12
a 
Interleukin 12A
 
1.8625
59067 
13.99
847037 
1.7467
23037 
0.110
462258 
0.278
794636 
14.10
11056 
11.82
19306 
12.28
02152 
13.17
41414 
12.34
59328 
14.06
93738 
13.92
37282 
18.35
90996 
14.11
51886 
14.77
33856 
14.20
66094 
14.81
09336 
N
M
_0
3119
9 
Tgf
a 
Transform
ing 
grow
th 
factor alpha 
-
0.2958
00933 
7.220
880617 
-
1.7648
38439 
0.107
248261 
0.278
794636 
7.494
1846 
7.369
7266 
7.451
1782 
7.063
2814 
7.362
4548 
7.193
7458 
7.175
2852 
7.081
2556 
7.031
7686 
7.200
1316 
6.975
8984 
7.251
6566 
N
M
_0
0950
6 
V
e
gfc 
V
ascular 
endothelial 
grow
th factor C
 
0.3881
22733 
9.746
123117 
1.7844
61755 
0.103
862999 
0.278
794636 
9.703
5556 
9.396
3526 
9.564
7672 
9.397
1664 
9.530
4628 
9.583
2078 
10.33
53682 
9.648
1926 
9.965
3606 
9.840
7256 
9.788
3484 
10.19
99696 
N
M
_0
1020
0 
Fgf
13 
Fibroblast 
grow
th 
factor 
13 
0.4148
45067 
8.592
814033 
1.5795
08529 
0.144
489001 
0.346
698088 
8.875
1626 
8.533
6686 
8.812
2092 
7.525
0804 
7.643
1268 
7.981
5008 
8.782
3912 
8.374
5446 
9.120
5086 
9.039
5006 
8.852
9884 
9.573
0866 
N
M
_0
0810
9 
G
df
5 
G
row
th 
differentiation 
factor 5 
1.162918 
14.50
696255 
2.1704
83779 
0.146
67996 
0.346
698088 
N
A
 
14.34
33456 
N
A
 
N
A
 
13.63
68528 
N
A
 
14.54
13882 
N
A
 
N
A
 
N
A
 
N
A
 
15.50
62636 
N
M
_0
2330
4 
Fgf
22 
Fibroblast 
grow
th 
factor 
22 
-
0.5494
06267 
11.97
653078 
-
1.5372
24185 
0.154
446803 
0.354
319137 
12.72
42316 
12.81
26376 
11.68
22042 
10.70
65134 
11.78
46838 
11.11
83528 
12.68
12432 
12.16
61746 
12.47
14736 
12.06
32416 
11.57
83384 
11.92
92746 
N
M
_0
0755
6 
B
m
p6 
B
one 
m
orphogenetic 
protein 6 
0.4599
864 
8.844
636783 
1.5169
00649 
0.159
442943 
0.355
329986 
9.318
0386 
8.320
3026 
8.915
4822 
8.228
5124 
8.099
5148 
8.227
0158 
9.024
5412 
9.116
3086 
8.952
1426 
8.889
7776 
9.137
4064 
9.906
5986 
  
 
182 
N
M
_0
1360
9 
N
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Chapter III: Genome Toxicity and Impaired 
Stem Cell Function After Conditional Activation 
of CreERT2 in the Intestine3 
3.1 Summary 
With the tamoxifen-inducible CreERT2 system, genetic recombination can 
be temporally controlled in a cell-type-specific manner in intact animals, permitting 
dissection of the molecular underpinnings of mammalian physiology. Here we 
present a significant drawback to CreERT2 technology for analysis of intestinal 
stem cells. Using the intestine-specific Villin-CreERT2 mouse strain, we observed 
delayed intestinal regeneration post irradiation. Villin-CreERT2 activation was 
associated with DNA damage and cryptic loxP site cleavage. Analysis of stem cell-
specific CreERT2 strains showed that the genome toxicity impairs function of crypt 
base columnar stem cells, resulting in loss of organoid initiating activity. 
Importantly, the stem cell impairment is short-lived, with return to normal by 7 days 
post tamoxifen treatment. Our findings demonstrate that mouse genetic 
experiments that utilize CreERT2 should consider the confounding effects of 
                                            
3 Note this chapter is adapted from the following published article: 
Bohin, N., Carlson, E. A., Samuelson, L. C. Genome Toxicity and Impaired Stem Cell 
Function After Conditional Activation of CreERT2 in the Intestine. Stem Cell Reports. 
(2018).354  
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enhanced stem cell sensitivity to genome toxicity resulting from 
CreERT2 activation. 
3.2 Introduction 
The Cre-loxP system is a powerful genome editing tool that revolutionized 
in vivo genetic studies. The site-specific Cre recombinase catalyzes recombination 
between two 34-bp loxP DNA recognition sites to induce deletion or activation of 
target transgenes.1 The adaptation of this system from its bacteriophage origin 
requires that Cre and loxP be engineered into the mouse genome. Since the 
mouse genome does not contain loxP sites, recombination is designed to be 
specific to the engineered target construct.  
One advance to the Cre-loxP system was the development of inducible Cre 
by fusion with a mutated ligand-binding domain of the estrogen receptor (ER).2 
The CreER recombinases (e.g. CreERT2) are activated by the estrogen receptor 
antagonist tamoxifen (TX), which allows temporal control of target gene 
rearrangement. In the absence of TX, CreER is cytoplasmic. TX binding induces 
CreER transfer into the nucleus to catalyze recombination between loxP sites. The 
recombined allele is a permanent genetic change. Thus, this system has been a 
powerful tool to study adult stem cell function. In particular, there are numerous 
CreER mouse strains used to study intestinal stem cells (ISC), including Villin-
CreERT2,3 which is expressed throughout the intestinal epithelium, including stem 
and progenitor cells, and ISC specific Olfm4-CreERT2 4 and Lgr5-CreERT2.5  
Off-target recombination has been observed at cryptic loxP (cloxP) sites, 
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which have DNA sequence similarity to loxP.6 The consequences of illegitimate 
Cre recombination vary from cellular toxicity to overt developmental and 
pathological defects. Cre expression in developing spermatids led to male sterility 
due to genomic rearrangements,7 and widespread developmental defects occurred 
after TX activation of CreERT2 during embryonic development.8 CreERT2 
genotoxicity in proliferating adult tissues has also been described, with TX-
activated CreERT2 causing epithelial atrophy and metaplasia in stomach,9 and 
chromosomal rearrangements in immature hematopoietic cells.10 These reports 
suggest that proliferating stem and progenitor cells may be particularly sensitive to 
Cre-mediated genotoxicity, although this has not been tested in most adult stem 
cell populations. 
One of the most proliferative adult tissues is the intestine, where adult stem 
cells fuel rapid epithelial cell turnover. Whether off-target DNA cleavage and 
genotoxicity are an issue for ISC Cre drivers has not been reported. In this study 
we observed functional ISC defects following TX-induction of CreERT2 in the 
mouse intestine. Whole body γ-irradiation subsequent to Villin-CreERT2 activation 
resulted in delayed intestinal regeneration. ISC defects were demonstrated by 
impaired organoid-forming efficiency. Our findings suggest that the flood of TX-
activated CreERT2 into the nucleus leads to cleavage at cloxP sites and DNA 
double stranded breaks (DSBs), which impair ISC function. Thus, this study holds 
significant implications for experiments studying intestinal homeostasis and 
regeneration in mouse genetic models to mitigate CreERT2 toxicity in ISCs.  
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3.3 Experimental Procedures 
3.3.1 Mice  
Mouse use was approved by the Institutional Animal Care & Use Committee 
at the University of Michigan. Mice were housed in ventilated and automated 
watering cages with a 12-hour light/dark cycle under specific pathogen-free 
conditions. The following mouse strains were employed: Villin-CreERT2,3 Villin-
Cre,11 Olfm4-ires-EGFP-CreERT2 (gift from Dr. Hans Clevers),4 Lgr5-EGFP-ires-
CreERT2 (JAX strain 008875),12 HopX-CreERT2 (JAX strain 017606).13 Mice were 
maintained on a C57BL/6 strain background. Mice of both sexes aged 1.5-4 
months were used. To activate CreERT2-mediated recombination, mice were 
injected intraperitoneally with TX (Sigma; 50 or 100 mg/kg; 10 mg/mL in 5% 
ethanol and 95% corn oil) or VEH (5% ethanol, 95% corn oil) once per day for 1 or 
5 days, and tissue was collected as indicated. To induce intestinal injury, mice 
were exposed to 1 dose of 12 Gy whole-body irradiation from a 137Cs source. 
Animals were injected intraperitoneally with 5-ethynyl-2’-deoxyuridine (EdU; 25 
mg/kg; Life Technologies) 2h prior to tissue collection.    
3.3.2 Tissue Collection 
Intestinal tissue was harvested following ad libitum feeding and fixed in 4% 
paraformaldehyde in 1X PBS overnight before paraffin processing, as previously 
described, or flash frozen for subsequent DNA extraction or protein extraction as 
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previously described,14 and as illustrated in Figure 2.1. Intestinal crypts were 
harvested from duodenum, as previously described.15 
3.3.3 Organoid Culture 
Mouse intestinal organoid cultures were established from duodenal crypts 
and maintained as described,16 with modifications. Longitudinally opened 6 cm of 
proximal intestinal tissue was washed in ice cold DPBS (Gibco), with antibiotics 
penicillin-streptomycin (1X) and gentamycin (1X; Gibco) for 20 min, cut into 1 cm 
pieces, and incubated in 15 mM EDTA in DPBS with antibiotics for 35 min at 4°C 
on a rocking platform. Tissue was vortexed for 2 min., and the solution was passed 
through a 70-µm filter. Crypts were gravity settled for 10min, the supernatant was 
decanted, the remaining pellet was resuspended in 1X DPBS with antibiotics, and 
centrifuged at 150xg for 10 min. The resulting crypt pellet was resuspended in 
complete culture media [50% L-WRN-conditioned media,17 20% fetal bovine 
serum (Atlas Biologicals), antibiotics, 2 mM L- glutamine (Gibco), 1X Fungizone 
(Gibco) and Y- 27632 (10 µM; Tocris) in advanced DMEM/F12 (Gibco)]. To test 
organoid formation efficiency, 600 crypts (extrapolated by determining crypt 
number per µL by counting crypts from a 5 µL droplet of crypt suspension) were 
mixed with 120 µL Matrigel (BD Biosciences), and 40 µL aliquots were plated in 
pre-warmed 24-well plates. After 30 min at 37°C, 500 µL complete culture media 
was overlaid. Culture media without Y-27632 was replaced every other day. The 
efficiency of organoid formation was determined by counting organoids at 3 days 
following plating, and normalizing to the number of plated crypts.  
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3.3.4 Western Blot Analysis  
Isolated duodenal crypts were lysed in RIPA buffer (Thermo, 89900) 
containing protease and phosphatase inhibitor cocktail (Thermo, 78440). Cell 
lysates (40 µg protein) were mixed with NuPAGE LDS Sample Buffer (Thermo, 
NP0007) and separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis using NuPAGE MOPS SDS Running Buffer (Thermo, NP0001) 
and NuPAGE 4-12% Bis-Tris gels (Thermo, NP0335), following manufacturer 
recommendations. Protein transfer onto 0.45µm pore size nitrocellulose 
membrane (GE Healthcare) at 100V for 45 min preceded blocking in Odyssey 
Blocking Buffer (Li-COR, 927-40000) for 1 hour at room temperature. 
Immunoblotting with rabbit α-γ-H2AX (1:50, Cell Signaling), rabbit α-cleaved 
caspase 3 (1:500, Cell Signaling), and mouse α-GAPDH (1:10,000, Thermo 
Scientific) was performed on a rocking platform overnight at 4°C. IRDye 800CW 
Goat α-rabbit (1:10,000, LI-COR 925-32211) and IRDye 680RD Goat α-mouse 
(1:10,000, LI-COR 925- 68070) secondary antibodies were used to visualize 
probed proteins. Membrane was scanned on an Odyssey Imager (LI-COR). 
Western blot analysis was performed using the free Image Studio Lite software (LI-
COR).  
3.3.5 Immunohistochemistry 
Duodenal paraffin sections (5µm) were stained with H&E to analyze 
intestinal morphology. Villus height was determined by measuring from the tip of 
intact villi to the top shoulder of adjacent crypts using ImageJ software (1.52a; 
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Wayne Rasband, National Institutes of Health). Immunostaining with rabbit α-Ki67 
(1:200, Thermo), and rabbit α-γ-H2AX (1:50, Cell Signaling) was performed as 
described.18 A goat anti-rabbit IgG Alexa Fluor 488 polyclonal secondary antibody 
was used (1:400, Invitrogen). EdU-Click-it kit (Life Technologies) was used to 
identify proliferating cells. The number of EdU-positive cells was counted from 
well-oriented crypts, identified from images obtained from adjacent H&E-stained 
sections. Regeneration was assessed using the adapted crypt microcolony 
survival assay method.19 Regenerating crypts were measured as the number of 
well-oriented crypts with 4 or more EdU-positive cells divided by the total number 
of well-oriented crypts. Images were captured on a Nikon E800 microscope with 
Olympus DP controller software, except for γ-H2AX-immunostained images, which 
were captured on a Leica SP5 inverted confocal microscope with Leica software.  
3.3.6 Gene integrity analysis 
For quantification of cloxP amplification, DNA from duodenal crypts was 
extracted using the Easy-DNA kit (Invitrogen, K1800-01). Quantitative polymerase 
chain reaction was performed as previously described,18 using 40ng DNA and 
cloxP primers with sequences: GGT CTG AGC TAT ACT TAC AAA GGT (forward) 
and GCT ATC ACA ATG GTG GTC CG (reverse), which yielded a 300 bp 
amplified product size. Assays for each sample were run in triplicate and 
normalized to Gapdh as an internal control, with primer sequences: TCA AGA 
AGG TGG TGA AGC AGG (forward) and TAT TAT GGG GGT CTG GGA TGG 
(reverse), which yielded a 350 bp amplified product size.  
 196 
 
3.3.7 Statistical analysis  
All experiments were performed with at least 3 biological replicates per 
group. Quantitative data are presented as mean ± SEM. Comparisons between 2 
groups were conducted with unpaired two-tailed Student t tests using the Prism 
software (Graphpad). Significance is reported as * (P<0.05), **(P<0.01), 
***(P<0.001), and #(P<0.0001).  
3.4 Results 
3.4.1 Impaired intestinal regeneration in Villin-CreERT2 mice  
We tested the effect of Villin-CreERT2 on ISC function after treatment with 
TX (100 mg/kg) or vehicle (VEH). Histological analysis did not reveal any gross 
intestinal changes induced by TX treatment; tissue architecture and cellular 
proliferation did not differ from controls (Figure 3.1). However, marked differences 
were observed between TX- and VEH-treated Villin-CreERT2 mice after challenge 
with 12 Gy irradiation (Figure 3.2). TX-treated mice had a more pronounced post-
irradiation weight loss compared to controls (Figure 3.2A) and histological 
analysis showed more extensive intestinal damage (Figure 3.2B-O). 3 days post-
irradiation (DPI), the intestines of VEH-treated mice began to recover with a typical 
regenerative response, characterized by expanded crypts and increased 
proliferation (Figure 3.2B,E). In contrast, TX-treated mice had extensive 
decellularized crypts and very few, small crypt structures (Figure 1C). We also 
observed decreased proliferation and fewer regenerating crypts in the TX group 
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(Figure 3.2G,H). At 5 DPI, the villi of TX-treated Villin-CreERT2 mice were blunted, 
consistent with impaired regeneration at 3 DPI (Figure 3.2I-K). However, crypts at 
this time point were undergoing robust regeneration, similar to control (Figure 
3.2L-O). Thus, TX-activation of Villin-CreERT2 results in delayed intestinal 
regeneration, consistent with enhanced damage following 12 Gy irradiation. 
3.4.2 Impaired organoid formation after Villin-CreERT2 
activation 
To understand the basis for the altered response of Villin-CreERT2 mice to 
irradiation, we tested if CreERT2 activation affects ISC function by measuring 
organoid forming efficiency in unirradiated, treated mice. Duodenal crypts were 
isolated from TX- or VEH-treated mice 1 day post-treatment, and cultured under 
conditions that support ISC growth (Figure 3.2P). While crypts isolated from VEH-
treated mice grew into typical spheroids by 3 days in culture, crypts isolated from 
TX-treated Villin-CreERT2 mice exhibited very poor organoid growth (Figure 3.2Q-
R). Quantification showed that 25-fold fewer organoids grew in cultures initiated 
from TX-treated mice than VEH-treated mice (Figure 3.2S). The extreme loss of 
organoid forming activity in TX-activated Villin-CreERT2 mice suggests impaired 
ISC function.  
3.4.3 Impaired ISC function is not due to tamoxifen toxicity 
We tested whether the delayed regenerative response to irradiation and the 
impaired organoid forming efficiency were due to TX toxicity, which has been 
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observed in other studies.20,21 Irradiated, nontransgenic C57BL/6 mice treated with 
TX or VEH had similar changes to body weight and intestinal histology, including 
villus height, proliferation rate, and crypt regeneration (Figure 3.3A-H). Further, 
TUNEL staining and organoid forming efficiency did not differ between the two 
groups (Figure 3.3I-K). These data showed that toxicity caused by TX treatment of 
Villin-CreERT2 mice was not a direct effect of TX.  
  Next, we determined whether the TX effect on Cre recombinase was 
independent of CreER-mediated nuclear translocation. We treated Villin-Cre mice, 
which exhibit constitutive Cre expression in intestinal epithelial cells 11, with TX or 
VEH, followed by 12 Gy irradiation. In contrast to the response in Villin-CreERT2 
mice, we saw no heightened sensitivity to irradiation in TX-treated Villin-Cre mice 
(Figure 3.3L-S). Further, there was no change in TUNEL staining or organoid 
forming efficiency (Figure 3.3T-V). Notably, these transgenic strains express 
similar amounts of Cre protein, so the toxicity is not due to higher levels of Cre 
recombinase expression in Villin-CreERT2 mice (Figure 3.3W). Together these 
results support the conclusion that TX-activation of Villin-CreERT2 mediates 
impaired intestinal regeneration and organoid formation, and not TX toxicity, or 
interactions between TX and constitutively active Cre recombinase. 
3.4.4 Impaired organoid formation after CreERT2 activation in 
ISCs 
Heightened sensitivity to radiation and impaired organoid forming capacity 
of Villin-CreERT2 mice after TX treatment suggested that CreER activation induced 
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stem cell damage. We tested ISC-specific CreERT2 mouse strains that target crypt 
base columnar (CBC) ISCs, including Olfm4-CreERT2 and Lgr5-CreERT2. Similar 
to our findings with Villin-CreERT2 mice, TX-treated Olfm4-CreERT2 mice had 
normal intestinal histology and proliferation under basal conditions (Figure 3.1F-
J). In contrast to the delayed regenerative response in TX-treated Villin-CreERT2 
mice, we observed normal responses to irradiation in TX-treated Olfm4-CreERT2 
and Lgr5-CreERT2 mice, with cellular proliferation and crypt regeneration at 3 DPI 
similar to VEH-treated controls (Figure 3.4A-B, D-E and Figure 3.5A-F). 
However, organoid forming activity was reduced in both strains after TX treatment, 
similar to Villin-CreERT2 (Figure 3.4G-H, J-K). TX treatment resulted in 10-fold 
fewer organoids in Olfm4-CreERT2 and 2-fold fewer organoids in Lgr5-CreERT2 
(Figure 3.4M-N). The results suggest that actively cycling, CBC ISCs are sensitive 
to CreERT2 activation, leading to impaired ISC function.  
We also tested one CreER strain that targets a facultative stem cell (FSC) 
population, HopX-CreERT2.13 The expression of this Cre driver is limited to very 
few cells in the crypt, which can participate in crypt regeneration after γ-
irradiation.22 In contrast to toxicity observed after TX activation of CreERT2 in 
CBCs, the response to radiation, and organoid forming ability were unchanged in 
HopX-CreERT2 mice (Figure 3.4C,F,I,L,O and Figure 3.5G-I).  
3.4.5 CreERT2 activates DNA cleavage at cryptic loxP sites 
We next considered the mechanism by which CreERT2 activation leads to 
impaired ISC function. We posited that TX-mediated CreERT2 nuclear translocation 
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induces DNA cleavage. To test this, we performed western blotting for γ-H2AX, 
which marks DNA DSBs 23 and observed a 3-fold increase in the crypts of TX-
treated Villin-CreERT2 mice compared to controls (Figure 3.6A,B). Analysis of 
C57BL/6 mice showed no differences in γ-H2AX levels between TX- and VEH-
treated mice, again demonstrating that the effect is due to activation of CreERT2 
and not to TX toxicity (Figure 3.6D,E). We also saw increased γ-H2AX staining in 
cells at the crypt base (Figure 3.6G). In agreement, TUNEL staining mirrored the 
γ-H2AX results, demonstrating increased DNA damage (Figure 3.6I). 
To determine whether TX-treated Villin-CreERT2 mice exhibited DNA 
damage-induced programmed cell death, we immunoblotted for the apoptotic 
marker cleaved caspase 3 and found levels to be unchanged in both TX-treated 
Villin-CreERT2 and C57BL/6 mice (Figure 3.6A,C,D,F). We also confirmed these 
results by quantifying the number of cleaved caspase 3-positive cells per crypt in 
tissue sections, showing that induction of DSBs did not induce apoptosis (Figure 
3.6H). The findings suggest that Villin-CreERT2 activation results in increased DNA 
cleavage without inducing apoptosis. This agrees with our results showing no 
obvious histological changes to the duodenum following TX activation under basal 
conditions (Figure 3.1A-E).  
We tested whether activated CreERT2 might induce DNA damage by 
inappropriately targeting regions in the mouse genome with sequence similarity to 
loxP. We designed real-time qPCR primers around the locus of a cloxP site 
(accession number AF033025) previously reported to serve as an active site for 
Cre recombinase.6 We assessed the integrity of this genomic region following 
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CreERT2 activation by comparing amplification from crypt cell DNA isolated from 
TX- and VEH-treated Villin-CreERT2 mice (Figure 3.6J). Real-time qPCR analysis 
revealed that TX-treated duodenal Villin-CreERT2 crypt DNA had reduced 
amplification of this genomic region compared to VEH-treated controls, indicating 
reduced concentration of this cloxP site in the genome (Figure 3.6K). These 
results demonstrate that TX-mediated translocation of CreERT2 to the nucleus is 
associated with illegitimate DNA cleavage at a cloxP site.  
3.4.6 Resolution of CreERT2-induced ISC genotoxicity 
Understanding the value of the inducible Villin-CreERT2 mouse strain for 
genetic analysis of mammalian ISC function, we investigated 3 methods to 
minimize ISC toxicity. The first, termed “delayed", involved postponing intestinal 
challenge for 1 week after the final TX injection (Figure 3.7A-J). Analysis of body 
weight after irradiation showed similar profiles in TX- and VEH-treated mice 
(Figure 3.7A). Analysis of intestinal regeneration at 3 and 5 DPI revealed no 
changes to intestinal histology, including cellular proliferation, crypt regeneration 
and villus height (Figure 3.7B-J).  
Further evidence in support of a delay resolving the Villin-CreERT2 
genotoxicity was shown by normal levels of γ-H2AX and cleaved caspase 3 in the 
duodenal crypts of Villin-CreERT2 mice isolated 7 days following the final TX or 
VEH injection (Figure 3.7K-M). Similarly, crypt DNA isolated from TX-treated 
Villin-CreERT2 mice 7 days following the final injection had normal cloxP 
amplification (Figure 3.7N). Further, TUNEL-labeling was similar between VEH- 
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and TX-treated Villin-CreERT2 animals with delay (Figure 3.7O). Finally, duodenal 
crypts isolated 7 days following treatment showed normal organoid forming 
efficiency (Figure 3.7P). Similar findings were observed for the CBC-specific 
Olfm4-CreERT2 mouse (Figure 3.8E-H; compare Figure 3.8D to Figure 3.4M).  
We investigated 2 additional methods of administering TX: daily 
administration of a lower TX dose (50mg/kg) over 5 days (5x50; Figure 3.7Q-R), 
and administration of a single 100mg/kg dose of TX (1x100; Figure 3.7S-T), with 
tissue harvest 1d later. The results revealed a modest increase in DSBs, as 
observed by TUNEL staining, in the 5x50 experimental paradigm (Figure 3.7Q) 
together with a significant decrease in organoid forming efficiency (Figure 3.7R). 
In contrast, we did not observe TX-mediated CreERT2 toxicity in the 1x100 
experiment (Figure 3.7S-T). Thus, we have shown that genotoxicity is dose- and 
time-dependent, and identified 2 methods that minimize damage by reducing the 
TX dose (1x100) or building in a delay after TX treatment.   
3.5 Discussion 
Our study shows that intestine-specific CreERT2 drivers promote illegitimate 
DNA cleavage events at cloxP sites and markedly diminish CBC ISC function. TX 
activation of the widely used Villin-CreERT2 resulted in delayed crypt regeneration 
after epithelial cell damage induced by γ-irradiation. The intestine normally has a 
remarkable regenerative capacity, with ISC replacement and crypt repair 
completed within a week after almost complete elimination of the proliferating crypt 
compartment with 12 Gy whole-body γ-irradiation.24 TX-treated Villin-CreERT2 
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mice exhibited enhanced weight loss and a delay in crypt regeneration after 
irradiation, in comparison to VEH-treated Villin-CreERT2 controls. The regenerative 
defect suggested a mechanism of ISC toxicity, which was confirmed by loss of 
organoid-forming activity in TX-treated CreERT2 mouse strains (Figure 3.9). 
Impaired organoid formation was observed in Villin-CreERT2 mice, a strain with 
broad CreERT2 expression in all intestinal epithelial cells, as well as 2 strains with 
expression limited to CBC ISCs, Olfm4-CreERT2 and Lgr5-CreERT2. These 
CreERT2 driver strains have been extensively used for studies of ISC function, 
including analysis of mechanisms regulating crypt regeneration after irradiation 
injury, and ISC activity by measurement of organoid forming potential. A review of 
the literature suggests that this is the first report of CBC stem cell toxicity resulting 
from Cre-mediated genotoxicity.  
While we observed changes to both crypt regeneration and organoid 
forming efficiency in TX-treated Villin-CreERT2 mice, we were surprised that TX-
treated Olfm4-CreERT2 and Lgr5-CreERT2 mice had impaired organoid forming 
efficiency but normal regenerative responses. Administration of γ-irradiation doses 
above 10 Gy has been shown to induce loss of CBC ISCs through apoptosis.25,26 
Normal regeneration in Olfm4-CreERT2 and Lgr5-CreERT2 mice suggests that the 
effect observed in Villin-CreERT2 animals may not be solely caused by CreERT2 
activation in CBCs. Rather, the delayed regenerative response could be a result of 
CreERT2-induced damage to FSCs, which are mobilized to repair the crypts 
following CBC loss.13,27–29 FSCs are also thought to contribute to organoid 
formation. This led to our analysis of the HopX-CreERT2 mouse strain, which 
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activates CreERT2 in a small subset of FSCs.13 This strain showed no effect on 
intestinal regeneration or organoid formation following TX administration. This may 
reflect the small number of crypt cells targeted by HopX-CreERT2. A rigorous 
interrogation of CreERT2 mouse strains with different coverage of FSCs may be 
warranted (e.g. Bmi1-CreERT2, Sox9-CreERT2). An additional possibility for our 
Hopx-CreERT2 results may be the different sensitivities of CreERT2 activation in 
FSCs vs. CBC stem cell populations. The susceptibility of various crypt cell 
populations to CreERT2-induced genotoxicity warrants further study.  
The Villin-CreERT2 and Lgr5-CreERT2 mouse strains are commonly used, 
with hundreds of published studies employing these Cre drivers to manipulate 
genes for analysis of intestinal development, physiology and pathophysiology. In 
particular, these strains have been important to study ISC function. The 
genotoxicity and ISC defects uncovered in our study are a serious consideration 
for studies that employ these, or other Cre drivers, expressed in the intestinal 
crypt.  
Mouse studies using Cre recombinase have become a mainstay for 
analysis of gene function in vivo. It is commonly assumed that Cre activation per 
se does not induce adverse events. However, Cre-mediated cellular toxicity 
resulting from illegitimate DNA cleavage at cloxP sites has been previously 
observed in cultured cells and mouse tissues.6,7,30,31 Cre-mediated genotoxicity 
appears to be dosage dependent, and proliferating cells seemingly exhibit 
enhanced sensitivity,7,8,10,30 which would predict that proliferating stem and 
progenitor cells would be particularly sensitive to Cre-mediated toxicity. However, 
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few studies have examined adult stem cell toxicity after CreERT2 activation in vivo. 
Our finding of CreERT2-induced ISC toxicity would prompt stem cell biologists 
studying other adult stem cell populations to be cautious when activating CreERT2 
alleles. Careful experimental design must include the proper controls to rule out 
Cre-mediated genotoxicity as a potential cause of stem cell phenotypes induced in 
studies using CreER mouse strains.  
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3.8 Figures 
 
Figure 3.1 Normal intestinal histology in tamoxifen-treated Villin-CreERT2 and Olfm4-CreERT2 mice.  
Villin-CreERT2 and Olfm4-CreERT2 mice were treated with tamoxifen (TX; 100 mg/kg) or vehicle (VEH) daily 
for 5 days, and intestinal tissue was collected 1 day following the final injection. Duodenal histology was 
assessed by (A-B, F-G) H&E staining. (C-E, H-J) Cellular proliferation was assessed by EdU incorporation. 
Proliferating cells are presented as the number of EdU-positive cells per crypt (mean +/- SEM, n=3-5 
mice/group). Scale bars = 100µm.  
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Figure 3.2 Impaired intestinal regeneration and organoid formation in tamoxifen-treated Villin-CreERT2 
mice. 
Villin-CreERT2 mice were treated with tamoxifen (TX; 100mg/kg) or vehicle (V; VEH) daily for 5 days, and 1 
day later either (A-O) challenged with 12 Gy γ-irradiation or (P-S) tested for organoid forming efficiency. (A) 
Mouse body weight relative to weight at the initiation of treatment (n=7-15 mice/group). (B-O) Duodenal crypt 
regeneration was assessed at (B-H) 3 days post irradiation (DPI), and (I-O) 5 DPI by (B-C, I-J) H&E staining, 
and (E-F, L-M) EdU incorporation. (D, K) Villus height (n=5-8 mice/group), (G, N) cellular proliferation and (H, 
O) crypt regeneration were measured (n=4-5 mice/group). (P) Schematic of organoid formation assay to test 
stem cell activity in non-irradiated Villin-CreERT2 mice. Duodenal crypts were isolated from TX- or VEH-treated 
mice and plated in Matrigel to form organoids. (Q-R) Brightfield images of organoids 3 days post-
establishment from crypts isolated from (Q) VEH-treated or (R) TX-treated Villin-CreERT2 mice. (S) Organoid 
forming efficiency was determined by counting organoid number and presented as percent of the number 
plated (n=3 mice/group with 3 technical replicates per mouse). Quantitative data are presented as mean +/- 
SEM (*P<0.05, **P<0.01, #P<0.0001 TX vs. VEH by Student’s t-test). Scale bars = 100µm (duodenum), 
250µm (organoids).  
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Figure 3.3 Normal intestinal regeneration and organoid formation in tamoxifen-treated C57BL/6 and 
Villin-Cre mice. 
(A-H) C57BL/6 and (L-S) Villin-Cre mice were treated with TX or VEH daily for 5 days, irradiated (12Gy) 1 day 
later, and intestinal tissue was collected at 5 DPI. (A, L) Mouse body weight relative to weight at the initiation 
of treatment is presented as mean +/- SEM (n=3-6 mice/group). Duodenal crypt regeneration post-irradiation 
was assessed by (B-C, M-N) H&E staining and (E-F, P-Q) EdU incorporation. (D, O) Villus height 
measurements presented as mean +/- SEM (n=3-4 mice/group). (G, R) Proliferating cells are presented as the 
number of EdU-positive cells per crypt. (H, S) Regenerating crypts were defined as intact crypts with 4 or 
more EdU-positive cells and presented as percent of the total crypts. Quantitative data are presented as mean 
+/- SEM (n=3 mice/group). (I-J, T-U) TUNEL staining of unirradiated (UNIRR) TX- and VEH-treated C57BL/6 
and Villin-Cre mice 24h following the last day of injection. (K, V) C57BL/6 and Villin-Cre duodenal crypts were 
isolated from UNIRR TX- or VEH-treated mice and plated (200 crypts/well) to form organoids. Organoid 
formation efficiency is presented as mean +/- SEM (n=3 mice/group with 3 technical replicates per 
mouse). (W) Western blot probing for Cre, and loading control GAPDH in duodenal crypt lysates of Villin-Cre 
and Villin-CreERT2 mice. Duodenum images scale bars = 100µm.   
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Figure 3.4 Reduced organoid forming efficiency after CreERT2 activation in intestinal stem cells.  
Mouse strains with TX-inducible CreERT2 drivers specific for CBC (Olfm4-CreERT2 and Lgr5-CreERT2) or 
facultative (Hopx-CreERT2) ISCs were tested for (A-C) proliferation and (D-F) crypt regeneration after 
irradiation, or for (G-O) organoid forming efficiency in non-irradiated mice. (A-F) Mice were treated with TX or 
VEH daily for 5 days, irradiated a day later, and tissue was collected 3 DPI. (A-C) Cellular proliferation and (D-
F) crypt regeneration were quantified (n=3-8 mice/group). (G-O) Organoids were established from duodenal 
crypts 1 day after TX- or VEH-treatment, imaged and counted at 3 days post establishment (n=3-7 mice/group 
with 3 technical replicates per mouse). Quantitative data are presented as mean +/- SEM (*P<0.05, 
***P<0.001 TX vs. VEH by Student’s t-test).   
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Figure 3.5 Normal post-irradiation regenerative responses after CreERT2 activation in intestinal stem 
cells.  
Mouse strains with TX-inducible CreERT2 drivers specific for active (Olfm4-CreERT2 and Lgr5-CreERT2) or 
facultative (HopX-CreERT2) intestinal stem cells were treated with TX or VEH daily for 5 days, irradiated 
(12Gy) 1 day later and tissue was collected at 3DPI. (A, D, G) Mouse body weight relative to weight at the 
initiation of treatment is presented as mean +/- SEM (n=3-14 mice/group). (B-C, E-F, H-I) Cellular proliferation 
was assessed by EdU incorporation (n=3-8). Scale bars = 100µm.  
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Figure 3.6 Villin-CreERT2 activation induces DNA cleavage at cryptic loxP sites.  
Villin-CreERT2 or C57BL/6 mice were treated with VEH or TX daily for 5 days and intestinal crypts were 
collected 1 day following the last injection. (A, D) Western blots probing for γ-H2AX, cleaved caspase 3 (CC3), 
and loading control GAPDH were generated from duodenal crypt lysates prepared from (A) Villin-CreERT2 or 
(D) C57BL/6 mice treated with VEH or TX. (B-C, E-F) γ-H2AX and CC3 band signals were quantified and are 
displayed as means +/- SEM (n=3-4 mice/group; *P<0.05 by Student’s t-test). Immunofluorescent images of 
(G) γ-H2AX- and (I) TUNEL-stained VEH- or TX-treated Villin-CreERT2 duodenum at 1 day post-treatment. (H) 
Quantified CC3-positive cells per crypt from Villin-CreERT2 mice 1d post-treatment. (J) Known loxP sequence 
compared to the reported cryptic loxP (cloxP) AF033025 site (GenBank). Schematic of the qPCR assay 
designed to measure the amount of intact cloxP genomic DNA. (K) qPCR results from cloxP assay normalized 
to Gapdh (n=3-6 mice/group; *P<0.05, **P<0.01 by Student’s t-test). Scale bars = 50 µm.  
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Figure 3.7 Villin-CreERT2 toxicity is mitigated by delay and reduced TX dose.  
Body weight data from Villin-CreERT2 mice treated with VEH or TX daily for 5 days, followed by γ-irradiation 
after a 7-day delay (n=3-4 mice/group). (B-C, F-G) EdU-stained duodenal tissue sections at (B-C) 3DPI and 
(F-G) 5 DPI. (D, H) Proliferation, (E, I) regenerating crypts and (J) villus height were quantified. (K) Western 
blot analysis probing for γ-H2AX, CC3 and GAPDH, using duodenal crypt lysates from Villin-CreERT2 mice 7 
days post-treatment. (L-M) γ-H2AX and CC3 band signal were quantified and displayed as mean +/- SEM 
(n=3 mice/group). (N) qPCR gene amplification of cloxP normalized to Gapdh (n=6 mice/group). TUNEL 
staining of duodenum of non-irradiated (O) “delayed” VEH- or TX-treated Villin-CreERT2 mice, (Q) Villin-
CreERT2 mice administered 5 daily doses of 50mg/kg TX and analyzed 1-day later (5x50), and (S) Villin-
CreERT2 mice administered a single dose of 100mg/kg TX and analyzed 1-day later (1x100). Organoid 
forming efficiency was also determined for (P) delayed, (R) 5x50 and (T) 1x100 VEH- and TX-treated Villin-
CreERT2 mice. (n=3-9 mice/group with 3 technical replicates per mouse; *P<0.05 by Student’s t-test). Scale 
bars = 100µm.   
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Figure 3.8 Tamoxifen-induced Olfm4-CreERT2 toxicity is abated by delay.  
(A) Schematic of organoid formation efficiency assay. Organoids were established from duodenal crypts 
isolated from Olfm4-CreERT2 mice 7 days after treatment with VEH or TX. (B,C) Brightfield images of 
organoids 3 days post-establishment. (D) Organoid forming efficiency was determined by counting the number 
of organoids in each well at 3 days post-establishment (n=3 mice/group with 3 technical replicates per 
mouse). Scale bars = 250µm.   
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Figure 3.9 Tamoxifen-activated Villin-CreERT2 animals have impaired intestinal stem cell function.  
Graphical model illustrating that isolated crypts from TX-activated Villin-CreERT2 mice have an impaired 
organoid forming capacity.   
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Chapter IV: Rapid Crypt Cell Remodeling 
Regenerates the Intestinal Stem Cell Niche 
After Notch Inhibition4 
4.1 Summary 
The Notch pathway has been established as a key niche factor important 
for intestinal stem cell (ISC) self-renewal. The current model posits that Notch 
inhibition causes ISC loss and secretory cell expansion, including Paneth cells. In 
this study, we observed rapid and dynamic crypt cell remodeling to restore 
homeostasis following disruption of the ISC Notch niche. Although ISCs were 
retained after Notch inhibition, we demonstrated reduced ISC function, and a 
surprising loss of Paneth cells by apoptosis. The rapid ISC-Paneth cell injury was 
followed by a proliferative surge and increased Notch signaling, with expansion of 
cells expressing Notch ligands Dll1 and Dll4. Lineage tracing showed that Dll1-
expressing cells were activated to proliferate and contribute to the replenishment 
of the vacant Paneth cell pool. Our study uncovered a dynamic, multi-cellular 
remodeling response to Notch inhibition in the intestinal crypt, with activation of 
                                            
4 Note this chapter is adapted from the following article in preparation: 
Bohin, N.*, Keeley, T. M.*, Carulli, A. J., Carlson, E. A., Gao, J., Aifantis, I., Siebel C. W., 
Rajala, M. W., Myers, M. G., Jones, J. C., Brindley, C. D., Dempsey, P. J., Samuelson, L. C. 
Rapid Crypt Cell Remodeling Regenerates the Intestinal Stem Cell Niche after Notch 
Inhibition. Cell Stem Cell. [In Preparation]. * Equal contribution. 
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Notch signaling to re-establish the niche and restore homeostasis. 
4.2 Introduction 
As one of the most rapidly renewing tissues, the intestine has a great 
capacity for regeneration. Under homeostatic conditions, Lgr5-expressing crypt 
base columnar stem cells (CBCs) are responsible for replenishing the intestinal 
epithelium throughout lifespan.1,2 This intestinal stem cell (ISC) population divides 
once a day to generate highly proliferative transit amplifying (TA) cells which 
differentiate into the various mature epithelial cell types. Most newly formed 
differentiated cells move out of the crypts and onto the villi, where they function in 
absorption or secretion before being extruded into the lumen. The exception is 
Paneth cells, which move to the crypt base to lie adjacent to CBCs, with a half-life 
of several weeks.3,4   
When CBCs are injured, other crypt cell populations can replace their 
function, acting as facultative stem cells (FSCs; also called +4 cells, reserve stem 
cells and quiescent stem cells) by re-entering the cell cycle to generate progeny 
that can maintain the epithelium during the repair process, and to occupy vacant 
stem cell niche spaces to replace lost CBCs. FSC activation after intestinal injury 
has been demonstrated by lineage tracing from several different Cre-drivers that 
mark various lineage-committed (Alpi, Dll1) or slowly cycling (Bmi1, HopX, Lrig1, 
mTert) crypt cell populations.5–13 In addition, recent studies have demonstrated 
that after radiation-induced crypt injury, even differentiated Paneth cells can 
reprogram into proliferative progenitors capable of forming various differentiated 
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intestinal cell types.14 Thus, in response to injury, cells in the intestinal crypt exhibit 
remarkable cellular plasticity to reprogram their cell fate to regenerate the crypt 
and return to homeostasis.  
Adult stem cells are regulated by their niche, the tissue-specific 
microenvironment of cells, secreted substances, and extracellular matrix that 
provide key signaling factors to orchestrate stem cell function. In the intestine, the 
stem cell niche includes both epithelial cell and stromal cell compartments. Wnt 
and Notch signaling have been identified as the primary niche pathways promoting 
ISC self-renewal.15 Disruption of either Wnt or Notch signaling has been shown to 
induce CBC loss and crypt collapse.16–19 While ISC Wnt signaling is regulated by 
ligands secreted from both epithelial and stromal cell sources,20–23 Notch signaling 
is likely to be epithelial specific because it requires direct cell-to-cell contact.15  
CBCs have been demonstrated to be Notch signaling cells,24 with Notch1 
identified as the primary receptor regulating CBC function.25,26 Both pharmacologic 
Notch inhibition as well as genetic disruption of Notch signaling results in CBC 
loss, and in a gain in secretory cells, which includes increased expression of 
Paneth cell markers.19,24,27,28 Paneth cells are the most likely source of Notch 
ligand due to their close association with CBCs at the crypt base.29 Moreover, 
Paneth cells have been described to express both Dll1 and Dll4,30,31 the key Notch 
ligands regulating crypt cell homeostasis.19 In spite of our understanding of niche 
regulation of ISCs during homeostasis, particularly with regards to Notch signaling, 
strikingly little is known about ISC niche responses following injury. Furthermore, 
earlier studies of pharmacologic or genetic Notch disruption were limited by the 
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reduced animal viability, which impeded analysis of the regeneration process. 
Here, we introduce an intestinal crypt injury model based on short-term 
niche factor inhibition. We probe the setting of pharmacologic Notch inhibition to 
investigate the acute cellular response to niche disruption. We demonstrate that 
short-term Notch niche disruption leads to ISC dysfunction and dynamic cellular 
remodeling highlighted by rapid Paneth cell loss, a novel contrast to existing 
thinking as established by studies employing longer time points of Notch inhibition 
that demonstrated Paneth cell expansion. After short-term Notch disruption we 
observed expansion of cells expressing Notch ligand, and increased Notch 
signaling, with a regenerative response characterized by a proliferative surge and 
activation of FSCs. We show that Dll1-expressing secretory progenitors were 
activated to function as FSCs to regenerate the vacant Paneth cell population. Our 
study sheds light into how niche pathways and crypt cell plasticity orchestrate 
intestinal repair.  
4.3 Experimental Procedures 
4.3.1 Mice 
Lgr5-GFP-IRES-CreERT2 (Jackson Lab, no. 008875),1 Olfm4-IRES-GFP-
CreERT2 (from Dr. Hans Clevers),32 Defensin-alpha4-Cre (from Dr. Martin 
Myers),33 Dll1-mCherry and Dll4-mCherry BAC transgenic mice (from Dr. Iannis 
Aifantis),34 Dll1-EGFP-ires-CreERT2 (from Dr. Hans Clevers),7 Hopx-CreER 
(Jackson Lab, no. 017606),5 ROSA26-LStopL-tdTomato (ROSA26-Tom; Jackson 
Lab, no. 007909),35 or ROSA26-LStopL-mTmG (ROSA26-mTmG; Jackson Lab, 
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no. 007576)36 alleles were verified by PCR genotyping. All mice were maintained 
on a C57BL/6 strain background. Mice were housed in ventilated and automated 
watering cages with a 12-hour light cycle under specific pathogen-free conditions. 
Protocols for mouse usage were approved by the University of Michigan 
Committee on Use and Care of Animals. Adult mice of both sexes were used for 
analyses. 
4.3.2 Animal treatment protocols and tissue collection 
Mice were injected intraperitoneally with DBZ (30 µmol/kg) (SYNCOM, 
Netherlands) or Veh as described,28 and intestinal tissue was collected at various 
time points. Some mice were injected with 5-ethynyl-2´-deoxyuridine (EdU, 25 
mg/kg) (Life Technologies) 1.5 hours before tissue collection. Intestinal tissue was 
fixed in 4% paraformaldehyde overnight for paraffin sections as previously 
described,24 as illustrated in Figure 2.1. Tissue prepared for frozen sections was 
fixed for 1 hour and incubated in 30% sucrose overnight before embedding in OCT 
(Tissue-Tek). Intestinal crypts were isolated for gene expression analysis or flow 
cytometry as described.25 Some mice were treated with a single intraperitoneal 
injection of 100 mg/kg tamoxifen prior to DBZ or Veh treatment, as detailed in 
figure legends. Defensin-alpha4-Cre; ROSA26-Tom mice were treated with a 
mixture of humanized neutralizing monoclonal antibodies directed against DLL1 or 
DLL4, or an irrelevant isotype control antibody against herpes simplex virus gD 
protein (Gd).37,38 Antibodies were injected intraperitoneally at 15 mg/kg for two 
daily doses and intestinal tissue was collected the next day.  
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4.3.3 Immunohistochemistry 
Paraffin sections (4-5µm) were stained with periodic acid-Schiff and alcian 
blue (Newcomer Supply) to visualize mucin-containing goblet cells. 
Immunostaining with rabbit α-lysozyme (1:200, DAKO), rabbit α-GFP (1:200, 
Invitrogen), and rabbit α-cleaved-caspase 3 (1:50, Cell Signaling), rabbit α-muc2 
(1:200, Santa Cruz), and rabbit α-CgA (1:200, Abcam) was performed as 
described (Lopez-Diaz, 2006). Co-immunostaining for cleaved caspase 3 and 
MMP7 was performed by co-incubating rabbit α-cleaved caspase 3 and rat α-
MMP7 (1:400, Vanderbilt). Rabbit α-cleaved Notch 1 (NICD; 1:50, Cell Signaling) 
was used in conjunction with a TSA Superboost kit (Thermo #B40943). EdU-Click-
iT kit (Life Technologies) was used to identify proliferating cells. Images were 
captured on a Nikon E800 microscope with Olympus DP controller software.  
4.3.4 In situ hybridization 
Olfm4 in situ hybridization was performed on paraffin sections as 
described.25 Lgr5 in situ hybridization was performed on frozen sections as 
described.39  
4.3.5 Quantitative morphometric analyses 
The number of EdU–positive cells was counted on both sides of well-
oriented crypts. At least 10 crypts were counted per animal for all analyses, and 
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counts were averaged per animal (N=3-4 animals/group). Nuclei per crypt were 
counted on both sides of well-oriented crypts on DAPI-stained fields. Lineage 
tracing was quantified by counting the number of lineage-marked cells and 
represented as the number of lineage-marked cells per crypt, or the number of 
lineage tracing events per crypt. Morphometric analyses were completed using 
ImageJ software (http://imagej.nih.gov/ij/). The number of cleaved caspase 3-
positive cells was counted and divided by the total number of crypts. 
Approximately 150 crypts were counted per mouse. 
4.3.6 Crypt isolation and gene expression analysis 
Crypts were isolated from mouse duodenum as previously described.25 
RNA was isolated using RNeasy Mini kit (Qiagen) with DNase I treatment as per 
manufacturer instructions. cDNA was reverse transcribed with the iScript cDNA 
synthesis kit (BioRad) using 1 µg of total RNA. qPCR was performed as previously 
described.40 Olfm4, Lgr5, Notch1, Notch2, and Hes1 primers were previously 
described.24,39,41 Dll1 primers have sequences: CTG AGG TGT AAG ATG GAA 
GCG (forward) and CAA CTG TCC ATA GTG CAA TGG (reverse). Dll4 primers 
have sequences: TCGTCGTCAGGGACAAGAATAGC (forward) and 
CTCGTCTGTTCGCCAAATCTTACC (reverse). Jag1 primers have sequences: 
CAG AAT GAC GCT TCC TGT CG (forward) and TGC AGC TGT CAA TCA CTT 
CG (reverse). Jag2 primers have sequences: TAT GAC AGC GGC GAC ACC TTC 
(forward) and CAA CAC AGA TGC CTC CGT TAT AGC (reverse). Hprt primers 
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have sequences: AGG ACC TCT CGA AGT GTT GGA TAC (forward) and AAC 
TTG CGC TCA TCT TAG GCT TTG (reverse). 
4.3.7 Fluorescence-activated cell sorting (FACS) and 
mCherry-positive cell plating to form organoids 
A previously described protocol for isolation, plating and culturing Lgr5-
positive antral stem cells was adapted for the FACS isolation of single Dll1-
mCherry-positive duodenal crypt cells from Veh and DBZ-treated mice, and their 
subsequent culture in Matrigel to form organoids.39 The efficiency of organoid 
formation was determined by counting organoids 7 days following plating and 
normalizing to the number of plated Dll1-mCherry-positive cells. 
4.3.8 Statistical analyses 
All experiments were performed with 3-8 biological replicates per group. 
Quantitative data are presented as mean ± SEM. Comparisons between two 
groups were conducted with unpaired two-tailed Student t tests. Comparisons 
between 3 or more groups were analyzed by one-way ANOVA with Dunett’s post-
test. Significance is reported as *(P<0.05), **(P<0.01), ***(P<0.001), and 
****(P<0.0001). Prism software (Graphpad) was used for statistical analyses. 
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4.4 Results 
4.4.1 Acute pan-Notch inhibition leads to functional 
impairment of ISCs 
We analyzed the immediate effect of Notch inhibition on ISC function and 
characterized the regenerative response after short-term Notch niche disruption by 
treating adult mice with a single dose of the gamma-secretase inhibitor 
dibenzazepine (DBZ). Intestinal tissue was isolated at various time points post-
DBZ, which has a plasma half-life of less than 12 hours,42 to characterize the 
dynamic crypt cell response to Notch inhibition (Figure 4.1A). We observed loss of 
expression of the CBC marker43 and Notch target gene24 Olfm4 as early as 12 
hours post-DBZ, with a return in expression by 3 days post-DBZ (Figure 4.1B,C). 
In contrast, Lgr5 expression was not changed (Figure 4.1B,C), suggesting that the 
dynamic changes to Olfm4 expression reflected loss of CBC Notch signaling rather 
than stem cell depletion.  
To assess the effect of acute Notch inhibition on CBC function, we 
measured lineage tracing using two different CBC-specific Cre driver strains 
crossed to the ROSA26-Tom reporter: Olfm4-GFP-CreERT2 and LGR5-GFP-
CreERT2. The Tom lineage mark was activated by treatment with tamoxifen, 
followed by DBZ or vehicle treatment and analysis 1 day later (Figure 4.1D). We 
observed significantly fewer lineage-traced cells in DBZ-treated animals compared 
to vehicle-treated controls (Figure 4.1E). Quantification of the number of Tom-
labeled cells per crypt showed that both Olfm4 and Lgr5 reporter mice had an 
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approximately 2-fold reduction in lineage tracing, indicating impaired CBC function 
(Figure 4.1E). Significantly reduced lineage tracing was observed in both proximal 
(Figure 4.1E) and distal small intestine (data not shown) after Notch inhibition.  
4.4.2 Paneth cell apoptosis following Notch inhibition 
 Histological analysis of the crypt post-DBZ showed dynamic cellular 
remodeling. Remarkably, granule-filled Paneth cells at the crypt base were rapidly 
lost within 12 hours of DBZ-treatment, associated with the appearance of 
delaminated cells (Figure 4.2A). To further examine this effect, we immunostained 
tissue sections from vehicle and DBZ-treated mice for the Paneth cell marker 
lysozyme (Figure 4.2B). Lysozyme staining was virtually absent from DBZ-treated 
crypts as soon as 12 hours following DBZ administration (Figure 4.2B). To 
determine whether the loss of cells exhibiting these distinctive Paneth cell features 
was due to cellular remodeling or cell loss, we treated Defensin 4-Cre;Tom mice, 
which permanently label Paneth cells with a Tom lineage mark. We observed a 
marked loss of Tom-labeled cells 1 day post DBZ in these mice, demonstrating 
that Notch inhibition results in rapid Paneth cell loss (Figure 4.2B insets). Analysis 
of apoptosis by staining for cleaved caspase 3 showed a significant increase in 
apoptotic cells, which peaked at 1 day post DBZ treatment (Figure 4.2C). Co-
staining for the Paneth cell marker MMP7 and cleaved caspase 3 showed that the 
apoptotic cells were Paneth cells (Figure 4.2D).  
These data suggest that Notch signaling is required for Paneth cell 
maintenance, which is an unexpected finding as Paneth cells are not thought to be 
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Notch signaling cells. To confirm that the Paneth cell loss is a consequence of 
Notch inhibition and not to the inhibition of another gamma-secretase target, we 
analyzed Defensin4-Cre;Tom mice that were treated with a mixture of inhibitory 
antibodies to DLL1 and DLL4, the two Notch ligands required for crypt cell 
homeostasis.38,44 Similar to our findings after inhibition of Notch signaling with 
DBZ, we observed reduced Paneth cell numbers after combined DLL1 and DLL4 
Notch signaling blockade, showing that Paneth cell loss is due to Notch inhibition 
(Figure 4.3). The loss of Paneth cells may explain reduced CBC function shown 
by diminished lineage tracing post-DBZ (Figure 4.1E) as Paneth cells are known 
to express several ISC niche factors 29. Notably, Paneth cells return by 3 days 
following acute Notch inhibition, with an apparent increase in numbers of granule-
containing cells and Tom-marked cells by day 7 (Figure 4.2A,B). The rapid 
Paneth cell loss and return suggests dynamic crypt cell remodeling in response to 
Notch niche disruption to return to homeostasis.  
4.4.3 Increased Notch activity and cell proliferation during the 
regenerative phase of crypt remodeling 
 We assessed proliferation at 1, 3 and 7 days following DBZ or vehicle 
treatment to determine if crypt remodeling included a regenerative response. 
Acute Notch inhibition resulted in a marked increase in proliferating cells at day 3, 
with 1.6-fold increased numbers of EdU-positive cells (Figure 4.4A,B). This 
proliferative surge was accompanied by dynamic changes in crypt cellularity. 
Decreased crypt cellularity was observed at 1 day post DBZ (Figure 4.4C), a time 
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point marked by loss of Paneth cells and diminished CBC stem cell function 
(Figures 4.1 and 4.2). However, at the time of the proliferative surge at day 3, 
crypts were expanded and there was increased cellularity, compared to vehicle-
treated mice (Figure 4.4A,C).  
 Given the well-characterized role of Notch signaling in stimulating intestinal 
proliferation,19,24,27,28,45,46 we investigated Notch signaling activity to determine if 
the hyperproliferative response coincided with the return of Notch signaling. 
Immunostaining for the Notch1 intracellular signaling domain (NICD) showed loss 
of Notch activity 12 hours post DBZ treatment (Figure 4.5A,B), which is consistent 
with the loss of expression of the Notch target gene Olfm4 at that time point 
(Figure 4.1). While the number of NICD-positive cells remained significantly lower 
at 1 day post DBZ, Notch activity was returning, and NICD-positive cell numbers 
increased over time as we might expect given the aforementioned half-life of DBZ 
(Figure 4.5B). By day 3 the number of NICD expressing cells was increased in 
comparison to vehicle control, which corresponds to the time that we observed 
increases in proliferation and crypt cellularity (Figure 4.4). Notably, NICD-positive 
cells are preferentially observed in the mid-crypt region when they are returning, in 
contrast to the crypt base, which normally included NICD-positive cells.  
The rebounding Notch activity following acute Notch inhibition is associated 
with increased mRNA abundance of Notch components, including the ligands Dll1 
and Dll4, and the Notch1 receptor (Figure 4.5C). No significant changes in 
expression were observed for the other Notch components expressed in the 
intestinal epithelium, except for Jag2 and Notch2 receptor (Figure 4.6). 
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Surprisingly, expression of the Notch target Hes1 was not changed following acute 
Notch inhibition (Figure 4.6). In summary, acute Notch inhibition stimulates 
expression of the primary intestinal Notch ligands, concomitant with increased 
Notch activity.  
4.4.4 Rapid expansion of Dll1- and Dll4-expressing cells 
during crypt regeneration  
We made use of Dll1-mCherry34 and Dll4-mCherry reporter mice to follow 
the cellular pattern of Notch ligand expressing cells during intestinal remodeling 
post DBZ treatment. Analysis of these reporter mice showed that Dll1- and Dll4-
positive cells are normally present in both intestinal crypt and villus compartments 
in a scattered pattern consistent with secretory cell distribution (Figure 4.7A). We 
determined which cell types express Dll1 and Dll4 by co-imaging mCherry with 
markers of differentiated Paneth (lysozyme), goblet (Muc2) and endocrine (CgA) 
cells (Figure 4.8). Analysis of Dll4-mCherry mice showed that all three secretory 
cell types are marked with the mCherry reporter (Figure 4.8). However, analysis of 
Dll1-mCherry mice showed expression in goblet and Paneth cells, but not 
endocrine cells (Figure 4.8). This is likely a limitation of this BAC transgene as a 
Dll1 knock-in allele has been shown to mark all three secretory cell types as well 
as secretory progenitor cells.7  
Analysis of Dll1-mCherry and Dll4-mCherry cells after Notch inhibition 
showed increased numbers of marked cells (Figure 4.7). This finding suggests 
that increased mRNA abundance of Notch ligands (Figure 4.5C) is due to 
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increased numbers of Dll1 and Dll4 expressing cells. The expansion of Dll1-
mCherry and Dll4-mCherry cells after Notch inhibition by DBZ corresponds to a 
surge in goblet cell numbers detected by PAS/Alcian blue staining (Figure 4.9). 
This finding is consistent with previous reports that showed secretory cell 
hyperplasia after several days of continuous Notch inhibition.24,28  
Dll1- and Dll4-expressing cell expansion was profound, with expanded 
crypts at day 3 almost completely composed of Notch ligand-expressing cells 
(Figure 4.7A). This expansion was first detected 1 day post DBZ, with ligand 
expressing cells localized to the crypt base. Quantification of Dll1-mCherry cells by 
flow cytometry showed that cell number increased almost 3-fold at 1 day post DBZ 
(Figure 4.7B). 
4.4.5 Acute Notch inhibition stimulates Paneth cell 
regeneration from Dll1-positive FSCs 
Dll1-expressing secretory progenitors can be activated to function as FSCs 
to regenerate CBCs after crypt injury.7 To determine whether Notch inhibition 
might activate Dll1-expressing cells, we measured the number of proliferating Dll1-
mCherry cells, showing a 5-fold increase in EdU/mCherry double positive cells at 1 
day post DBZ compared to vehicle-treated controls (Figure 4.10A,B). We next 
tested stem/progenitor function by measuring organoid-forming potential of sorted 
Dll1-mCherry crypt cells 1 day post DBZ. This analysis showed a 2-fold increase in 
organoid forming efficiency compared to Dll1-mCherry cells isolated from vehicle-
treated mice (Figure 4.10C).  
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We tested whether Notch inhibition activated Dll1-expressing cells to 
function as FSCs to regenerate the Paneth cell pool using a lineage tracing 
approach. Dll1-GFP-CreERT2; ROSA26-Tom mice were treated with tamoxifen to 
activate the lineage mark, followed by a single dose of vehicle or DBZ 24 hours 
later, and intestine was harvested 7 days later (Figure 4.11A). At this time point, 
the only Tom-marked cells in the Veh-treated control crypts were Paneth cells due 
to their longer half-life; all other Dll1-expressing cells had turned over (Figure 
4.11B). In contrast, the DBZ-treated crypts contained numerous Tom-labeled crypt 
cells, including frequent lineage stripes (Figure 4.11B inset). Quantification of 
lineage traces showed that only the DBZ-treated mice exhibited lineage stripes 
(Figure 4.11C). Importantly, we found that Tom-positive cells generated from Dll1-
positive FSCs post-DBZ included Paneth cells (Figure 4.11D). Quantification of 
lysozyme/Tom double positive cells showed increased numbers of labeled Paneth 
cells in DBZ-treated crypts compared to vehicle-treated crypts (Figure 4.11D). In 
light of the Paneth cell loss and regeneration after DBZ treatment, the observation 
of Tom-labeled Paneth cells in crypts from DBZ-treated mice demonstrates that 
Notch inhibition induced Dll1-expressing progenitors to function as FSCs and 
regenerate the Paneth cell pool.  
We also carried out lineage tracing studies for another FSC marker using 
HopX-CreERT2; ROSA26-mTmG mice, but did not observe enhanced lineage 
tracing events after DBZ treatment (Figure 4.12). Together these data indicate 
that Notch inhibition leads to activation of a subset of FSCs, Dll1-positive FSCs, 
facilitating their contribution to the recovery of the depleted Paneth cell pool. 
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However, Dll1-expressing progenitors did not contribute to the CBC pool, as 
lineage stripes were short lived, with no lineage traces detected at 2 months after 
treatment (Figure 4.11B). Thus Dll1-expressing progenitors were activated to 
contribute to crypt regeneration after injury induced by Notch inhibition, but did not 
displace the resident CBCs from the crypt base. 
4.5 Discussion 
Our study uncovered a rapid and dynamic crypt cell remodeling program 
stimulated by disruption of the ISC niche. We revealed that a pulse of Notch 
inhibition induces a multicellular crypt damage response, highlighted by a dramatic 
early Paneth loss by apoptotic cell death. Although CBC stem cells are retained, 
they exhibit impaired lineage-tracing activity and loss of Notch signaling, as shown 
by loss of expression of the Notch target gene Olfm4. A regenerative response 
follows the Paneth cell–CBC stem cell injury, with repair and return to homeostasis 
within a few days. The repair response involves expansion of Notch ligand-
expressing cells, followed by a concurrent surge in both Notch signaling and crypt 
cell proliferation. The regenerative response involves cells expressing the Notch 
ligand Dll1, which are activated to proliferate and function as FSCs to transiently 
generate new epithelial cells, including Paneth cells, essentially adopting a CBC-
like function to maintain the epithelium and replenish the Paneth cell pool. To our 
knowledge, this is the first report of acute Paneth cell loss resulting from inhibition 
of the ISC niche and the first report of a regenerative crypt response that is not 
associated with CBC stem cell loss.  
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Our findings differ in some respects from previous studies of Notch 
inhibition, which analyzed longer-lasting pharmacologic24,28,47 or genetic19,25,48 
Notch depletion. In these studies, more long-lasting Notch inhibition led to Lgr5 
stem cell loss and a marked decrease in crypt cell proliferation. Thus, our 
observation of Lgr5 stem cell retention and increased cell proliferation after a short 
Notch disruption was unexpected. Further, reduced lineage tracing from Lgr5 and 
Olfm4 reporter mice following our acute Notch inhibition studies could reflect a 
block in stem cells transitioning to TA cells, or defects in early daughter cell 
proliferation rather than, or in addition to CBC dysfunction. Nevertheless, there is 
general agreement among past studies that continuous Notch signaling is required 
to maintain the ISC compartment, with pathway interruption leading to rapid stem 
cell dysfunction and ultimately stem cell loss, depending on the timing of pathway 
inhibition.  
Paneth cells have been proposed to be Notch niche cells due to their close 
physical association with CBCs at the crypt base and their expression of Dll1 and 
Dll4, the two key Notch ligands regulating CBC function in the intestine.19,29,31 
Additionally, Paneth cells are thought to generate a number of other niche factors, 
including Wnt ligands and growth factors, as well as metabolic products, 
suggesting a more expanded niche role for Paneth cells to support their stem cell 
neighbors.29,49 However, niche function for Paneth cells has been controversial, 
with some studies showing that Paneth cells can enhance stem cell function,29,50 
while others demonstrate apparently normal CBC function after Paneth cell 
depletion.51–53 Our observation of reduced stem cell lineage tracing activity 
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associated with Paneth cell loss, and a return to normal stem cell activity with 
Paneth cell return (Figure 4.13B-E), would support a functional niche role for 
Paneth cells. Further, Notch signaling at the crypt base did not recover until 
Paneth cells were restored, suggesting that Paneth cells are the key Notch niche 
cells presenting Notch ligand to the CBC stem cell.  
Our demonstration that CBCs restored their normal lineage tracing capacity 
several days after DBZ treatment, and are capable of contributing to Paneth cell 
restitution (Figure 4.13B,D), also supports a mutually supportive relationship 
between Paneth and CBC cells. This idea is in agreement with past literature, 
which provides evidence that ISCs have the capacity to reform their niche in an 
injury context.54,55 This supports the higher level concept that, in addition to 
responding to niche signals, CBCs may also partner with the niche towards its re-
formation when damaged.   
Our observation of crypt hyperproliferation and FSC activation after short 
term Notch inhibition are hallmarks of the intestinal regenerative response to repair 
crypt damage. The damage induced by Notch interruption is different from 
previously described crypt injury methods, which target stem and proliferating 
progenitor cells by radiation or chemotherapeutic drug treatment, resulting in stem 
cell loss and crypt collapse. Short term Notch inhibition results in more modest 
crypt cell effects and CBC retention, which nevertheless stimulates a regenerative 
response. Interestingly, in accordance with our finding, another study observed a 
proliferative surge with increased crypt height after depletion of Paneth cells and 
other secretory cell types from the adult mouse intestine.51 Thus, Paneth cell loss 
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might stimulate the regenerative response.   
The second hallmark of intestinal regeneration is FSC activation to fuel 
epithelial cell restitution and CBC stem cell replacement.56 In our study we 
observed activation of Dll1-expressing cells to function as FSCs to restore the 
Paneth cell pool. The rapid Paneth cell restoration by Dll1-expressing cells 
suggests that there is a concerted differentiation program to replenish this pool of 
cells and repair the Notch niche. Surprisingly, the activated Dll1-expressing cells 
did not contribute to the CBC pool, as lineage traces were short-lived. However, 
we showed that activated Dll1-expressing cells had increased organoid forming 
efficiency, suggesting that they have the potential to become stem cells if open 
niche spots occur because of CBC cell loss. Indeed, previous studies showed that 
Dll1-expressing progenitor cells have the capacity to regenerate lost CBCs after 
crypt damage caused by radiation.7 Thus, FSC function is dependent on the 
specific cellular damage induced by the injury, underscoring the cellular plasticity 
and exquisite drive to regain homeostasis in the crypt. In contrast to Dll1-
expressing cells, another FSC population that expresses HopX was not activated 
by Notch inhibition, showing that mobilization of distinct FSC populations also 
depends on the specific crypt cell damage.    
To conclude, we propose a process whereby acute Notch inhibition 
stimulates a regenerative response stemming from rapid Paneth cell loss and 
impaired CBC activity, which is fueled by Dll1-expressing cell expansion and 
activation. This study introduces acute pan-Notch inhibition as a novel intestinal 
injury model targeting Paneth cells, to study selective activation of a subset of Dll1-
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expressing secretory cell progenitors.  
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4.8 Figures 
 
Figure 4.1 Impaired CBC function after Notch inhibition.  
(A) Mice were treated with dibenzazepine (DBZ; 30 µmol/kg) or vehicle (Veh) and duodenal tissue was 
collected at various times. (B) In situ hybridization for crypt base columnar (CBC) stem cell markers Olfm4 and 
Lgr5. Insets are 3x original magnification. Scale bars = 100µm. (C) qPCR analysis of stem cell marker mRNA 
abundance. (D) Stem cell function was measured by lineage tracing after tamoxifen activation and DBZ or Veh 
treatment, as depicted. (E) tdTomato (Tom) lineage stripes were measured in Olfm4-GFP-CreERT2;ROSA26-
Tom (top) or Lgr5-GFP-CreERT2;ROSA26-Tom (bottom) duodenum. Insets show green channel to image 
CBCs. Quantification of the number of Tom+ cells per duodenal crypt in Veh- vs. DBZ-treated mice. Scale 
bars = 50µm. Quantitative data are presented as mean +/- SEM (***P<0.001, Veh vs. DBZ by Student t-test; 
n=3-4 mice per group, as shown). 
  
 241 
 
 
Figure 4.2 Paneth cell apoptosis after Notch inhibition. 
Mice were treated with DZB or Veh and intestinal tissue was analyzed at various times. (A) H&E-stained 
duodenal crypts. Black arrowheads denote delaminated cells. (B) Duodenal tissue sections were 
immunostained for the Paneth cell marker lysozyme (green), with nuclear DAPI (blue). Insets depict ileal 
crypts from mice (Defensin-alpha4-Cre;ROSA26-Tom) with Paneth cells marked with Tom (red) and DAPI 
(green). (C, D) Apoptotic cells were detected by immunostaining for cleaved caspase 3 (CC3; green), (C) 
quantified in the duodenum at various time points following Veh or acute DBZ treatment, and (D) co-stained 
with the Paneth cell marker MMP7 (red) with DAPI (blue). Single green and red channel images are shown in 
the right. White arrowheads denote co-stained cells. Scale bars = 50µm. Quantitative data are presented as 
mean +/- SEM (***P<0.001 Veh vs. DBZ by one-way ANOVA and Dunnett’s post-test; n=4-8 animals/group, 
as shown).  
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Figure 4.3 Loss of Paneth cells after Notch inhibition.  
Paneth cells were visualized in Defensin-alpha4-Cre; ROSA26-Tom (Defensin-Cre;Tom) mice after Notch 
inhibition, as described in Methods. (A) These mice were treated with gamma-secretase inhibitor 
dibenzazepine (DBZ; 30 µmol/kg) or vehicle (Veh), and harvested 24 hours post-DBZ. (B) Defensin-Cre;Tom 
mice were treated with humanized monoclonal antibodies directed against control (Gd) or a mixture targeting 
DLL1 and DLL4 (15mg/kg) daily for 2 days, and analyzed the following day. 
 
  
 243 
 
 
Figure 4.4 Proliferative surge and crypt expansion after Notch inhibition.  
(A) Cellular proliferation was assessed in Veh- and DBZ-treated mouse duodenum at various time points by 
EdU incorporation (green) with DAPI (red). White brackets highlight crypt depth. (B) Quantification of the 
number of EdU-positive cells per crypt. (C) Crypt cellularity was determined by the number of DAPI-stained 
nuclei per crypt. Scale bars = 100µm. Quantitative data are presented as mean +/- SEM (*P<0.05, **P<0.01, 
***P<0.001 Veh vs. DBZ by one-way ANOVA and Dunnett’s post-test; n=3-4 animals/group, as shown).  
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Figure 4.5 Notch activity surges during the regenerative phase.  
(A) Notch activity at various times post DBZ treatment was determined by immunostaining for the Notch 1 
intracellular domain NICD (green) with DAPI (blue). (B) Quantification of NICD-positive cells per duodenal 
crypt following Veh- or DBZ-administration. (C) qPCR analysis of mRNA abundance of key Notch components 
in Veh- and DBZ-treated mouse duodenal crypts. Scale bars = 50µm. Quantitative data are presented as 
mean +/- SEM (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 Veh vs. DBZ by One-way ANOVA and Dunnett’s 
post-test; n-3-4 animals/group as shown).  
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Figure 4.6 Analysis of Notch pathway component expression after Notch inhibition.  
qPCR analysis of mRNA abundance of Notch components in duodenal crypt RNA isolated from Veh- or DBZ-
treated mice at indicated time points (n=3-4 animals/group). Quantitative data are presented as mean +/- 
SEM. 
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Figure 4.7 DLL1- and DLL4-positive cell expansion after Notch inhibition.  
(A) Dll1-mCherry and Dll4-mCherry mice were treated with Veh or DBZ and mCherry marked cells (red) were 
imaged in duodenal sections with DAPI (blue). (B) FACS analysis of mCherry-positive cells in Dll1-mCherry 
duodenal crypts 1 day post Veh- or DBZ-treatment. Scale bars = 25m. Quantitative data are presented as 
mean +/- SEM (***P<0.001 Veh vs. DBZ by Student’s t-test; n=3-4 animals/group).  
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Figure 4.8 Dll1-mCherry and Dll4-mCherry transgenes are expressed in secretory cell types.  
Analysis of Veh- and DBZ-treated (A) Dll1-mCherry and (B) Dll4-mCherry duodenum and ileum 1 day 
following treatment. Intestinal sections were imaged for mCherry and immunostained for various secretory cell 
markers (green), including the Paneth cell marker lysozyme (Lyz), the goblet cell marker mucin 2 (Muc2) and 
the enteroendocrine cell marker chromogranin A (CgA), with nuclear DAPI (blue). Scale bar = 25µm. 
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Figure 4.9 Notch inhibition results in secretory cell hyperplasia.  
(A) Periodic acid-Schiff/ alcian blue (PAS/AB) stained duodenum at various times after acute DBZ treatment 
(n=3-5 animals/group). Scale bar = 100µm.  
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Figure 4.10 DLL1-positive cells form proliferating progenitors after Notch inhibition.   
(A) Dll1-mCherry mice were treated with Veh or DBZ and proliferation was measured 1 day later by EdU 
incorporation. Arrowheads highlight mCherry (red) and EdU (green) co-stained cells, which represent 
proliferating Dll1-expressing progenitors. (B) The number of co-stained cells was quantified (n=3 mice/group). 
Scale bars = 25µm. (C) Schematic of organoid formation assay used to measure stem cell-like activity of 
mCherry-positive cells isolated from Dll1-mCherry mice 24 hours after Veh or DBZ. After FACS isolation, Dll1-
mCherry positive cells were plated in Matrigel to form organoids. Organoid formation efficiency was 
determined by counting organoid number and presented as percent of the number of cells plated (n=6 
mice/group with 3 technical replicates per mouse). Quantitative data are presented as mean +/- SEM (*P<0.05 
Veh vs. DBZ by Student’s t-test; n=3 animals/group). 
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Figure 4.11 DLL1-positive progenitor cells regenerate Paneth cells.  
(A) Schematic of the experimental design. Dll1-GFP-CreERT2;ROSA26-Tom mice were treated with TX 
followed by Veh or DBZ, with duodenal tissue harvested at 8 days or 2 months as indicated. (B-C) Analysis of 
duodenal lineage tracing. (B) Duodenal sections were stained for GFP (green) to visualize Dll1-expressing 
cells, and tdTomato (red) to visualize Tom lineage-marked cells at 8 days (left and middle) and 2 months 
(right) following TX treatment. The inset in the middle image shows an example of a lineage trace. Scale bars 
= 50 µm. (C) The number of lineage traces, defined as a ribbon of 4 or more Tom-positive cells, was 
quantified. (D) Paneth cells arising from Dll1-expressing progenitors were identified at 8 days by visualizing 
Tom and staining for lysozyme, and presented as the number of Tom/lysozyme double positive cells per 
duodenal crypt. Quantitative data are presented as mean +/- SEM (***P<0.001, *P<0.05 Veh vs. DBZ by One-
way ANOVA and Dunnett’s post-test , or Student’s t-test).  
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Figure 4.12 Notch inhibition does not activate HopX-positive cells to contribute to Paneth cell 
regeneration.  
(A) Schematic of experimental design. HopX-CreERT2;ROSA26-mTmG animals were administered Veh or 
DBZ 24 hours following a single 100 mg/kg dose of TX, and tissue was harvested at 8 days. (B) HopX-
CreERT2;mTmG animals displayed lineage traces (green) from HopX-marked facultative intestinal stem cells. 
The number of lineage traces, as defined by a ribbon of 4 or more GFP cells per crypt was quantified. (n=3 
animals/group). Scale bar = 100µm. Quantitative data are presented as mean +/- SEM (Veh vs. DBZ by 
Student’s t-test). 
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Figure 4.13 Impaired CBC function following acute Notch inhibition resolves concomitantly with 
Paneth cell return.  
(A) Schematic of experimental design. Lgr5-GFP-CreERT2;Tom and Olmf4-GFP-CreERT2;Tom animals were 
administered Veh or DBZ 6 hours following a single 100 mg/kg dose of TX, and tissue was harvested (B,D) 3 
or (C,E) 7 days after treatment. (B,C) Lgr5-GFP-CreERT2;Tom and (D,E) Olmf4-GFP-CreERT2;Tom mice 
displayed lineage tracing (red) from Lgr5- and Olfm4-marked CBCs, with (D) insets staining for Lyz-marked 
Paneth cells. (n=3 animals/group). Scale bar = 25µm.  
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Chapter V: Summary and Perspectives 
5.1 Molecular mechanism of FSC contribution to 
irradiation-induced intestinal regeneration  
5.1.1 Summary  
In Chapter II, I propose a mechanism of intestinal response to injury by 
which paracrine IGF1 signaling from the mesenchyme stimulates mTORC1 activity 
in FSCs, priming them for activation, leading to their subsequent contribution to the 
regenerative response (Figure 2.10). We show that the hallmark intestinal 
response to irradiation injury enhances expression of many different growth 
factors, pertinently IGF1, which we show to be expressed in pericryptal 
subepithelial cells (Figure 2.2). We find that inhibition of IGF1 signaling is 
prohibitive to proper intestinal regeneration (Figure 2.3), and that this effect is 
mimicked by inhibition of downstream mTORC1 signaling (Figure 2.6 and 2.9). 
We show that mTORC1 is critical to FSC contribution to the intestinal regenerative 
response 24-48 HPI (Figure 2.8). We also demonstrate that genetic intestinal 
epithelial cell-specific enhancement of mTORC1 activity has no discernable impact 
on intestinal regeneration (Figure 2.9). We also show that mTORC1-depleted 
mice display a significantly greater enhancement in IGF1 expression post-
irradiation, compared to control animals (Figure 2.9), indicative of a feedback 
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mechanism potentially compensating for depleted mTORC1 activity. Thus, my 
data suggests that increased IGF1 expression post-injury leads to increased 
mTORC1 activity in crypt cells, promoting FSC contribution to intestinal 
regeneration. 
5.1.2 Perspectives  
We show that intestinal injury results in increased IGF1 expression from a 
pericryptal subepithelial cell (Figure 2.2). Identifying whether increased IGF1 
expression results in increased secretion of IGF1 will be critical to show paracrine 
effects of IGF1 signaling. To this aim, determining the identify of these injury-
responsive Igf1-expressing pericryptal subepithelial cells would be critical. A good 
place to start in identifying IGF1-expressing pericryptal subepithelial cells would be 
to test whether the Kaestner group’s Foxl1-positive pericryptal telocytes or the 
Basler group’s Wnt2b-secreting Gli1 or Acta2-positive subepithelial myofibroblasts 
express IGF1 (e.g. using the Kaestner laboratories’ published RNA sequencing 
data to see if Igf1 is expressed in Foxl1-positive cells),1–3 and if they respond to 
injury. Knowing the identity of IGF1-expressing cells would allow us to isolate them 
(via FACS sorting if a marker for which good FACS antibodies or a reporter mouse 
model exists, or laser capture microdissection) and test their function by co-
culturing them with organoids. We could assess whether injury stimulates 
increased IGF1 secretion (e.g. testing cultured media from these cells in a 
baseline and injury context for IGF1) which we could test by Western Blotting 
analysis. We could also ablate Igf1 in these cells (e.g. using the resulting cross 
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between the Kaestner laboratory’s Foxl1-CreERT2 mice,2 and floxed Igf1 mice)4 
and assess whether we lose the injury-stimulated increased Igf1 expression, and 
with it, whether intestinal regeneration is impaired. If we do see impaired intestinal 
regeneration with loss of Igf1-expressing pericryptal subepithelial cells, it would be 
requisite to check if IP administration of IGF1 rescues intestinal regeneration, 
given that we expect these cells to secrete other factors contributing to repair.1,2 If 
that is the case, we could then conclude that injury stimulates IGF1 secretion from 
pericryptal subepithelial cells, and that this response is critical to effective intestinal 
regeneration.  
The mechanism by which the injured intestine stimulates increased IGF1 
levels has not yet been investigated. Perhaps specific signals coming from the 
damaged epithelium or inflammatory cells induce this response, and could be 
interrogated by cross-referencing factors shown to be secreted post-injury (e.g. 
inflammatory cytokines) with factors capable of stimulating increased Igf1 
expression (e.g. Interleukin-1)5. We could then test if these are the right signaling 
factors by looking to see if their injection can mimic the increased Igf1 expression 
observed following injury. We could also assess if these same factors are 
responsible for enhancing the expression of the other growth factors that we 
identified in our qPCR array. 
It would be interesting to test whether the other growth factors identified in 
our qPCR array as having their expression enhanced post-irradiation (e.g. Ereg 
coding for epiregulin, Hgf) are also secreted by the same pericryptal subepithelial 
cells that secrete IGF1. Interestingly, our in situ hybridization data maps Ereg 
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expression to the epithelium rather than the mesenchyme like Igf1 (data not 
shown), suggesting that the growth factors that we identified to be associated with 
intestinal regeneration are coming from various intestinal cellular sources.  
To conclusively determine that the pro-regenerative effect of IGF1 works 
through mTORC1, we would need to carry out an experiment to assess if 
mTORC1 can rescue regeneration in animals depleted of IGF1 signaling. This 
experiment could be carried out a number of ways, using a combination of 
pharmacological and genetic methods of modulating mTORC1 and IGF1. We 
might start by assessing whether activation of mTORC1 via leucine administration 
(as has been done previously)6 rescues the impaired regenerative capacity 
observed by globally inhibiting IGF1 signaling pharmacologically (BMS 
administration). Another method we might employ would be to test the 
consequences of genetic depletion of IGF1 signaling (e.g. Igf1 deletion) broadly 
throughout the intestinal mesenchyme (e.g. PDGFRα-CreERT2 mice), to more 
restricted intestinal mesenchymal populations (e.g. Gli1-CreERT2 mice) or in 
specific subepithelial cellular populations (e.g. Foxl1-CreERT2), post-injury. We 
expect the results to mimic the regenerative impairment observed with 
pharmacologic inhibition of IGF1. We would then administer leucine to these 
animals6 and assess regenerative capacity. We would expect leucine-mediated 
activation of mTORC1 to rescue the impaired regeneration of genetic depletion of 
IGF1 signaling.  
An additional method by which we might determine that IGF1 works through 
mTORC1 to promote intestinal regeneration would be by assessing whether Villin-
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CreERT2;RaptorF/F mice depleted of mTORC1 activity are spared from the pro-
regenerative effect of IGF1 administration by IP injection. We would expect control 
(tamoxifen-treated Villin-CreERT2) animals to have enhanced intestinal repair 
following IGF1 administration, as previously reported,7 but that animals genetically 
depleted of mTORC1 would retain the impaired regenerative capacity that our 
studies report. This would indicate that the role of IGF1 in mediating effective 
intestinal repair occurs through the activity of mTORC1. Interestingly, our findings 
that genetically increased mTORC1 activity (albeit p-S6(S240/244)) is only slightly 
increased in this model; Figure 2.9) does not result in enhanced regeneration, 
while injection of IGF1 has been shown to lead to enhanced intestinal 
regeneration,7 suggests there may be other mTORC1-independent mechanisms 
mediating the pro-regenerative effect of IGF1. Certainly, how different molecular 
mechanisms integrate their signals to regulate the intestinal regenerative response 
is an area that warrants further study. 
My work proposed a mechanism by which injury-stimulated IGF1 signals to 
the crypts, and activates mTORC1 in FSCs, leading to their mobilization and 
contribution to the regenerative response. We show that mTORC1 activity is 
increased in the intestinal crypts post-injury (Figure 2.5), and that it is critical to 
FSC contribution to crypt re-population (Figure 2.8). However, to assess if the 
proposed model is valid, future work will first need to determine if mTORC1 activity 
is increased in FSCs in response to injury and IGF1 administration. This can be 
done in many different ways including: co-staining for p-S6(S240/244) and FSC 
markers for which immunostaining antibodies have been developed (e.g. HopX, 
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Bmi1), staining for p-S6(S240/244) on tissues from FSC reporter mouse models 
(e.g. Bmi1-CreERT2;ROSA26-lacZ), or looking for p-S6(S240/244) in sorted FSCs. 
The different FSC populations should be examined to determine if mTORC1 
mobilizes a subset of FSCs over others (e.g. mitotically dormant Bmi1-positive 
FSCs). In addition to verifying if mTORC1 activity is induced in FSCs following 
damage, future work needs to determine if mTORC1 activity induces a change of 
FSC state from its homeostatic role to a stem cell pro-regenerative role. This has 
been proposed to occur in mitotically dormant satellite cells in skeletal muscle,8 as 
described in Chapter I, with mTORC1 activity inducing their change to a mitotically 
active state able to repair injured muscle tissue. It has also been suggested in 
dormant FSCs by the Breault lab,9,10 but has yet to be tested.  
Further, significant work is also needed to determine whether non-quiescent 
FSC populations are differentially affected by mTORC1 status. One way to test 
this would be to isolate mRNA from Bmi1-expressing FSCs (whose contribution to 
repair we have shown to be regulated by mTORC1 in Figure 2.8), using reporter 
mice Bmi1-CreERT2;ROSA26-Tom to label FSCs, prior to and following mTORC1 
activation (e.g. administer vehicle, leucine or IGF1, and FACS sort Tom-labeled 
cells). We would then assess whether mTORC1 activity leads to gene signature 
changes that might correspond to changes in functional states. Subsequently to 
testing Bmi1-expressing FSC populations, we could broaden our analysis to other 
FSC populations, such as fated progenitors (e.g. Dll1-expressing FSCs) or 
differentiated cells (e.g. Paneth cells) to assess if their mobilization post-injury 
might be differentially regulated by mTORC1 activity. We would propose that the 
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regenerative capacity of these cells would also be regulated by mTORC1 in a 
process recently described in other organs and coined “paligenosis.”11 Paligenosis 
is a cellular process by which mature gastric chief cells and pancreatic acinar cells 
re-enter the cell cycle and fuel regeneration following injury in an mTORC1-
dependent manner.11 This process has yet to be investigated in the intestine. 
Our findings reveal that understanding IGF1/mTORC1 signaling is critically 
important to understand mechanisms of crypt cell plasticity and cellular remodeling 
after stem cell injury. Further, our work studies the regulation of stem cell 
restitution by both epithelial and mesenchymal cell compartments, thus 
contributing to a fuller understanding of the various components of the stem cell 
niche. Understanding the pro-regenerative role of IGF1/mTORC1 signaling could 
lead to the conception of therapies aimed at treating intestinal disorders 
associated with mucosal injury. 
5.2 Mechanism of intestinal stem cell sensitivity to 
CreERT2-induced DNA damage 
5.2.1 Summary  
In Chapter III, we discovered that activation of CreERT2 throughout the 
intestinal epithelium is genotoxic, and that CBCs are particularly sensitive to 
CreERT2 activation. In Villin-CreERT2 mice, activation of Cre recombinase by  
tamoxifen treatment results in impaired regenerative capacity following irradiation 
(Figure 3.2). We also show that CreERT2 activation in Olfm4- and Lgr5-positive 
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CBCs, using Olfm4-CreERT2 and Lgr5-CreERT2 respectively, results in impaired 
organoid formation, indicative of reduced stem cell function (Figure 3.4). 
Investigations into the mechanism by which CreERT2 activation could lead to 
impaired cellular functions found increased incidence of DSBs in intestinal crypts, 
and cloxP site cleavage (Figure 3.6). No increase in apoptosis was associated 
with this observation (Figure 3.6), suggesting DNA repair mechanisms may be 
engaged to resolve the activated CreERT2-inflicted cellular damage, which would 
explain the lack of observable intestinal phenotype in unchallenged CreERT2-
activated mice (Figure 3.1). We conclude our studies by showing that impaired 
CBC function and genotoxicity is repaired by 7 days after activation, and that no 
toxicity is observed when a single dose of tamoxifen is administered to activate 
CreERT2  (Figure 3.7). My findings suggest that investigators should delay 
organoid formation and inflicting intestinal damage following tamoxifen activation 
of CreER drivers.    
5.2.2 Perspectives  
  An interesting question that arises from our studies is how Cre protein 
levels correlate to genotoxicity. We showed similar levels of Cre protein in our 
Villin-CreERT2 (which displayed toxicity) and Villin-Cre (which did not) mouse 
strains (Figure 3.3W), indicating the differences in toxicity are not related to 
differences in Cre protein levels. Rather, our data suggests that the genotoxicity 
has to do with the nuclear translocation properties of CreERT2.  
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 The long-term outcome of Cre action at cloxP sites would be an interesting 
avenue of research to the field. We show that impaired ISC function and 
genotoxicity is repaired a week after CreERT2 activation, however, we did not test 
for activated CreERT2-induced mutations at cloxP sites resulting from inaccurate 
DNA repair. This could have significant implications to intestinal epithelial 
homeostasis and tumorigenesis. The literature reports that CreERT2 genome 
cleavage can lead to chromosomal abnormalities,12–14 suggesting that CreERT2 
may be capable of mutagenesis in the mouse intestine. Assessing the extent and 
occurrence of mutagenic events in response to CreERT2 induction would require 
importing new genetic models and developing new assays. One such method 
might be sequencing the cloxP region some time after CreERT2 activation and 
aligning with the cloxP sequence prior to activation to determine if mutagenesis 
has occurred. The mechanism of DNA repair might also be interrogated, as certain 
mechanisms are more likely to result in mutagenic events. Mouse models to detect 
intestinal mutagenesis could also be employed, testing enhanced tumor formation 
as a consequence of inaccurate DNA repair that would occur with cloxP cleavage. 
This remains an interesting area of future study that would certainly benefit the 
vast number of laboratories employing intestinal CreERT2 mouse models.  
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5.3 Mechanism of FSC repopulation following acute 
niche factor inhibition-mediated Paneth cell loss  
5.3.1 Summary  
 In Chapter IV, I propose a novel method of intestinal damage targeting 
Paneth cells via acute inhibition of the niche Notch signaling pathway. We 
demonstrate that acute Notch inhibition results in a rapid loss of Paneth cells by 
apoptosis (Figure 4.2) concomitant with impaired CBC activity (Figure 4.1). This 
crypt damage stimulates a proliferative surge reminiscent of the post-irradiation 
regenerative response characterized in Chapter II (Figure 4.4 compared to Figure 
2.1). We see increased numbers of Notch signaling crypt cells (Figure 4.5), and 
an expansion of Dll1-expressing cells (Figure 4.7) that, our data confirms, includes 
DLL1-expressing FSCs being mobilized to contribute to Paneth cell repopulation 
(Figure 4.10 and 4.11). Interestingly, we demonstrate that Dll1-expressing, but not 
HopX-positive FSCs contribute to Paneth cell repopulation (Figure 4.12). Our data 
not only describe a novel method of ablating Paneth cells to further our 
understanding of the stem cell niche, and the critical role of Notch in its 
maintenance, but they demonstrate selective activation of a particular FSC 
population. We propose a model by which acute Notch inhibition results in Paneth 
cell loss, which contributes to impaired CBC activity and Dll1-expressing FSC 
contribution to repopulating the vacant Paneth cell population.  
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5.3.2 Perspectives   
 While our studies focused on characterizing the intestinal response to acute 
Notch inhibition, future work is needed to determine the mechanism by which 
acute Notch inhibition leads to Paneth cell apoptosis. Previous mouse studies of 
Notch inhibition for a longer time (via genetic or pharmacological means) has been 
reported to lead to secretory cell expansion (including Paneth cell) rather than 
Paneth cell loss.15 However, the Paneth cell expansion observed under these 
conditions was based on a limited number of markers, and the morphology of the 
cells expressing Paneth cell markers was abnormal and could indicate immature 
secretory progenitors.16 Accumulation of immature Paneth cells in response to 
damage via niche disruption could be a result of a process recently described by 
Klein and Jensen labs known as fetal reversion, describing cells’ ability to revert to 
a fetal-like or immature generative state,17,18 a plasticity that Paneth cells have 
been reported to possess.19 Further work is required to determine if fetal reversion 
is induced following niche disruption, and to understand how the cellular changes 
observed after long-term (6 days) Notch inhibition relate to the acute cellular 
changes we observed with acute Notch inhibition.   
Paneth cell differentiation and maintenance at the crypt base requires Wnt 
signaling.15 Given a prior report showing that manipulation of Notch activity can 
impact Wnt signaling status in ISCs,20 it could be posited that an interruption to 
Notch signaling could effect Wnt, thereby resulting in Paneth cell damage. 
However, the study employed chronic Notch inhibition methods, and showed an 
increase in Wnt signaling, and resulting secretory cell hyperplasia.20 Nonetheless, 
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our studies of acute Notch inhibition demonstrate findings distinct from studies 
employing chronic Notch inhibition methods, it would thus be interesting to see 
what happens to Wnt signaling in response to acute Notch inhibition. To answer 
this question, Wnt signaling status could be evaluated in acutely Notch inhibited 
intestinal crypts via qPCR analysis of Wnt target genes, and assessment of 
nuclear β-catenin levels as a read-out of Wnt activity. Albeit preliminary, our 
assessment of some Wnt target genes following acute Notch inhibitor 
administration did not reveal changes in Wnt signaling (data not shown), 
suggesting that other mechanisms may be at play. Certainly, significant work is 
needed to delineate the integration of Notch signaling with other pathways in 
regulating the ISC niche.  
We could also propose another hypothesis for the cause of Paneth cell loss 
following acute Notch inhibition. From our studies in Chapter IV and the intestinal 
Notch signaling literature, we understand that Notch is critical to regulating CBC 
survival and function.15 As such, we might postulate that there exists a yet 
undiscovered Notch-dependent survival signal that CBCs deliver to Paneth cells, 
whose delivery is disrupted following acute Notch inhibition. Interruption of this 
survival-promoting signaling from CBCs to Paneth cells could fathomably cause 
Paneth cell apoptosis. We could test this hypothesis by performing gene 
expression profiling of CBCs (e.g. FACS sorting Lgr5-expressing CBCs using the 
Lgr5-GFP-CreERT2 mouse model) prior to and following acute administration of 
Notch inhibitor DBZ, to determine if they are undergoing genetic changes post-
acute Notch inhibition that would indicate they have ceased signaling to Paneth 
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cells. Significant work would subsequently be needed to characterize this CBC-
secreted Notch-dependent Paneth cell survival factor. 
 As we did not initially seek out to establish a new intestinal injury model, our 
discovery that niche disruption via acute Notch inhibition results in intestinal 
damage and stimulation of a regenerative response was of great surprise. The 
initial damage induced by Notch inhibition in Chapter IV differed from the effects of 
12 Gy γ-irradiation first described in Chapter II in that acute Notch inhibition did not 
result in the CBC loss reported with many damage models aimed at stimulating a 
regenerative response (including irradiation),21 but rather led to loss of CBC-
supporting Paneth cells and impaired CBC activity. Both CBC loss post-irradiation 
and CBC damage post-DBZ, although the latter has not been as extensively 
characterized as the former, resulted in a regenerative response characterized by 
increased proliferation and crypt hyperplasia at 3 days post-injury (comparing 
Figures 2.1 and 4.4). In both models, regeneration was fueled by FSCs mobilized 
to repair the damage, we showed Bmi1-positive and Dll1-positive FSCs 
contributed to intestinal repair following irradiation and acute Notch inhibition 
respectively (comparing Figures 2.9 and 4.11). Further, in both injury models, the 
intestinal epithelium was being repaired towards a return to homeostasis by 7 days 
post-injury. However, while post-irradiation, FSCs repopulated the CBC 
compartment, in our Notch inhibition model FSCs contributed to repopulation of 
the vacant Paneth cell population. Further, in the latter model, we showed 
selective activation of Dll1-positive, and not HopX-positive FSCs (Figure 4.12). 
While we did not investigate epithelial reconstitution by different FSC populations 
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in our irradiation model ourselves, other labs have shown activation of HopX-
positive and Dll1-positive FSCs post-irradiation,22,23 indicating an inherent 
difference in the cellular remodeling incurred by our two injury models, which 
warrants further study. 
As discussed, our finding that acute Notch inhibition results in Paneth cell 
loss with CBC retention, with stimulation of a regenerative response, was 
unexpected, as previously reported regenerative responses stem from CBC loss.21 
However, we do show that CBCs have impaired activity following acute Notch 
inhibition, which could indicate that even CBC damage can stimulate repair 
responses. We show that this impaired activity is transient, with CBC lineage 
tracing from Notch inhibited mice returning to control levels within a few days after 
Notch inhibitor administration, which also tracks with the return of Paneth cells. 
While these findings are indicative of Paneth cells serving a CBC-supporting 
function, our data showing CBCs contributing to the return of Paneth cells (Figure 
4.13) puts into question whether the return of CBC activity is a result of Paneth cell 
re-emergence. Rather, we suggest that while Paneth cell return is driven in part by 
CBCs, the resolved CBC activity is a result of returning Notch signaling. Hence, we 
propose that the return in Notch signaling drives the return of baseline CBC 
activity, which, alongside DLL1-expressing FSCs, fuels Paneth cell repopulation.  
 An outstanding question from our study demonstrating that both CBCs and 
Dll1-expressing FSCs give rise to Paneth cells, is the question of how Dll1-
expressing cells emerge. One theory is that CBCs give rise to these cells. 
However, concomitant with the expansion of Dll1-expressing cells as early as day 
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1 after administration of the Notch inhibitor, is the absence of Paneth cells and 
impaired CBC activity. It would seem unlikely from our data, that, with their 
impaired lineage tracing ability, acutely Notch inhibited CBCs are driving the 
dramatic expansion of Dll1-expressing cells. Rather, it would seem more likely that 
the crypt damage induced by acute Notch inhibition is resulting in remodeling of 
crypt cells to activate expression of Notch ligands DLL1 and DLL4 to enhance 
Notch activity. The mechanism for this could be such that the interruption in lateral 
inhibition resulting from loss of Notch signaling allows the de-repression of Notch 
ligand expression. One of our hypotheses posits that CBCs may be turning on Dll1 
expression, thereby changing their identity and function. This would be in line with 
a possible mechanism of Notch signaling support of CBCs in immature, post-natal 
intestine, via autocrine Notch signaling to support ISC function. 
One method by which we might address the question of autocrine Notch 
signaling being induced following damage to support CBC function, is by crossing 
a CBC reporter mouse model, such as Olfm4-GFP-CreERT2;ROSA26-LSL-YFP, 
with Dll1-mCherry reporter mice to generate mice in which we can lineage trace 
from CBCs, and visualize Dll1-expressing cells. These mice would allow us to 
determine whether CBCs are giving rise to the expanded Dll1-expressing cell 
compartment that we observe following acute Notch inhibition, or whether acute 
Notch inhibition is inducing CBC cell reprogramming to a Dll1-expressing state.  
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5.4 Conclusions 
Given the incredible plasticity of the intestinal crypt, cell reprogramming 
following the injury induced by acute Notch inhibition and Paneth cell loss is a 
likely scenario by which Dll1-expressing cells are arising. The emergence of a 
multitude of different markers to describe the FSC appears to describe cells with 
distinct cellular characteristics, and has given rise to many questions about how 
we characterize these cells prior to and following injury. The question of how 
damage might alter expression of putative FSC markers is an important question 
that is important to understanding the intestinal regenerative response,24 and that 
our work in Chapter IV begins to address. 
While our studies in Chapters II and IV begin to scratch the surface 
regarding understanding mechanisms of crypt cellular plasticity to return to 
homeostasis following injury, it is worth noting that very little is understood about 
the niche requirements of FSCs. While evidence is emerging to define cells 
serving a niche-supporting role to CBCs (e.g. Paneth cells,25 Foxl1-positive 
telocytes)2, little to no work has come to light about a niche cell serving a 
regulatory function to FSCs. Perhaps niche cells are common to both CBCs and 
FSCs. Our studies in Chapter II are in favor of this idea, suggesting that an IGF1-
secreting pericryptal subepithelial cell, potentially the same CBC niche-supporting 
cell identified by other groups,1–3 plays a critical role in the FSC niche. On the 
other hand, our studies in Chapter IV suggest that the epithelial niche Paneth cell, 
which we suggest is critical to maintaining proper CBC activity, is dispensable to 
the activity of Dll1-expressing FSCs, as we report these cells contribute to 
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regeneration in the absence of Paneth cells. Our studies suggest that the identity 
of the niche signals, rather the identity of the niche-supporting cells, are key to 
regulating FSC contribution to mucosal repair.  
Nonetheless, myriad outstanding intestinal niche questions remain. Given 
the complexity of the intestinal niche, more work needs to be done to understand 
the intricate crosstalk between the various intestinal compartments, which will be 
critical to our understanding of intestinal remodeling following injury. Specifically, 
we have yet to understand how crypt plasticity is regulated by these different 
compartments. We and others have suggested that epithelial (e.g. Paneth cells)25 
and subepithelial cells (e.g. telocytes,2 pericryptal myofibroblasts)1 are involved in 
signaling to ISCs, potentially mediating remodeling of the crypts, although the 
specific mechanisms have not all yet been delineated. Additionally, infiltrating 
inflammatory cells responding to injury could also play a role in regulating these 
different compartments, likely through their secretion of specific cytokines.26 It 
could be conceived that inflammatory signals stimulate cellular remodeling of the 
crypts directly, and/or that these signals regulate epithelial or subepithelial niche 
cell production of specific secreted factors (e.g. growth factors), which are 
themselves responsible for pro-regenerative crypt remodeling. Not to say that 
there couldn’t also be feedback signaling from the epithelium to other cellular 
compartments stimulating or repressing secretion of pro-regenerative factors 
based on environmental cues (e.g. apoptosis, juxtacrine signaling). All in all, 
understanding the convoluted crosstalk of signaling between the various cellular 
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compartments in the intestinal niche would be a tremendous advance in our 
understanding of intestinal repair.  
Our research contributes significantly to the field’s understanding of the key 
niche pathways regulating ISC function during mucosal regeneration after stem 
cell damage. We have identified DLL1/DLL4/Notch and IGF1/mTORC1 signaling 
as critical niche signaling axes to regulating crypt cell plasticity and cellular 
remodeling post-injury. Our new acute Notch inhibition stem cell injury method will 
be a powerful research tool to understand cellular plasticity in the crypt, which is a 
poorly understood area of research. Our discoveries regarding the genotoxicity of 
widely employed CreERT2 mouse models caution the field about using the proper 
controls in order to promote dissemination of correctly interpreted findings, hence 
building on our work. We show that Notch and growth factor signaling play a major 
role in cellular remodeling. Overall these contributions have led to the 
characterization of some key players in intestinal regeneration, which will be vital 
to the eventual development of regenerative therapies for intestinal disorders, and 
the design of treatments for intestinal diseases associated with mucosal injury. 
Further, understanding mechanisms of cellular plasticity and pro-regenerative or 
protective mechanisms may also advance our understanding of how to block such 
processes in the context of oncogenic malignancies.  
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